Condensed triazinone derivatives and methods of using same

Novel small molecule splicing modulators address the limitations of current treatments by targeting RNA cis elements, enhancing splicing regulation and improving disease treatment efficacy.

JP2024543450AInactive Publication Date: 2024-11-21RGENTA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527744
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-11-11
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for diseases related to splicing dysregulation, such as CRISPR-based genome editing and oligonucleotide-based therapies, face challenges including unfavorable pharmacokinetics, limited oral administration, and ineffective tissue delivery, particularly to the brain, while small molecule drugs for modulating RNA splicing are limited in chemical series.

Method used

Development of novel small molecule splicing modulators (SMSMs) targeting cis elements in RNA transcripts, such as splice sites, branch points, splicing enhancers, or silencers, which can interact with spliceosomes and RNA-binding proteins to regulate splicing.

Benefits of technology

The SMSMs can modulate the sequence or abundance of mature transcripts, potentially treating a wide range of diseases, including cancer, with improved pharmacokinetics and delivery compared to existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543450000001_ABST
    Figure 2024543450000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to compounds of formula (I) or (II), or subformulas thereof: (I), and their prodrugs, pharma- ceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of preparation thereof. The compounds of the present disclosure may function as small molecule splicing modulator compounds that modulate the splicing of mRNAs, such as pre-mRNAs, the encoded genes, and methods of using the compounds to modulate splicing and treat related diseases and conditions. The compounds disclosed herein may have activity on a variety of genetic pathways and are therefore useful in methods of treatment of the human or animal body. JPEG2024543450000105.jpg38165
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 278,726, filed November 12, 2021, the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] Over 90% of human genes produce multiple mature transcripts through alternative splicing. This process is essential for generating distinct transcripts in different cell and tissue types during development and in response to internal and external signals. Alternative splicing is common not only for protein-coding genes but also for most other types of genes, including microRNA genes and long non-coding genes. Splicing is carried out by the spliceosome. Small nuclear RNAs (snRNAs) are key components of the spliceosome. The main spliceosome, containing U1, U2, U4, U5, and U6 snRNAs, catalyzes the removal of approximately 95% of human introns. The remaining introns (referred to as U12-type introns) are removed by smaller spliceosomes containing U11, U12, U4atac, U5, and U6atac snRNAs. These snRNAs form complexes with their respective protein partners to form the functional units of small nuclear ribonucleoproteins (snRNPs).

[0003] Splicing is a highly regulated process, regulated by both cis- and trans-factors. Cis-elements recognized by snRNAs include 5' splice sites, 3' splice sites, and branch points, each of which is associated with sequence motifs recognized by components of the spliceosome. Additionally, there are intronic splicing enhancers (ISEs), intronic splicing silencers (ISSs), exonic splicing enhancers (ESEs), and exonic splicing enhancers (ESSs), which are recognized by numerous trans-factors, commonly known as RNA-binding proteins (RBPs). Some of these RBPs directly bind to cis-elements in a sequence-specific manner, while others recognize RNA structures (e.g., RNA duplexes or unpaired loop regions), and still others function through protein-protein interactions. Approximately 1,600 RBPs have been annotated in the human genome, which are expressed in a cell-type-specific manner and form an extensive regulatory network for splicing regulation.

[0004] Dysregulation of splicing is involved in approximately half of human diseases. Some diseases are caused by mutations in spliceosome components or RBPs, while others are caused by mutations in cis-elements such as splice sites, branch points, or various splicing enhancers and silencers. Current approaches to treat these diseases, such as CRISPR-based genome editing, viral-assisted gene therapy, or various oligonucleotide-based technologies, continue to improve, but they still suffer from significant technical and clinical challenges. In particular, oligonucleotide-based therapeutics exhibit unfavorable pharmacokinetics, cannot be administered orally, and cannot be effectively delivered to many tissues, particularly the brain. Small molecule drugs, with excellent pharmacokinetics, effective delivery, and bioavailability, have only recently become available to modulate RNA splicing. However, current molecules are limited to a few chemical series. Therefore, there is a great need to develop additional small molecule splicing modulators (SMSMs). Summary of the Invention [Means for solving the problem]

[0005] Here, we describe a series of novel small molecule splicing modulators (SMSMs) that can be used to treat a wide variety of diseases, including cancer. These SMSMs target regions of primary RNA transcripts that are cis-elements, such as splice sites, branch points, splicing enhancers, or splicing silencers. These regions may contain unpaired nucleotides in the RNA duplex, called bulges. Bulges can occur naturally or be caused by disease. When SMSMs contact an RNA transcript, they can be bound by spliceosomes or other trans-factors, most notably RNA-binding proteins (RBPs). The SMSMs reported herein can cause changes in the sequence or abundance of the mature transcript, which can result in differences in the sequence or abundance of a functional protein if the transcript is protein-coding, or in the sequence or abundance of a functional RNA if the transcript is non-coding.

[0006] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently selected from halogen, hydroxy, cyano, -COOH, -C(O)-C1-C6 alkyl, -C(O)O-C1-C6 alkyl, C1-C7 alkyl, C1-C8 heteroalkyl, C 1-7 Alkoxy-heterocycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -(CH2) 0-2 selected from the group consisting of -C3-C8 cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, NH, NH(C1-C6 alkyl), N(C1-C6 alkyl), -NHC(O)-C1-C6 alkyl, -N(C1-C6 alkyl)-C(O)-C1-C6 alkyl, -C(O)-NH, -C(O)-NH(C1-C6 alkyl), and -C(O)-N(C1-C6 alkyl), wherein alkyl, alkenyl, alkynyl, and alkoxy are optionally substituted with one or more halogen, hydroxyl, or NH, and cycloalkyl and heterocycloalkyl are optionally substituted with one or more halogen, hydroxyl, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, or NH; or Two R on the same carbon 6 can be taken together as keto (=O) or Two R6s together form C 1-7 Forming an alkylene each R7 independently represents halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; R 16 But, H, Halo, C1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R 17 But, H, Halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein the compound is cycloalkyl, or heterocycloalkyl.

[0007] In some aspects, the disclosure provides compounds that can be obtained by or are obtained by a method for preparing a compound described herein (e.g., a method comprising one or more steps described herein).

[0008] In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable diluent or carrier.

[0009] In some aspects, the present disclosure provides intermediates described herein that are suitable for use in the methods for preparing the compounds described herein (e.g., the intermediates are selected from the intermediates described herein).

[0010] In some aspects, the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition of the present disclosure.

[0011] In some aspects, the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition of the present disclosure.

[0012] In some aspects, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a disease or disorder disclosed herein.

[0013] In some aspects, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in treating a disease or disorder disclosed herein.

[0014] In some aspects, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for treating or preventing a disease or disorder disclosed herein.

[0015] In some aspects, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for treating a disease or disorder disclosed herein.

[0016] In some aspects, the disclosure provides the use of a compound of the disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.

[0017] In some aspects, the disclosure provides the use of a compound of the disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in the manufacture of a medicament for treating a disease or disorder disclosed herein.

[0018] In some aspects, the disclosure provides methods of preparing the compounds of the disclosure.

[0019] In some aspects, the disclosure provides methods of preparing compounds comprising one or more of the steps described herein.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Additionally, the materials, methods, and examples are merely illustrative and are not intended to be limiting.

[0021] Other features and advantages of the present disclosure will become apparent from the following detailed description and claims. DETAILED DESCRIPTION OF THE INVENTION

[0022] The compounds described herein are generally designed to treat the diseases and disorders disclosed herein.

[0023] definition Unless otherwise stated, the following terms used in the specification and claims have the following meanings, as set forth below.

[0024] As used herein, "alkyl," "C1, C2, C3, C4, C5, C6, or C7 alkyl," or "C1-C7 alkyl" is intended to include C1, C2, C3, C4, C5, C6, or C7 straight-chain (straight-chain) saturated aliphatic hydrocarbon groups and C3, C4, C5, C6, or C7 branched saturated aliphatic hydrocarbon groups. For example, C1-C7 alkyl is intended to include C1, C2, C3, C4, C5, C6, and C7 alkyl groups. Examples of alkyl include moieties having 1 to 6 carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, or n-hexyl. In some embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms (e.g., C1-C6 for straight chain, C3-C6 for branched chain), and in other embodiments, a straight chain or branched chain alkyl has 4 or fewer carbon atoms.

[0025] As used herein, "alkenyl" is intended to mean a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, containing one or more carbon-carbon double bonds, and no triple bonds ("C 2- C6 alkenyl). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). C 2- Examples of C6 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.

[0026] As used herein, "alkynyl" is intended to include straight or branched chain hydrocarbon groups having 2 to 6 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds ("C 2- C6 alkynyl). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). C 2-Examples of C4 alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like.

[0027] As used herein, the term "optionally substituted alkyl" refers to an unsubstituted alkyl or an alkyl having specified substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocycloalkyl, alkylaryl, or aromatic or heteroaromatic moieties.

[0028] Other optionally substituted moieties (such as optionally substituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl) include both unsubstituted moieties and moieties with one or more of the specified substituents. For example, substituted heterocycloalkyls include those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.

[0029] As used herein, "heteroalkyl," "C, C, C, C, C, C, C, or C heteroalkyl," or "C-C heteroalkyl" is intended to include C, C, C, C, C, C, C, C, or C straight-chain (straight-chain) saturated aliphatic hydrocarbon groups and C, C, C, C, C, C, or C branched saturated aliphatic hydrocarbon groups, wherein at least one of the carbons is replaced with N, O, or S. The heteroatom is bonded to any necessary hydrogens to complete the valence of the heteroatom (e.g., CH may be replaced with "O" or "NH," CH may be replaced with N, etc.). Such substituents may include, for example, -O-CH(CH), -CH-N(CH)-CHCHOCH, -S-CHCH-O-CHCH, and the like.

[0030] As used herein, "alkylene," "C, C, C, C, C, C, or C alkylene," or "C-C alkylene" is a divalent branched or straight-chain alkyl group having two open valences connecting the alkylene to two other groups. Examples of alkylene include -CH-, -CHCH-, -CHCHCH-, and -CH(CHCH)-CH-. When an alkylene connects its open valences to the same atom or to separate atoms that are already part of a chain or ring, the alkylene, together with the atom or atoms to which it is attached, forms a ring.

[0031] As used herein, the term "alkoxy" refers to the group -OR, where R is alkyl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e., having 1 to 7 carbon atoms.

[0032] As used herein, the term "cycloalkyl" refers to a group having 3 to 30 carbon atoms (e.g., C3-C 12 , C3-C10 , or C3-C8), a saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (e.g., fused, bridged, or spirocyclic) system. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl. In the case of polycyclic cycloalkyl, only one of the rings in the cycloalkyl need be non-aromatic.

[0033] As used herein, the term "heterocycloalkyl" or "heterocyclyl," unless otherwise specified, refers to a saturated or partially unsaturated 3-8 membered monocyclic (e.g., 4-7 membered monocyclic), 7-12 membered bicyclic (fused, bridged, or spirocyclic), or 11-14 membered tricyclic (fused, bridged, or spirocyclic) ring system (e.g., monocyclic or bicyclic 4-9 membered heterocycloalkyl) having one or more heteroatoms (such as O, N, S, P, or Se) independently selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., 1, 1-2, 1-3, 1-4, 1-5, or 1-6 heteroatoms, or e.g., 1, 2, 3, 4, 5, or 6 heteroatoms.Examples of heterocycloalkyl groups include piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-Oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 1,4-dioxa-8-azaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1-oxaspiro[4.5]decanyl, 1-azaspiro[4.5]decanyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl , 7'H-spiro[cyclohexane-1,5'-furo[3,4-b]pyridin]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridin]-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexan-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl Examples of heterocycloalkyls include, but are not limited to, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptanyl, 2-methyl-2-azaspiro[3.3]heptanyl, 2-azaspiro[3.5]nonanyl, 2-methyl-2-azaspiro[3.5]nonanyl, 2-azaspiro[4.5]decanyl, 2-methyl-2-azaspiro[4.5]decanyl, 2-oxa-azaspiro[3.4]octanyl, 2-oxa-azaspiro[3.4]octan-6-yl, and the like. For polycyclic heterocycloalkyls, only one of the rings in the heterocycloalkyl must be non-aromatic (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).

[0034] As used herein, the term "aryl" refers to the radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and the like. For convenience, aryl is phenyl.

[0035] As used herein, the term "heteroaryl" is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic heteroaromatic ring consisting of carbon atoms and one or more heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., 1, 1-2, 1-3, 1-4, 1-5, or 1-6 heteroatoms, or e.g., 1, 2, 3, 4, 5, or 6 heteroatoms. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or other defined substituent). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N→O and S(O)). p , where p=1 or 2). Note that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like. Heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings that are not aromatic so as to form a polycyclic system (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).

[0036] Furthermore, the terms "aryl" and "heteroaryl" include polycyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphtholidine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.

[0037] The bicyclic and tricyclic systems can be edge-fused, spiro-fused, or bridged.

[0038] A cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring can have one or more ring positions (e.g., a ring-forming carbon or heteroatom such as N) bearing a substituent as described above, e.g., alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, The aryl and heteroaryl groups may be substituted with carboxyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocycloalkyl, alkylaryl, or aromatic or heteroaromatic moieties. Aryl and heteroaryl groups may also be fused or bridged with alicyclic or heterocyclic rings that are not aromatic so as to form polycyclic systems (e.g., tetralin, methylenedioxyphenyl such as benzo[d][1,3]dioxol-5-yl).

[0039] As used herein, the term "substituted" means that any one or more hydrogen atoms on the designated atom are replaced with a selection from the designated group, provided that the replacement does not exceed the normal valence of the designated atom, and that the substitution results in a stable compound. When the substituent is oxo or keto (i.e., =0), two hydrogen atoms on the atom are replaced. Keto substituents are not present in aromatic moieties. As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N). "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and formulation into an effective therapeutic agent.

[0040] When a bond to a substituent is shown to cross the bond joining two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is recited without indicating the atom through which it is bonded to the remainder of the compound of a given formula, then such substituent may be bonded through any atom in such formula. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0041] When any variable (e.g., R) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0 to 2 R moieties, that group may be optionally substituted with up to 2 R moieties, and R at each occurrence is selected independently of the definition of R. Also, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0042] As used herein, the term "hydroxy" or "hydroxyl" refers to an -OH or -O - The group includes a group having the formula:

[0043] As used herein, the term "cyano" refers to the group --CN.

[0044] As used herein, the term "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.

[0045] As used herein, the term "haloalkyl" refers to a branched or unbranched alkyl substituted with one or more halogens. For example, C 1-7 Haloalkyl is an alkyl group of 1 to 7 carbons in which at least one H is replaced by a halogen. Examples of haloalkyl include, but are not limited to, CFH, CF, CH, CF, CF, C(F)(CH), CHCHBr, CH(I)CHF, and CHCl.

[0046] As used herein, the term "haloalkoxy" refers to an alkoxy structure substituted with one or more halo groups or combinations thereof. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.

[0047] As used herein, the term "amino" refers to the radical -NH. In certain embodiments described herein, one or both hydrogen atoms of -NH can be replaced by a different group, e.g., amino-C 1-7 It may be replaced by alkyl.

[0048] As used herein, the term "optionally substituted haloalkyl" refers to an unsubstituted haloalkyl having specified substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocycloalkyl, alkylaryl, or aromatic or heteroaromatic moieties.

[0049] As used herein, phrases such as "one or more of A, B, or C," "one or more of A, B, and C," "one or more of A, B, and C," "one or more of A, B, and C," "one or more of A, B, and C," "selected from the group consisting of A, B, and C," "selected from A, B, and C," and the like are used interchangeably and all refer to a selection from the group consisting of A, B, and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof, unless otherwise indicated.

[0050] It is to be understood that the present disclosure provides methods for the synthesis of any compound of the formula described herein. The present disclosure also provides detailed methods for the synthesis of the various disclosed compounds of the present disclosure according to the following schemes, as well as those shown in the Examples.

[0051] It should be understood that throughout this specification, when a composition is described as having, including, or comprising particular components, it is contemplated that the composition also consists essentially of, or consists of, the recited components. Similarly, when a method or process is described as having, including, or comprising particular process steps, the process also consists essentially of, or consists of, the recited process steps. Furthermore, it should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be conducted simultaneously.

[0052] It will be understood that the synthetic processes of the present disclosure can tolerate a wide variety of functional groups, and thus variously substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although in some cases it may be desirable to further convert the compound to a pharmaceutically acceptable salt thereof.

[0053] It will be understood that the compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or readily preparable intermediates by employing standard synthetic methods and procedures that are known to those skilled in the art or that will be apparent to those skilled in the art in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. See, for example, but not limited to, any one or more sources, Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th edition, John Wiley & Sons: New York, 2001, Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3 rdedition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), are classic texts incorporated herein by reference and are useful and recognized reference texts in organic synthesis known to those skilled in the art.

[0054] Those skilled in the art will note that the order of certain steps, such as the introduction and removal of protecting groups, may be varied during the reaction sequences and synthetic schemes described herein. Those skilled in the art will recognize that certain groups may require protection from the reaction conditions through the use of protecting groups. Protecting groups may also be used to distinguish between similar functional groups in a molecule. A list of protecting groups and methods for introducing and removing these groups can be found in Greene, T.W., Wuts, P.G.M., Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons: New York, 1999.

[0055] Unless otherwise specified, any description of a method of treatment will be understood to include the use of the compounds to provide treatment or prophylaxis as described herein, as well as the use of the compounds to prepare a medicament for treating or preventing such conditions. Unless otherwise specified, any description of a method of treatment will be understood to include the use of the compounds to provide treatment or prophylaxis as described herein, as well as the use of the compounds to prepare a medicament for treating such conditions. Treatment includes the treatment of humans or non-human animals, including rodents and other disease models.

[0056] As used herein, the term "subject" is interchangeable with the term "subject in need thereof," and both refer to a subject having a disease or at high risk of developing a disease. "Subject" includes mammals. A mammal can be, for example, a human or a suitable non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. A subject can also be a bird or poultry. In one embodiment, the mammal is a human. A subject in need thereof can be a subject previously diagnosed or identified as having a disease or disorder disclosed herein. A subject in need thereof can also be a subject suffering from a disease or disorder disclosed herein. Alternatively, a subject in need thereof can be a subject at high risk of developing such a disease or disorder compared to the general population (i.e., a subject who is prone to developing such a disorder compared to the general population). A subject in need thereof can have a refractory or resistant disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment). The subject may be resistant to treatment at the beginning or may become resistant during treatment. In some embodiments, the subject in need thereof has undergone and failed all known effective treatments for the diseases or disorders disclosed herein. In some embodiments, the subject in need thereof has undergone at least one prior treatment.

[0057] As used herein, the term "treating" or "treat" describes the management and care of a subject for the purpose of combating a disease, condition, or disorder, and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt or solvate thereof, to alleviate the symptoms or complications of the disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The term "treat" can also include the treatment of a cell in vitro or in an animal model.

[0058] It should be understood that references to "treating" or "treatment" include the alleviation of established symptoms of a condition. Thus, "treating" or "treatment" of a health condition, disorder, or condition includes (1) delaying the onset of clinical symptoms of the health condition, disorder, or condition that develop in a person who may be suffering from or predisposed to the health condition, disorder, or condition but who has not yet experienced or exhibited clinical or subclinical symptoms of the health condition, disorder, or condition; (2) inhibiting the health condition, disorder, or condition, i.e., preventing, alleviating, or delaying the onset or recurrence of the disease (in the case of maintenance treatment) or at least one clinical or subclinical symptom thereof; or (3) palliating or attenuating the disease, i.e., causing regression of the health condition, disorder, or condition, or at least one of its clinical or subclinical symptoms.

[0059] It is to be understood that the compounds of the present disclosure, or pharmaceutically acceptable salts or solvates thereof, can also be or can be used to prevent associated diseases, conditions, or disorders, or to identify suitable candidates for such purposes.

[0060] As used herein, the terms "preventing," "prevent," or "protecting against" describe reducing or eliminating the onset of symptoms or complications of such disease, condition, or disorder.

[0061] It should be understood that those skilled in the art may refer to general reference texts for detailed descriptions of known techniques described herein or equivalent techniques. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3 rd edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2000), Colligan et al., Current Protocols in Immunology, John Wiley & Sons, NY, Enna et al., Current Protocols in Pharmacology, John Wiley & Sons, NY, Fingl et al., The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing. Co.,Easton,PA,18 th Edition (1990), which texts may, of course, be referenced when making or using aspects of the present disclosure.

[0062] It should be understood that the present disclosure also provides pharmaceutical compositions comprising any of the compounds described herein in combination with at least one pharmaceutically acceptable excipient or carrier.

[0063] As used herein, the term "pharmaceutical composition" refers to a formulation containing a compound of the present disclosure in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or unit dosage form. The unit dosage form may be in any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a vial. The amount of active ingredient (e.g., a formulation of the disclosed compound or its salt, hydrate, solvate, or isomer) in a unit dose composition is an effective amount and varies according to the specific treatment involved. Those skilled in the art will understand that routine variations in dosage may be necessary depending on the age and condition of the subject. Dosage also varies depending on the route of administration. Various routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and any required preservatives, buffers, or propellants.

[0064] As used herein, the term "pharmaceutically acceptable" refers to compounds, anions, cations, materials, compositions, carriers, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, and that are within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0065] As used herein, the term "pharmaceutically acceptable excipient" means an excipient that is generally safe, non-toxic, and not biologically or otherwise undesirable and is useful in preparing pharmaceutical compositions, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. As used in the specification and claims, "pharmaceutically acceptable excipient" includes both one and more than one such excipient.

[0066] It should be understood that the pharmaceutical compositions of the present disclosure are formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., ingestion), inhalation, transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; an antimicrobial agent such as benzyl alcohol and methylparaben; an antioxidant such as ascorbic acid and sodium bisulfite; a chelating agent such as ethylenediaminetetraacetic acid; a buffer such as acetate, citrate, and phosphate; and an agent for adjusting osmolality such as sodium chloride or dextrose. pH can be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. Parenteral preparations can be enclosed in glass or plastic ampoules, disposable syringes, or multiple-dose vials.

[0067] It should be understood that the compound or pharmaceutical composition of the present disclosure can be administered to a subject by many of the well-known methods currently used in chemotherapy treatment.For example, the compound of the present disclosure can be injected into the bloodstream or body cavity, can be taken orally, or can be applied through the skin with a patch.The selected dose should be sufficient to constitute effective treatment, but not so high as to cause unacceptable side effects.The disease state (e.g., the disease or disorder disclosed herein) and the subject's health condition should be closely monitored during and for a reasonable period after treatment.

[0068] As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that treats, ameliorates, or prevents a specified disease or condition, or that exhibits a detectable therapeutic or inhibitory effect. This effect can be detected by any assay method known in the art. The precise effective amount for a subject will vary depending on the subject's weight, size, and health, the nature and extent of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation, which is within the skill and judgment of the clinician.

[0069] A "therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject being treated.

[0070] It is understood that for any compound, the therapeutically effective amount can be initially estimated either in cell culture assays, e.g., tumor cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined using standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 / ED 50 Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage can vary within this range depending on the dosage form used, the sensitivity of the subject, and the route of administration.

[0071] Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors that may be taken into consideration include the severity of the disease state, the subject's general health, the subject's age, weight, and sex, diet, time and frequency of administration, drug combination(s), reaction sensitivity, and tolerance / response to therapy.

[0072] The pharmaceutical composition containing the active compound of the present disclosure can be prepared by a generally known method, for example, by conventional mixing, dissolving, granulating, dragee making, suspending, emulsifying, encapsulating, encapsulating or lyophilizing process.The pharmaceutical composition can be formulated by a conventional method using one or more pharmaceutically acceptable carriers, including excipients and / or auxiliary agents that facilitate the processing of active compound into pharmaceutically usable preparations.Of course, the appropriate formulation depends on the selected route of administration.

[0073] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and fluid to the extent that easy syringability exists. The composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols (such as mannitol and sorbitol), and sodium chloride in the composition. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

[0074] Sterile injectable solution can be prepared by incorporating the required amount of active compound into a suitable solvent with one or a combination of the above-listed ingredients as needed, and then sterilize by filtration.Generally, dispersion is prepared by incorporating active compound into a sterile vehicle that contains a basic dispersion medium and other ingredients required from the above-listed ingredients.For the preparation of sterile powder for sterile injectable solution, the preparation method is vacuum drying and freeze-drying, which produces a powder containing active compound and any additional desired ingredients from its previously sterile-filtered solution.

[0075] Oral compositions generally contain an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with an excipient and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, in which the compound in the fluid carrier is orally applied, allowed to flow in the mouth, and then expectorated or swallowed. Pharmaceutically compatible binders and / or adjuvants can be included as part of the composition. Tablets, pills, capsules, troches, etc. may contain any of the following ingredients: a binder such as microcrystalline cellulose, gum tragacanth, or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetener such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring, or compounds of a similar nature.

[0076] For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.

[0077] Systemic administration can also be via transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels, or creams, as generally known in the art.

[0078] The active compounds can be prepared in pharmaceutically acceptable carriers that prevent the compound from being rapidly removed from the body, such as controlled-release formulations, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, can be used. Methods for preparing such formulations will be apparent to those skilled in the art. Materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells using monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0079] For ease of administration and dosage uniformity, it is particularly advantageous to formulate oral or parenteral compositions in dosage unit form.The unit dosage form used herein refers to a physically separate unit that is suitable as a unitary dosage for treating a subject; each unit contains a predetermined amount of active compound, calculated to produce desired therapeutic effect in association with required pharmaceutical carrier.The specification of the unit dosage form of the present disclosure is determined and directly depends on the unique characteristics of active compound and the specific therapeutic effect that is to be achieved.

[0080] In therapeutic applications, dosages of pharmaceutical compositions used in accordance with the present disclosure will vary depending on, among other factors, the agent, the age, weight, and clinical condition of the recipient subject, and the experience and judgment of the clinician or medical professional administering the treatment, which will affect the selected dosage. Generally, the dose should be sufficient to alleviate, preferably cause regression, and preferably cause complete regression of the symptoms of the diseases or disorders disclosed herein. An effective amount of a pharmaceutical agent is one that provides an objectively identifiable improvement as noted by a clinician or other qualified observer. Improved survival and growth indicate regression. As used herein, the term "dosage effective manner" refers to the amount of active compound to achieve a desired biological effect in a subject or cell.

[0081] It will be appreciated that the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0082] For compounds of the present disclosure that are capable of further forming salts, it should be understood that all of these forms are also contemplated within the scope of the claimed disclosure.

[0083] As used herein, the term "pharmaceutically acceptable salts" refers to derivatives of the compounds of the present disclosure, where the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, etc. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound, formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycollyarsanilic acid, hexylresorcinic acid, hydrabamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, and the like. The preferred carboxylic acids include, but are not limited to, those derived from inorganic and organic acids selected from acetic acid, isethionic acid, lactic acid, lactobionic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and commonly occurring amino acids such as glycine, alanine, phenylalanine, arginine, and the like.

[0084] In some embodiments, the pharmaceutically acceptable salt is a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a diethylamine salt, a choline salt, a meglumine salt, a benzathine salt, a tromethamine salt, an ammonia salt, an arginine salt, or a lysine salt.

[0085] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, etc. The present disclosure also encompasses salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, alkaline earth ion, or aluminum ion, or when coordinated with an organic base, e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc. It is understood that in the salt form, the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, for example, 3:1, 2:1, 1:2, or 1:3.

[0086] It should be understood that all references to pharmaceutically acceptable salts include the solvent addition forms (solvates) of the same salt as defined herein.

[0087] The compound, or a pharmaceutically acceptable salt thereof, may be administered orally, nasally, transdermally, pulmonary, inhalation, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.

[0088] Salts can be formed, for example, between an anion and a positively charged group (e.g., amino) on a substituted compound disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).

[0089] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between a cation on a substituted compound disclosed herein and a negatively charged group (e.g., a carboxylate). Suitable cations include sodium, potassium, magnesium, calcium, and ammonium cations such as tetramethylammonium or diethylamine. The substituted compounds disclosed herein also include salts thereof containing a quaternary nitrogen atom.

[0090] It should be understood that the compounds of the present disclosure, for example, salts of the compounds, can exist in either hydrated or non-hydrated (anhydrous) form, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.

[0091] As used herein, the term "solvate" refers to a solvent addition form that contains either stoichiometric or non-stoichiometric amounts of solvent.Some compounds have the tendency to trap a certain molar ratio of solvent molecules in the crystalline solid state, thereby forming a solvate.When the solvent is water, the solvate formed is a hydrate, and when the solvent is alcohol, the solvate formed is an alcoholate.A hydrate is formed by the combination of one or more water molecules with one molecule of a substance, where water retains its molecular state as HO.

[0092] As used herein, the term "analog" refers to a compound that is structurally similar to another but differs slightly in composition (such as the replacement of one atom with an atom of a different element or the presence of a particular functional group, or the replacement of one functional group with another). Thus, an analog is a compound that is similar or equivalent in function and appearance, but not in structure or origin, to the reference compound.

[0093] As used herein, the term "derivative" refers to compounds that have a common core structure and are substituted with various groups as described herein.

[0094] As used herein, the term "bioisostere" refers to a compound resulting from the exchange of an atom or group of atoms with another, broadly similar atom or group of atoms. The goal of bioisostere replacement is to create a new compound with similar biological properties as the parent compound. Bioisostere replacement can be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonamides, tetrazoles, sulfonates, and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.

[0095] It is also to be understood that a particular compound of any one of the formulas disclosed herein can exist in solvated, e.g., hydrated, and unsolvated forms. Suitable pharmaceutically acceptable solvates are hydrates, e.g., hemihydrate, monohydrate, dihydrate, or trihydrate.

[0096] Compounds of any one of the formulas disclosed herein can exist in several different tautomeric forms, and references to compounds of formulas (I) and (II) include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms and only one is specifically described or shown, all other compounds are nevertheless encompassed by formulas (I) and (II). Examples of tautomeric forms include keto-, enol-, and enolate-forms of the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enithiol, and nitro / acintro. [ka]

[0097] A compound of any one of the formulas disclosed herein containing an amine functional group can also form an N-oxide. Reference herein to a compound of formula (I) or (II) containing an amine functional group also includes the N-oxide. When a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form an N-oxide. Specific examples of N-oxides are the N-oxides of tertiary amines or nitrogen atoms of nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., a peroxycarboxylic acid), see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 1977. More specifically, N-oxides can be prepared by the procedure of L.W. Deady (see, for example, Syn. Comm. 1977, 7, 509-514), in which an amine compound is reacted with meta-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.

[0098] The compounds of any one of the formulas disclosed herein can be administered in the form of prodrugs, which are decomposed in the human or animal body to release the compounds of the present disclosure. Prodrugs can be used to modify the physical properties and / or pharmacokinetic properties of the compounds of the present disclosure. Prodrugs can be formed when the compounds of the present disclosure contain a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents in the ester or amide group of any one of the formulas disclosed herein.

[0099] As used herein, the term "isomerism" means compounds that have the same molecular formula but differ in the sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers." Stereoisomers that are not mirror images of one another are termed "diastereomers," and stereoisomers that are non-superimposable mirror images of each other are termed "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual optical isomeric forms of opposite chirality is termed a "racemic mixture."

[0100] As used herein, the term "chiral center" refers to a carbon atom bonded to four non-identical substituents.

[0101] As used herein, the term "chiral isomer" means a compound having at least one chiral center. Compounds having more than one chiral center can exist as individual diastereomers or as a mixture of diastereomers, termed a "diastereomeric mixture." When one chiral center is present, a stereoisomer can be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked according to the Sequence Rule of Cahn, Ingold and Prelog (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; Errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).

[0102] As used herein, the term "geometric isomer" refers to diastereomers that owe their existence to hindered rotation about a double bond or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are distinguished in their names by the prefixes cis and trans or Z and E, which indicate whether the groups are on the same or opposite sides of a double bond in the molecule, according to the Cahn-Ingold-Prelog rules.

[0103] It is understood that the compounds of the present disclosure may be represented as different chiral or geometric isomers, and when a compound has chiral or geometric isomeric forms, all isomeric forms are intended to be included within the scope of the present disclosure, and it is understood that the naming of the compound does not mean that all isomers may have the same level of activity.

[0104] It is understood that the structures and other compounds discussed in this disclosure include all atropisomers thereof, and it is also understood that not all atropisomers may have the same level of activity.

[0105] As used herein, the term "atropisomer" refers to a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropisomers exist because of restricted rotation of large groups around a central bond. Such atropisomers typically exist as mixtures, although recent advances in chromatography have made it possible to isolate mixtures of two atropisomers in selected cases.

[0106] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by the switching of adjacent conjugated double bonds. Tautomers exist as a mixture of tautomeric sets in solution. In solutions where tautomerization is possible, a chemical equilibrium of tautomers is reached. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertible by tautomerism is called tautomerism. Of the various types of tautomerism possible, two are commonly observed: keto-enol tautomerism, in which a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism occurs when an aldehyde group (-CHO) in a sugar molecule reacts with one of the hydroxyl groups (-OH) in the same molecule to give a cyclic (annular) form, such as that exhibited by glucose.

[0107] It is understood that the compounds of the present disclosure may be represented as different tautomeric forms. It is also understood that, where a compound has tautomeric forms, all tautomeric forms are intended to be included within the scope of the present disclosure, and the naming of a compound does not exclude any tautomeric form. It is understood that certain tautomers may have a higher level of activity than other tautomers.

[0108] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and stereoisomers that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of optical isomers is possible. An optical isomer can be characterized by the absolute configuration of its asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light and is designated as dextrorotatory or levorotatory (i.e., as (+)- or (-)-isomers, respectively). Chiral compounds can exist as either individual optical isomers or as mixtures thereof. A mixture containing equal proportions of optical isomers is called a "racemic mixture."

[0109] The compounds of the present disclosure may have one or more asymmetric centers, and therefore, such compounds can be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless otherwise specified, the description or naming of a particular compound in the present specification and claims is intended to include both individual optical isomers and their racemic or other mixtures. Methods for determining stereochemistry and separating stereoisomers are well known in the art, for example, by synthesis from optically active starting materials or by resolution of racemic forms (see the discussion in Chapter 4 of "Advanced Organic Chemistry," 4th edition, J. March, John Wiley and Sons, New York, 2001). Some of the compounds of the present disclosure may have geometric isomeric centers (E isomers and Z isomers).

[0110] Thus, the present disclosure includes compounds of any one of the formulas disclosed herein as defined herein when made available by organic synthesis and made available in the human or animal body by cleavage of the prodrug. Thus, the present disclosure also includes compounds of any one of the formulas disclosed herein produced by organic synthetic means, as well as such compounds produced in the human or animal body by metabolism of precursor compounds, and compounds of any one of the formulas disclosed herein can be synthetically produced compounds or metabolically produced compounds.

[0111] Suitable pharmaceutically acceptable prodrugs of a compound of any one of the formulae disclosed herein are those that, based on sound medical judgment, are suitable for administration to a subject without undesirable pharmacological activity and without undue toxicity. Various forms of prodrugs are described, for example, in the following documents: a) Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard, pp. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al. al., Chem. Pharm. Bull., 32, 692 (1984), g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACS Symposium Series, Volume 14, and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0112] Suitable pharmaceutically acceptable prodrugs of the compounds of any one of the formulas disclosed herein having a hydroxy group are, for example, in vivo cleavable esters or ethers thereof. The in vivo cleavable esters or ethers of the compounds of any one of the formulas disclosed herein containing a hydroxy group are, for example, pharmaceutically acceptable esters or ethers that are cleaved in a subject to generate the parent hydroxy compound. Suitable pharmaceutically acceptable ester-forming groups for the hydroxy group include inorganic esters such as phosphate esters (including phosphoramido cyclic esters). Further suitable pharmaceutically acceptable ester-forming groups for the hydroxy group include C1-C esters such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. 10 C1-C groups such as alkanoyl groups and ethoxycarbonyl groups 10 Examples of suitable phenylacetyl and benzoyl ring substituents include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C-C alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether-forming groups for hydroxy groups include α-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl.

[0113] Suitable pharmaceutically acceptable prodrugs of a compound of any one of the formulae disclosed herein having a carboxy group include, for example, an in vivo cleavable amide thereof, an amine such as ammonia, a C group such as methylamine, etc. 1-4Alkylamines, (C1-C4 alkyl)2 amines, for example, dimethylamine, N-ethyl-N-methylamine or diethylamine, C1-C4 alkoxy-C2-C4 alkylamines such as 2-methoxyethylamine, phenyl-C1-C4 alkylamines such as benzylamine, and amides formed with amino acids or esters thereof, such as glycine.

[0114] Suitable pharmaceutically acceptable prodrugs of a compound of any one of the formulae disclosed herein having an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example, C1-C2 acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. 10 Included are amides formed with alkanoyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C1-C4 alkyl)piperazin-1-ylmethyl.

[0115] The dosage regimen utilizing the compound is selected according to various factors, including the type, species, age, weight, sex, and medical condition of the subject, the severity of the condition being treated, the route of administration, the subject's renal and hepatic function, and the particular compound or salt thereof used. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progression of the condition. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to counter or stop the progression of the condition.

[0116] Techniques for formulation and administration of the disclosed compounds of this disclosure are described in Remington: The Science and Practice of Pharmacy, 1999. thEdition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents, and sterile aqueous or organic solutions. The compound is present in such pharmaceutical compositions in an amount sufficient to provide the desired dosage within the range described herein.

[0117] Unless otherwise indicated, all percentages and ratios used herein are by weight. Other features and advantages of the present disclosure are apparent from the different examples. The examples provided illustrate different components and methodologies useful for implementing the present disclosure. These examples do not limit the claimed disclosure. Based on the present disclosure, one skilled in the art can identify and employ other components and methodologies useful for implementing the present disclosure.

[0118] In the synthetic schemes described herein, compounds may be depicted in one specific configuration for simplicity. Such specific configurations should not be interpreted as limiting the present disclosure to one or more isomers, tautomers, positional isomers, or stereoisomers, nor do they exclude mixtures of isomers, tautomers, positional isomers, or stereoisomers. However, it should be understood that a given isomer, tautomer, positional isomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, positional isomer, or stereoisomer.

[0119] All publications and patent documents cited herein are incorporated by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date thereof. While the present disclosure has now been described by way of written description, those skilled in the art will recognize that the present disclosure can be practiced in various embodiments, and that the following foregoing description and examples are for illustrative purposes only and are not intended to limit the scope of the claims that follow.

[0120] As used herein, the phrase "compounds of the present disclosure" refers generically and specifically to those compounds disclosed herein. Compounds of the Disclosure

[0121] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently selected from halogen, hydroxy, cyano, -COOH, -C(O)-C1-C6 alkyl, -C(O)O-C1-C6 alkyl, C1-C7 alkyl, C1-C8 heteroalkyl, C 1-7 Alkoxy-heterocycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -(CH2) 0-2 selected from the group consisting of -C3-C8 cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, NH, NH(C1-C6 alkyl), N(C1-C6 alkyl), -NHC(O)-C1-C6 alkyl, -N(C1-C6 alkyl)-C(O)-C1-C6 alkyl, -C(O)-NH, -C(O)-NH(C1-C6 alkyl), and -C(O)-N(C1-C6 alkyl), wherein alkyl, alkenyl, alkynyl, and alkoxy are optionally substituted with one or more halogen, hydroxyl, or NH, and cycloalkyl and heterocycloalkyl are optionally substituted with one or more halogen, hydroxyl, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, or NH; or Two R on the same carbon 6 can be taken together as keto (=O) or Two R6s together form C 1-7 Forming an alkylene each R7 independently represents halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; R 16 But, H, Halo, C1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R 17 But, H, Halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein the compound is cycloalkyl, or heterocycloalkyl.

[0122] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; R 16 But, H, Halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R 17 But, H, Halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein the compound is cycloalkyl, or heterocycloalkyl.

[0123] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; R 16 is H, R 17 is H, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0124] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; R 16 But, H, Halo, C 1-7 alkyl, or OR5; R 17 But, H, Halo, C 1-7 alkyl, or OR5, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0125] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is nitrogen-containing heterocycloalkyl or NRR, where the nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently H, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 haloalkoxy, R 16 But, H, Halo, C 1-7 alkyl, OR5, or N(R5)2; R 17 But, H, Halo, C 1-7alkyl, OR5, or N(R5)2, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0126] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is nitrogen-containing heterocycloalkyl or NRR, where the nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently H, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C1-7 haloalkoxy, R 16 is H, R 17 is H, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0127] In some embodiments, the present disclosure provides, inter alia, compounds of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a nitrogen-containing heterocycloalkyl, which contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently H, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 haloalkoxy, R 16 But, H, Halo, C 1-7alkyl, or OR5; R 17 But, H, Halo, C 1-7 alkyl, or OR5, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0128] In some embodiments, the present disclosure provides, inter alia, a compound of formula (II): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7Forming an alkylene Each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 Provided is the compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein alkyl is optionally substituted with OH.

[0129] In some embodiments, the present disclosure provides, inter alia, a compound of formula (II): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is nitrogen-containing heterocycloalkyl or NRR, where the nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein the compound is haloalkoxy.

[0130] In some embodiments, the present disclosure provides, inter alia, a compound of formula (II): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a nitrogen-containing heterocycloalkyl, which contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene Each R7 is independently halo or C 1-7or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein R is alkyl.

[0131] In some embodiments, the present disclosure provides, inter alia, a compound of formula (II): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a nitrogen-containing heterocycloalkyl, which contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene Each R7 is independently halo or C 1-7 or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein R is alkyl.

[0132] For compounds of formula (I) or (II), A, R1, R2, R3, R4, R5, R6, and R7 can each be selected from the groups described herein, where applicable, and it is understood that any group described herein for any of A, R1, R2, R3, R4, R5, R6, and R7 can be combined with any group described herein for one or more of the remainder of A, R1, R2, R3, R4, R5, R6, and R7, where applicable.

[0133] In some embodiments, A is a nitrogen-containing heterocycloalkyl, the nitrogen-containing heterocycloalkyl containing 1 or 2 nitrogen ring atoms and optionally substituted with 1, 2, 3, or 4 R6 and attached to formula (I) or (II) by one of its nitrogen atoms, and each R6 is independently selected from the group consisting of C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forms an alkylene.

[0134] In some embodiments, each R6 is independently C 1-7 Alkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1- In some embodiments, each R6 is independently methyl, ethyl, isopropyl, methoxy-azetidinyl, or pyrrolidinyl, or two R6 together form ethylene or propylene. In some embodiments, two R6 together form C 1-7 Forms an alkylene.

[0135] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NR1R2, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0136] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0137] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0138] In some embodiments, A is a saturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0139] In some embodiments, A is a saturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0140] In some embodiments, A is a partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0141] In some embodiments, A is a partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0142] In some embodiments, A is a saturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0143] In some embodiments, A is a saturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0144] In some embodiments, A is a partially unsaturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0145] In some embodiments, A is a partially unsaturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0146] In some embodiments, A is a saturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0147] In some embodiments, A is a saturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0148] In some embodiments, A is a partially unsaturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0149] In some embodiments, A is a partially unsaturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0150] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0151] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0152] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0153] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0154] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0155] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0156] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-5 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0157] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-5 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0158] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0159] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0160] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0161] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0162] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0163] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0164] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0165] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0166] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0167] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0168] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0169] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0170] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0171] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0172] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0173] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0174] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 9-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0175] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 9-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0176] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 8-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0177] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 8-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0178] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0179] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0180] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0181] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0182] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0183] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0184] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.

[0185] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.

[0186] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 1, 2, 3, or 4 R6.

[0187] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 1, 2, or 3 R6.

[0188] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 1 R6.

[0189] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 2 R6.

[0190] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 3 R6.

[0191] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains one nitrogen ring atom.

[0192] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains two nitrogen ring atoms.

[0193] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains one nitrogen ring atom and is optionally substituted with 1, 2, 3, or 4 R6.

[0194] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains two nitrogen ring atoms and is optionally substituted with 1, 2, or 3 R6.

[0195] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains one nitrogen ring atom and is substituted with 1, 2, 3, or 4 R6.

[0196] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains two nitrogen ring atoms and is substituted with 1, 2, or 3 R6.

[0197] In some embodiments, A is piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl, each optionally substituted with 1, 2, 3, or 4 R6.

[0198] In some embodiments, A is [ka] wherein: Y is absent, N or CH; R9 is hydrogen, C 1-7 Alkyl, or (CH2) m -NR 14 R 15 and R 10 is hydrogen or C 1-7 is alkyl, R 11 is hydrogen or C 1-7 is alkyl, R 12 is hydrogen or C 1-7 is alkyl, R 13 is hydrogen or C 1-7 is alkyl, Each R 14 and R 15 are independently hydrogen, C 1-7 Alkyl, and C 3-8 is cycloalkyl, n is 0, 1, or 2; m is 0, 1, or 2, Or R9 and R 10 Together, C 1-7 Forming an alkylene, or Or R9 and R 12 Together, C 1-7 Forming an alkylene, or Or R 10 and R 11 Together, C 2-7 Alkylene, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 12 Together, C 1-7 Alkylene, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 14 Together, C 1-7 Forming an alkylene, or Or R 12and R 13 Together, C 2-7 Forming an alkylene, or Or R 12 and R 14 Together, C 1-7 Forming an alkylene, or Or R 14 and R 15 Together, C 2-7 Forms an alkylene, which is C 1-7 Optionally substituted with alkoxy.

[0199] In some embodiments, Y is N or CH. In some embodiments, Y is absent. In some embodiments, Y is N. In some embodiments, Y is CH.

[0200] In some embodiments, R9 is hydrogen, C 1-7 Alkyl, or (CH2) m -NR 14 R 15 In some embodiments, R is hydrogen. In some embodiments, R is C 1-7 In some embodiments, R is (CH) m -NR 14 R 15 is.

[0201] In some embodiments, R 10 is hydrogen or C 1-7 In some embodiments, R 10 is hydrogen. In some embodiments, C 1-7 Alkyl.

[0202] In some embodiments, R 11 is hydrogen or C 1-7 In some embodiments, R 11 is hydrogen. In some embodiments, C 1-7 Alkyl.

[0203] In some embodiments, R12 is hydrogen or C 1-7 In some embodiments, R 12 is hydrogen. In some embodiments, C 1-7 Alkyl.

[0204] In some embodiments, R 13 is hydrogen or C 1-7 In some embodiments, R 13 is hydrogen. In some embodiments, C 1-7 Alkyl.

[0205] In some embodiments, R 14 is hydrogen, C 1-7 Alkyl, or C 3-8 In some embodiments, R 14 is hydrogen. In some embodiments, R 14 is C 1-7 In some embodiments, R 14 is C 3-8 It is cycloalkyl.

[0206] In some embodiments, R 15 is hydrogen, C 1-7 Alkyl, or C 3-8 In some embodiments, R 15 is hydrogen. In some embodiments, R 15 is C 1-7 In some embodiments, R 15 is C 3-8 It is cycloalkyl.

[0207] In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0208] In some embodiments, m is 0, 1, or 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2.

[0209] In some embodiments, R and R 10 Together, C 1-7 Forms an alkylene.

[0210] In some embodiments, R and R 12 Together, C 1-7 Forms an alkylene.

[0211] In some embodiments, R 10 and R 11 Together, C 2-7 Alkylene, or C 1-7 In some embodiments, R 10 and R 11 Together, C 2-7 Forms an alkylene.

[0212] In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 Forms a 6-membered heterocycloalkyl optionally substituted with alkyl.

[0213] In some embodiments, R10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 Forms a 6-membered heterocycloalkyl substituted with alkyl.

[0214] In some embodiments, R 10 and R 12 Together, C 1-7 Alkylene, or C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 Forms an alkylene.

[0215] In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7Forms a 6-membered heterocycloalkyl optionally substituted with alkyl.

[0216] In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 Forms a 6-membered heterocycloalkyl substituted with alkyl.

[0217] In some embodiments, R 10 and R 14 Together, C 1-7 Forms an alkylene.

[0218] In some embodiments, R 12 and R 13 Together, C 2-7 Forms an alkylene.

[0219] In some embodiments, R 12 and R 14 Together, C 1-7 Forms an alkylene.

[0220] In some embodiments, R 14 and R 15 Together, C 2-7 Forms an alkylene.

[0221] In some embodiments, R 14 and R 15 Together, C 2-7Forms an alkylene, which is C 1-7 Optionally substituted with alkoxy.

[0222] In some embodiments, R 14 and R 15 Together, C 2-7 Forms an alkylene, which is C 1-7 Substituted with alkoxy.

[0223] In some embodiments, Y is CH and R is (CH) m -NR 14 R 15 is.

[0224] In some embodiments, R9 is hydrogen, pyrrolidinyl, or methoxy-azetidinyl.

[0225] In some embodiments, R 10 is hydrogen, methyl, ethyl, or isopropyl.

[0226] In some embodiments, R 11 is hydrogen or methyl.

[0227] In some embodiments, R 12 is hydrogen or methyl.

[0228] In some embodiments, R and R 10 together to form propylene.

[0229] In some embodiments, R 10 and R 11 together to form ethylene.

[0230] In some embodiments, R 14 and R 15 together to form propylene or butylene.

[0231] In some embodiments, A is [ka] and In the formula, R9, R 10 , R 11 , R 12 , and R 13 is as defined in any one of the preceding claims, and R 16 is hydrogen or C 1-7 It is alkyl.

[0232]

[0233] In some embodiments, A is [ka] and In the formula, R9, R 10 , R 11 , R 12 , and R 13 is as defined in any one of the preceding claims, and R 16 is hydrogen or C 1-7 It is alkyl.

[0234] In some embodiments, R 16 is hydrogen or C 1-7 In some embodiments, R 16 is hydrogen. In some embodiments, R 16 is C 1-7 It is alkyl.

[0235] In some embodiments, A is [ka] is.

[0236] In some embodiments, A is [ka] is.

[0237]

[0238] In some embodiments, A is NR1R2.

[0239] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom.

[0240] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 R6.

[0241] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 1, 2, 3, or 4 R6.

[0242] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 1, 2, or 3 R6.

[0243] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 1 R6.

[0244] In some embodiments, R1 is a heterocycloalkyl containing one nitrogen ring atom, and the heterocycloalkyl is substituted with two R6.

[0245] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom and the heterocycloalkyl is substituted with 3 R6.

[0246] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom and the heterocycloalkyl is substituted with 4 R6.

[0247] In some embodiments, R2 is hydrogen, C 1-7 Alkyl, or C 3-8It is cycloalkyl.

[0248] In some embodiments, R2 is hydrogen or C 1-7 It is alkyl.

[0249] In some embodiments, R2 is hydrogen.

[0250] In some embodiments, R2 is C 1-7 In some embodiments, R2 is alkyl. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl. In some embodiments, R2 is propyl. In some embodiments, R2 is butyl. In some embodiments, R2 is pentyl. In some embodiments, R2 is hexyl. In some embodiments, R2 is heptyl. In some embodiments, R2 is isopropyl. In some embodiments, R2 is isobutyl. In some embodiments, R2 is isopentyl. In some embodiments, R2 is isohexyl. In some embodiments, R2 is secbutyl. In some embodiments, R2 is secpentyl. In some embodiments, R2 is sechexyl. In some embodiments, R2 is tertbutyl.

[0251] In some embodiments, R2 is C 3-8 In some embodiments, R2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

[0252] In some embodiments, R3 is H, halo, C 1-7 Alkyl, -OR5, -N(R5)2, C 3-8 It is cycloalkyl, or heterocycloalkyl.

[0253] In some embodiments, R3 is H, C 1-7 Alkyl, -OR5, -N(R5)2, C 3-8It is cycloalkyl, or heterocycloalkyl.

[0254] In some embodiments, R3 is H or C 1-7 It is alkyl.

[0255] In some embodiments, R3 is H.

[0256] In some embodiments, R3 is halo. In some embodiments, R3 is F, Cl, Br, or I. In some embodiments, R3 is F, Cl, or Br. In some embodiments, R3 is F or Cl. In some embodiments, R3 is F. In some embodiments, R3 is Cl. In some embodiments, R3 is Br. In some embodiments, R3 is I.

[0257] In some embodiments, R3 is C 1-7 In some embodiments, R3 is alkyl. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl. In some embodiments, R3 is propyl. In some embodiments, R3 is butyl. In some embodiments, R3 is pentyl. In some embodiments, R3 is hexyl. In some embodiments, R3 is heptyl. In some embodiments, R3 is isopropyl. In some embodiments, R3 is isobutyl. In some embodiments, R3 is isopentyl. In some embodiments, R3 is isohexyl. In some embodiments, R3 is secbutyl. In some embodiments, R3 is secpentyl. In some embodiments, R3 is sechexyl. In some embodiments, R3 is tertbutyl.

[0258] In some embodiments, R3 is -OR5 or -N(R5)2. In some embodiments, R3 is -OR5. In some embodiments, R3 is -N(R5)2.

[0259] In some embodiments, R3 is C 3-8 It is cycloalkyl or heterocycloalkyl.

[0260] In some embodiments, R3 is C 3-8 In some embodiments, R3 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

[0261] In some embodiments, R3 is heterocycloalkyl.

[0262] In some embodiments, R 4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, or S.

[0263] In some embodiments, R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N or O.

[0264] In some embodiments, R4 is aryl.

[0265] In some embodiments, R4 is aryl optionally substituted with 1, 2, or 3 R7.

[0266] In some embodiments, R4 is aryl substituted with 1, 2, or 3 R7. In some embodiments, R4 is aryl substituted with 1 R7. In some embodiments, R4 is aryl substituted with 2 R7. In some embodiments, R4 is aryl substituted with 3 R7.

[0267] In some embodiments, R4 is phenyl.

[0268] In some embodiments, R4 is phenyl optionally substituted with 1, 2, or 3 R7.

[0269] In some embodiments, R4 is phenyl substituted with 1, 2, or 3 R7. In some embodiments, R4 is phenyl substituted with 1 R7. In some embodiments, R4 is phenyl substituted with 2 R7. In some embodiments, R4 is phenyl substituted with 3 R7.

[0270] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S.

[0271] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O.

[0272] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N, O, and S.

[0273] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O.

[0274] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7.

[0275] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 optionally substituted R7.

[0276] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N, O, and S, wherein R4 is optionally substituted with 1, 2, or 3 R7.

[0277] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.

[0278] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.

[0279] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.

[0280] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.

[0281] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.

[0282] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.

[0283] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.

[0284] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.

[0285] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.

[0286] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.

[0287] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.

[0288] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with one R7.

[0289] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with two R7.

[0290] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with three R7.

[0291] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.

[0292] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.

[0293] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.

[0294] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.

[0295] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.

[0296] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.

[0297] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.

[0298] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.

[0299] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.

[0300] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.

[0301] In some embodiments, R4 is imidazo[1,2-a]pyrazine, benzo[d]oxazole, triazolo-pyridazinyl, or imidazo[1,2-a]pyrazine, each optionally substituted with 1, 2, 3, or 4 R7.

[0302] In some embodiments, R4 is [ka] is.

[0303] In some embodiments, R4 is [ka] is.

[0304] In some embodiments, R4 is [ka] is.

[0305] In some embodiments, R4 is [ka] is.

[0306] In some embodiments, each R5 is independently C 1-7 Alkyl, C 3-8 It is cycloalkyl, or heterocycloalkyl.

[0307] In some embodiments, each R5 is independently C 1-7In some embodiments, each R is independently alkyl. In some embodiments, each R is independently methyl. In some embodiments, each R is independently ethyl. In some embodiments, each R is independently propyl. In some embodiments, each R is independently butyl. In some embodiments, each R is independently pentyl. In some embodiments, each R is independently hexyl. In some embodiments, each R is independently heptyl. In some embodiments, each R is independently isopropyl. In some embodiments, each R is independently isobutyl. In some embodiments, each R is independently isopentyl. In some embodiments, each R is independently isohexyl. In some embodiments, each R is independently secbutyl. In some embodiments, each R is independently secpentyl. In some embodiments, each R is independently sechexyl. In some embodiments, each R is independently tertbutyl.

[0308] In some embodiments, each R5 is independently C 3-8 It is cycloalkyl or heterocycloalkyl.

[0309] In some embodiments, each R5 is independently C 3-8 In some embodiments, R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

[0310] In some embodiments, each R5 is independently heterocycloalkyl.

[0311] In some embodiments, each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C1-7 Forms an alkylene.

[0312] In some embodiments, each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 It is an alkoxy-heterocycloalkyl.

[0313] In some embodiments, each R6 is independently C 1-7 In some embodiments, each R is independently alkyl. In some embodiments, each R is independently methyl. In some embodiments, each R is independently ethyl. In some embodiments, each R is independently propyl. In some embodiments, each R is independently butyl. In some embodiments, each R is independently pentyl. In some embodiments, each R is independently hexyl. In some embodiments, each R is independently heptyl. In some embodiments, each R is independently isopropyl. In some embodiments, each R is independently isobutyl. In some embodiments, each R is independently isopentyl. In some embodiments, each R is independently isohexyl. In some embodiments, each R is independently secbutyl. In some embodiments, each R is independently secpentyl. In some embodiments, each R is independently sechexyl. In some embodiments, each R is independently tertbutyl.

[0314] In some embodiments, each R6 is independently amino or amino-C 1-7 It is alkyl.

[0315] In some embodiments, each R6 is independently amino. In some embodiments, R6 is independently amino-C 1-7 It is alkyl.

[0316] In some embodiments, each R6 is independently C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 It is an alkoxy-heterocycloalkyl.

[0317] In some embodiments, each R6 is independently C 3-8 It is cycloalkyl.

[0318] In some embodiments, each R is independently selected from heterocycloalkyl and C 1-7 It is an alkoxy-heterocycloalkyl.

[0319] In some embodiments, each R is independently heterocycloalkyl. In some embodiments, each R is independently C 1-7 It is an alkoxy-heterocycloalkyl.

[0320] In some embodiments, two R6 together represent C 1-7 Forms an alkylene.

[0321] In some embodiments, each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy C 1-7 Haloalkoxy, or C 3-8 It is cycloalkyl.

[0322] In some embodiments, each R7 is independently halo or cyano.

[0323] In some embodiments, each R7 is independently halo. In some embodiments, each R7 is independently selected from F, Cl, Br, and I. In some embodiments, each R7 is independently selected from F, Cl, or Br. In some embodiments, each R7 is independently F. In some embodiments, each R7 is independently Cl. In some embodiments, each R7 is independently Br. In some embodiments, each R7 is independently I.

[0324] In some embodiments, each R7 is independently cyano.

[0325] In some embodiments, each R7 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy C 1-7 Haloalkoxy, or C 3-8 It is cycloalkyl.

[0326] In some embodiments, each R7 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 It is derived from haloalkoxy.

[0327] In some embodiments, each R7 is independently C 1-7In some embodiments, each R7 is independently alkyl. In some embodiments, each R7 is independently methyl. In some embodiments, each R7 is independently ethyl. In some embodiments, each R7 is independently propyl. In some embodiments, each R7 is independently butyl. In some embodiments, each R7 is independently pentyl. In some embodiments, each R7 is independently hexyl. In some embodiments, each R7 is independently heptyl. In some embodiments, each R7 is independently isopropyl. In some embodiments, each R7 is independently isobutyl. In some embodiments, each R7 is independently isopentyl. In some embodiments, each R7 is independently isohexyl. In some embodiments, each R7 is independently secbutyl. In some embodiments, each R7 is independently secpentyl. In some embodiments, each R7 is independently sechexyl. In some embodiments, each R7 is independently tertbutyl.

[0328] In some embodiments, each R7 is independently C optionally substituted with OH. 1-7 It is alkyl.

[0329] In some embodiments, each R7 is independently a C substituted with OH. 1-7In some embodiments, each R7 is independently methyl substituted with OH. In some embodiments, each R7 is independently ethyl substituted with OH. In some embodiments, each R7 is independently propyl substituted with OH. In some embodiments, each R7 is independently butyl substituted with OH. In some embodiments, each R7 is independently pentyl substituted with OH. In some embodiments, each R7 is independently hexyl substituted with OH. In some embodiments, each R7 is independently heptyl substituted with OH. In some embodiments, each R7 is independently isopropyl substituted with OH. In some embodiments, each R7 is independently isobutyl substituted with OH. In some embodiments, each R7 is independently isopentyl substituted with OH. In some embodiments, each R7 is independently isohexyl substituted with OH. In some embodiments, each R7 is independently secbutyl substituted with OH. In some embodiments, each R7 is independently sec-pentyl substituted with OH. In some embodiments, each R7 is independently sec-hexyl substituted with OH. In some embodiments, each R7 is independently tert-butyl substituted with OH.

[0330] In some embodiments, each R7 is independently C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 It is haloalkoxy.

[0331] In some embodiments, each R7 is independently C 1-7 It is haloalkyl.

[0332] In some embodiments, each R7 is independently C 1-7 It is an alkoxy.

[0333] In some embodiments, each R7 is independently C 1-7 It is haloalkoxy.

[0334] In some embodiments, each R7 is independently C 3-8 It is cycloalkyl.

[0335] For clarity, in all embodiments where two variables are taken together to form an alkylene, those groups, together with the atoms to which they are attached and possible intervening atoms, form a ring. This ring may be cycloalkyl or heterocyclyl depending on the point of attachment of the variables, but the variable itself is an alkylene and therefore does not contain any heteroatoms of its own.

[0336] In some embodiments, the compound is selected from the compounds set forth in Table 1 and their pharmaceutically acceptable salts, solvates, or prodrugs.

[0337] In some embodiments, the compound is selected from the compounds set forth in Table 1 and their pharmaceutically acceptable salts.

[0338] In some embodiments, the compound is selected from prodrugs of the compounds set forth in Table 1 and pharmaceutically acceptable salts thereof.

[0339] In some embodiments, the compound is selected from the compounds set forth in Table 1 or from this disclosure.

[0340] In some embodiments, the compound is selected from the compounds set forth in Table 1.

[0341] For the avoidance of doubt, it is to be understood that, as used herein, when a group is modified by "as described herein," that group encompasses the broadest definition on the first occurrence, as well as each and every specific definition for that group.

[0342] The various functional groups and substituents comprising the compounds of formula (I) or (II) are typically selected so that the molecular weight of the compound does not exceed 1000 daltons. More typically, the molecular weight of the compound is less than 900, e.g., less than 800, or less than 750, or less than 700, or less than 650 daltons. More conveniently, the molecular weight is less than 600, e.g., 550 daltons or less.

[0343] It will be understood that the compounds of any one of the formulae disclosed herein, and any pharmaceutically acceptable salts thereof, include all isomeric forms of stereoisomers and mixtures of stereoisomers of the compounds.

[0344] It should be understood that compounds of any formula described herein include the compound itself, as well as salts thereof, and solvates thereof, if applicable.

[0345] The in vivo effects of any one of the compounds of the formulas disclosed herein may be exerted in part by one or more metabolic products formed in the human or animal body after administration of any one of the compounds of the formulas disclosed herein.As described herein, the in vivo effects of any one of the compounds of the formulas disclosed herein may also be exerted by the metabolism of a precursor compound (prodrug).

[0346] Preferably, the present disclosure excludes any individual compound that does not have biological activity as defined herein.

[0347] Synthesis method By way of example only, schemes for preparing the small molecule splicing modulators (SMSMs) described herein are provided.

[0348] In some embodiments, a scheme for preparing SMSM is set forth herein in Scheme 1 below. [ka]

[0349] In some aspects, the disclosure provides methods of preparing the compounds of the disclosure.

[0350] In some aspects, the disclosure provides methods of preparing compounds comprising one or more of the steps described herein.

[0351] In some aspects, the present disclosure provides compounds that can be obtained by, are obtained by, or are obtained directly by the methods for preparing the compounds described herein.

[0352] In some aspects, the present disclosure provides intermediates described herein that are suitable for use in methods for preparing compounds described herein.

[0353] The compounds of the present disclosure may be prepared by any suitable technique known in the art. Specific processes for preparing these compounds are further described in the accompanying Examples.

[0354] In the descriptions of synthetic methods described herein and in any reference synthetic methods used to prepare starting materials, it is understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment, and work-up procedures, can be selected by one of ordinary skill in the art.

[0355] One skilled in the art of organic synthesis understands that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions employed.

[0356] It will be understood that during the synthesis of the compounds of the present disclosure in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituents to prevent their undesired reactions. Those skilled in the art will understand when such protection is necessary and how such protecting groups can be introduced and subsequently removed. For examples of protecting groups, see one of the many general textbooks on this subject, for example, "Protective Groups in Organic Synthesis" by Theodora Green (Publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to chemists of ordinary skill as suitable for removing the protecting group in question, and such methods will be selected to remove the protecting group while minimizing interference with groups elsewhere in the molecule. Thus, when reactants contain groups such as amino, carboxy, or hydroxy, it may be desirable to protect the group in some of the reactions described herein.

[0357] For example, suitable protecting groups for amino or alkylamino groups include, for example, acyl groups, such as alkanoyl groups (e.g., acetyl), alkoxycarbonyl groups (e.g., methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl), arylmethoxycarbonyl groups (e.g., benzyloxycarbonyl), or aroyl groups (e.g., benzoyl). The deprotection conditions for the above-mentioned protecting groups necessarily vary depending on the choice of protecting group. Thus, for example, acyl groups or aroyl groups, such as alkanoyl or alkoxycarbonyl groups, can be removed by hydrolysis using a suitable base, such as an alkali metal hydroxide, for example, lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butoxycarbonyl groups may be removed by treatment with a suitable acid, for example hydrochloric, sulfuric or phosphoric acid, or trifluoroacetic acid, and arylmethoxycarbonyl groups (such as benzyloxycarbonyl groups) may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid, for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or hydrazine.

[0358] Suitable protecting groups for hydroxyl groups include, for example, acyl groups, such as alkanoyl groups (e.g., acetyl), aroyl groups (e.g., benzoyl), or arylmethyl groups (e.g., benzyl). The deprotection conditions for the above-mentioned protecting groups necessarily vary depending on the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or aroyl groups, can be removed by hydrolysis using a suitable base, such as an alkali metal hydroxide, for example, lithium, sodium hydroxide, or ammonia. Alternatively, arylmethyl groups, such as benzyl groups, can be removed by hydrogenation over a catalyst, such as palladium on carbon.

[0359] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or ethyl group, which may be removed by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group, which may be removed by treatment with an acid, for example an organic acid, such as trifluoroacetic acid, or for example a benzyl group, which may be removed by hydrogenation over a catalyst such as palladium on carbon.

[0360] Once a compound of formula (I) or (II) has been synthesized by any one of the processes defined herein, the process may then further comprise the additional steps of (i) removing any protecting groups present, (ii) converting the compound of formula (I) to another compound of formula (I) or (II), (iii) forming a pharmaceutically acceptable salt, hydrate, or solvate thereof, and / or (iv) forming a prodrug thereof.

[0361] The resulting compounds of formula (I) or (II) can be isolated and purified using techniques well known in the art.

[0362] The reaction of the compounds is advantageously carried out in the presence of a suitable solvent, preferably inert under the respective reaction conditions. Examples of suitable solvents include hydrocarbons such as hexane, petroleum ether, benzene, toluene, or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform, or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), methyl tert-butyl ether (MTBE), or dioxane; ethylene glycol ethers, propylene ... Examples of suitable solvents include, but are not limited to, glycol ethers such as ethanol monomethyl or monoethyl ether, or ethylene glycol dimethyl ether (diglyme); ketones such as acetone, methyl isobutyl ketone (MIBK) or butanone; amides such as acetylamide, dimethylacetylamide, dimethylformamide (DMF) or N-methylpyrrolidinone (NMP); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or methyl acetate; or mixtures of such solvents, or mixtures with water.

[0363] The reaction temperature is preferably between about -100°C and 300°C, depending on the reaction step and conditions used.

[0364] The reaction time generally ranges from 1 minute to several days, depending on the reactivity of each compound and the reaction conditions. Suitable reaction times can be easily determined by methods known in the art, such as reaction monitoring. Based on the reaction temperature described above, suitable reaction times are generally within the range of 10 minutes to 48 hours.

[0365] Moreover, by utilizing the procedures described herein, in conjunction with ordinary skill in the art, additional compounds of the present disclosure can be readily prepared. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. As will be appreciated by those skilled in the art of organic synthesis, the compounds of the present disclosure are readily accessible by a variety of synthetic routes, some of which are illustrated in the accompanying examples. Those skilled in the art will readily recognize what types of reagents and reaction conditions to use and how to apply and adapt them, whenever necessary or useful, to obtain compounds of the present disclosure. Furthermore, some of the compounds of the present disclosure can be readily synthesized by reacting other compounds of the present disclosure under suitable conditions, for example, by applying standard synthetic methods such as reduction, oxidation, addition, or substitution reactions, to convert one specific functional group present in a compound of the present disclosure or a suitable precursor molecule to another functional group, which methods are well known to those skilled in the art. Similarly, those skilled in the art will apply synthetic protecting (or protecting) groups whenever necessary or useful. Suitable protecting groups, as well as methods for introducing and removing them, are well known to those skilled in the art of chemical synthesis and are described in more detail, for example, in P.G.M.Wuts, T.W. Greene, "Greene's Protective Groups in Organic Synthesis," 4th edition (2006) (John Wiley & Sons).

[0366] General routes for preparing the compounds of the present application are described herein.

[0367] Biological assays Once produced, compounds designed, selected, and / or optimized by the above methods can be characterized using a variety of assays known to those of skill in the art to determine whether the compounds have biological activity. For example, molecules can be characterized by conventional assays, including but not limited to, the assays described below, to determine whether they have the predicted activity, binding activity, and / or binding specificity.

[0368] Cell proliferation assay Various cancer cell lines, including K562, HL60, COLO201, COLO205, can be treated with compounds of the present disclosure to assess their effectiveness in inhibiting cell proliferation.

[0369] Test compounds may be diluted in duplicate and dispensed into assay plates. Positive and negative controls may be used (e.g., staurosporine). Frozen cell line stocks are prepared and cell suspensions dispensed into assay plates. After incubation, the luminescence (RLU) signal in each well may be recorded and converted to a percentage inhibition value using the signals in the negative and positive control standards. IC 50 The value can be determined by curve fitting in the Levenberg-Marquardt algorithm.

[0370] Pharmaceutical Compositions In some aspects, the present disclosure provides pharmaceutical compositions comprising a compound of the present disclosure as an active ingredient. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound of each of the formulas described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound selected from Table 1 or the present disclosure. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound selected from Table 1.

[0371] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product resulting directly or indirectly from combining the specified ingredients in the specified amounts. The compounds of the present disclosure can be formulated for oral administration in the form of tablets, capsules (each of which includes sustained- or time-release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, emulsions, etc. The compounds of the present disclosure can also be formulated for intravenous (bolus or intrafusion), intraperitoneal, topical, subcutaneous, intramuscular, or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.

[0372] The formulation of the present disclosure may be in the form of an aqueous solution containing an aqueous vehicle. The aqueous vehicle component may include water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from the group consisting of solubility enhancers, chelating agents, preservatives, isotonicity agents, viscosity / suspending agents, buffers, and pH adjusters, and mixtures thereof.

[0373] Any suitable solubility enhancer can be used. Examples of solubility enhancers include cyclodextrins such as those selected from the group consisting of hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, randomly methylated-β-cyclodextrin, ethylated-β-cyclodextrin, triacetyl-β-cyclodextrin, peracetylated-β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonio)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated-β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin, sulfobutyl ether, branched-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, randomly methylated-γ-cyclodextrin, and trimethyl-γ-cyclodextrin, and mixtures thereof.

[0374] Any suitable chelating agent can be used, examples of suitable chelating agents include those selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts, edetate disodium, edetate trisodium, and edetate tetrasodium, and mixtures thereof. Any suitable preservative can be used. Examples of preservatives include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetylpyridinium chloride, benzyl bromide, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric neodecanoate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, and butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.

[0375] The aqueous vehicle may also contain a tonicity agent to adjust tonicity (osmotic pressure), which may be selected from the group consisting of glycols (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and mixtures thereof.

[0376] The aqueous vehicle may also contain a viscosity / suspending agent. Suitable viscosity / suspending agents include those selected from the group consisting of cellulose derivatives such as methylcellulose, ethylcellulose, hydroxyethylcellulose, polyethylene glycol (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethylcellulose, hydroxypropylmethylcellulose, and crosslinked acrylic acid polymers (carbomers), such as acrylic acid polymers crosslinked with polyalkenyl ethers or divinyl glycol (Carbopols—e.g., Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974, and Carbopol 974P), and mixtures thereof.

[0377] To adjust the formulation to an acceptable pH (typically in the pH range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH modifier. The pH modifier is typically a mineral acid or metal hydroxide base selected from potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or basic pH modifiers are added to adjust the formulation to a target acceptable pH range. Therefore, depending on the formulation, it may not be necessary to use both an acid and a base; adding one of the acids or bases may be sufficient to bring the mixture to the desired pH range.

[0378] The aqueous vehicle may also contain a buffering agent to stabilize the pH. If used, the buffer is selected from the group consisting of phosphate buffers (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), borate buffers (such as boric acid or salts thereof including disodium tetraborate), citrate buffers (such as citric acid or salts thereof including sodium citrate), and ε-aminocaproic acid, and mixtures thereof.

[0379] The formulation may further comprise a wetting agent. Suitable types of wetting agents include those selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oil, polyoxyethylated sorbitan esters (polysorbates), polymers of oxyethylated octylphenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty acid esters, and polyoxyethylene fatty acid esters, and mixtures thereof.

[0380] According to a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound of the present disclosure as defined above, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0381] Compositions of the present disclosure may be in a form suitable for oral use (e.g., as tablets, troches, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as a finely divided powder or liquid aerosol), administration by insufflation (e.g., as a finely divided powder), or parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal, or intramuscular administration, or as a suppository for rectal administration).

[0382] The compositions of the present disclosure can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring agents, sweeteners, flavoring agents, and / or preservatives.

[0383] An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat or prevent, slow the progression of, and / or alleviate the symptoms associated with the disease or disorder referred to herein.

[0384] An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat, slow the progression of, and / or alleviate the symptoms associated with the disease or disorder referred to herein.

[0385] The size of a dose of a compound of formula (I) or (II) for therapeutic or prophylactic purposes will naturally vary depending on the nature and severity of the condition, the age and sex of the animal or subject, and the route of administration, in accordance with well-known medical principles.

[0386] How to use In one aspect, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating or preventing cancer.

[0387] In one aspect, the present disclosure provides a method for treating or preventing cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of a compound or pharmaceutical composition of the present disclosure. In some embodiments, the cancer is a liquid cancer. In some embodiments, the cancer is a leukemic cancer. In some embodiments, the cancer is leukemia or lymphoma. In some embodiments, the cancer is colorectal cancer, breast cancer, or prostate cancer. In some embodiments, the cancer is leukemia, acute myeloid leukemia, colon cancer, gastric cancer, acute monocytic leukemia, breast cancer, hepatocellular carcinoma, alveolar soft part sarcoma, myeloma, cutaneous melanoma, pancreatic cancer, adenocarcinoma, adenoiditis, adenoid cystic carcinoma, gastrointestinal stromal tumor, sarcoma, prostate adenocarcinoma, Hodgkin's lymphoma, ovarian cancer, non-Hodgkin's lymphoma, multiple myeloma, chronic myeloid leukemia, acute lymphoblastic leukemia, renal cell carcinoma, transitional cell carcinoma, colorectal cancer, chronic lymphocytic leukemia, anaplastic large cell lymphoma, kidney cancer, breast cancer, or cervical cancer.

[0388] In some embodiments, the cancer is a solid cancer or solid tumor. In some embodiments, the tumor is selected from the group consisting of adenocarcinoma, melanoma (e.g., metastatic melanoma), liver cancer (e.g., hepatocellular carcinoma, hepatoblastoma, liver cancer), prostate cancer (e.g., prostate adenocarcinoma, androgen-independent prostate cancer, androgen-dependent prostate cancer, prostate cancer), sarcoma (e.g., leiomyosarcoma, rhabdomyosarcoma), brain cancer (e.g., glioma, malignant glioma, astrocytoma, brainstem glioma, epithelioma, oligodendroglioma, non-neuronal tumor, acoustic neuroma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma, anaplastic astrocytoma, juvenile pilocytic astrocytoma, mixture of oligodendroglioma and astrocytoma elements), breast cancer (e.g., triple-negative breast cancer, metastatic breast cancer, breast cancer, breast sarcoma, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast carcinoma, mucinous breast carcinoma, tubular breast carcinoma, papillary breast carcinoma, inflammatory breast carcinoma), Paget's disease, juvenile Paget's disease, lung cancer (e.g., KRAS-mutated non-small cell lung cancer, non-small cell lung carcinoma, squamous cell carcinoma ( epidermoid carcinoma), adenocarcinoma, large cell carcinoma, small cell lung carcinoma, lung carcinoma), pancreatic cancer (e.g., insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, carcinoid tumor, islet cell tumor, pancreatic carcinoma), skin cancer (e.g., cutaneous melanoma, basal cell carcinoma, squamous cell carcinoma, melanoma, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentigo melanoma, skin carcinoma), cervical cancer (e.g., squamous cell carcinoma, adenocarcinoma, cervical carcinoma), ovarian cancer (e.g., ovarian epithelial carcinoma, borderline ovarian cancer), oral cancer, nervous system cancer (e.g., central nervous system cancer, CNS germ cell tumor), goblet cell metaplasia, kidney cancer (e.g., renal cell carcinoma, adenocarcinoma, adrenal gland tumor, Wilms' tumor, fibrosarcoma, transitional cell carcinoma (renal pelvis and / or ureter), renal cell carcinoma, kidney cancer), bladder cancer (e.g., transitional cell carcinoma, squamous cell carcinoma, carcinosarcoma), gastric cancer (e.g., mycotic (polypoid), ulcerating, superficial spreading, diffuse spreading, liposarcoma, fibrosarcoma, carcinosarcoma), uterine cancer (e.g., endometrial cancer, endometrial carcinoma), esophageal cancer (e.g., squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma, esophageal cancer), colon cancercancer) (e.g., colon carcinoma), cancer of the rectum (e.g., rectal cancer), colorectal cancer (e.g., colorectal carcinoma, metastatic colorectal cancer, hereditary nonpolyposis colorectal cancer, KRAS-mutated colorectal cancer), gallbladder cancer (e.g., adenocarcinoma, cholangiocarcinoma, papillary cystadenocarcinoma, nodular cholangiocarcinoma, diffuse cholangiocarcinoma), testicular cancer (e.g., embryonal tumor, seminoma, undifferentiated testicular cancer, classic (typical) testicular cancer, spermatocytic testicular cancer, nonseminoma testicular cancer), embryonal cancer (e.g., teratoma carcinoma, choriocarcinoma (yolk sac tumor)), gastric cancer (e.g., gastrointestinal stromal tumor, other gastrointestinal cancer, gastric carcinomas), bone cancer (e.g., connective tissue sarcoma, osteosarcoma, cholesteatoma-induced osteosarcoma, Paget's disease of bone, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibroma of bone, chordoma, periosteal sarcoma, soft tissue sarcoma, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, alveolar soft part sarcoma), liposarcoma, lymphangiosarcoma, nerve sheath tumor, rhabdomyosarcoma, synovial sarcoma, lymph node cancer (e.g., lymphoma) intraductal sarcoma), adenoid cystic carcinoma, vaginal cancer (e.g., squamous cell carcinoma, adenocarcinoma, melanoma), vulvar cancer (e.g., squamous cell carcinoma, melanoma, adenocarcinoma, sarcoma, Paget's disease), other reproductive organ cancers, thyroid cancer (e.g., papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma), salivary gland cancer (e.g., adenocarcinoma, mucoepidermoid carcinoma), eye cancer (e.g., ocular melanoma, iris melanoma, choroidal melanoma, ciliary body melanoma, retinoblastoma), penile cancercancer), oral cancer (e.g., squamous cell carcinoma, basal carcinoma), pharyngeal cancer (e.g., squamous cell carcinoma, verrucous pharyngeal carcinoma), head cancer, neck cancer, throat cancer, breast cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, adrenal gland cancer, pheochromocytoma, adrenocortical carcinoma, pituitary cancer, Cushing's disease, prolactin-secreting tumors, acromegaly, diabetes insipidus, myxosarcoma, osteosarcoma, endothelial sarcoma, mesothelioma, synovial tumor, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bladder adenocarcinoma, bronchial carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary adenocarcinoma, epithelioma, optic nerve glioma, primary neuroectodermal tumor, rhabdoid tumor, kidney cancer, glioblastoma multiforme, neurofibroma, neurofibromatosis, childhood cancer, neuroblastoma, malignant melanoma, epidermal carcinoma, polycythemia vera, Waldenstrom's macroglobulinemia, The tumor is selected from the group consisting of monoclonal gammopathy of undetermined significance, benign monoclonal gammopathy, heavy chain disease, solid tumors of childhood, Ewing's sarcoma, Wilms' tumor, epidermoid carcinoma, HIV-associated Kaposi's sarcoma, rhabdomyosarcoma, theca cell tumor, virilizing tumor, cavernous hemangioma, hemangioblastoma, endometrial hyperplasia, endometriosis, fibrosarcoma, choriocarcinoma, nasopharyngeal carcinoma, laryngeal carcinoma, hepatoblastoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, hemangioblastoma, retinoblastoma, glioblastoma, schwannoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, urinary tract carcinoma, abnormal blood vessel proliferation associated with phacomatosis, edema (such as that associated with brain tumors), Meigs' syndrome, pituitary adenoma, primary neuroectodermal tumor, medulloblastoma, and acoustic neuroma.

[0389] A method for treating, preventing, or delaying cancer can include administering a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof to a subject with basal cell carcinoma, goblet cell metaplasia, or malignant glioma.A method for treating, preventing, or delaying cancer can include administering a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof to a subject with cancer of the liver, breast, lung, prostate, cervix, uterus, colon, pancreas, kidney, stomach, bladder, ovary, or brain.

[0390] Methods for treating, preventing, or delaying cancer can include administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to a subject with cancer of the head, neck, eye, mouth, throat, esophagus, breast, bone, lung, kidney, colon, rectum, or other gastrointestinal organs, stomach, spleen, skeletal muscle, subcutaneous tissue, prostate, breast, ovary, testicle, or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system.

[0391] Route of administration The compounds of the present disclosure or pharmaceutical compositions containing these compounds may be administered to a subject by any convenient route of administration, whether systemic / peripheral or local (ie, to the desired site of action).

[0392] Routes of administration include, but are not limited to, oral (e.g., by ingestion), buccal, sublingual, transdermal (e.g., by patch, plaster, etc.), transmucosal (e.g., by patch, plaster, etc.), intranasal (e.g., by nasal spray), intraocular (e.g., by eye drops), pulmonary (e.g., using an aerosol, e.g., via an aerosol, e.g., through the mouth or nose, by inhalation or insufflation therapy), rectal (e.g., by suppository or enema), vaginal (e.g., by pessary), parenteral, e.g., by injection including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, intraarterial, subarachnoid, and intrapleural, by implantation of a depot or reservoir, e.g., subcutaneous or intramuscular injection. [Example]

[0393] For illustrative purposes, neutral compounds of formula (I) or (II) are synthesized and tested in the Examples. It is understood that neutral compounds of formula (I) or (II) can be converted to the corresponding pharmaceutically acceptable salts of the compounds using routine techniques in the art (e.g., by saponifying an ester to a carboxylic acid salt, or by hydrolyzing an amide to form the corresponding carboxylic acid and then converting the carboxylic acid to a carboxylic acid salt).

[0394] Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz or 300 MHz as indicated; chemical shifts (δ) are reported in parts per million (ppm). Spectra were recorded using Bruker or Varian instruments with 8, 16, or 32 scans.

[0395] Unless otherwise noted, LC-MS chromatograms and spectra were recorded using an Agilent 1200 or Shimadzu LC-20 AD&MS 2020 instrument with a C-18 column, such as a C18 2.1 x 30 mm column. The injection volume was 0.7-8.0 μl, and the flow rate was typically 0.8 or 1.2 ml / min. Detection methods were diode array (DAD) or evaporative light scattering (ELSD) with positive ion electrospray ionization. The MS range was 100-1000 Da. The solvent was a gradient of water and acetonitrile containing a polymerization modifier, such as trifluoroacetic acid or ammonium carbonate (typically 0.01-0.04%).

[0396] Shorthand: [Table 1]

[0397] Example 1. Synthesis of 2-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 99) [ka] Step 1: Synthesis of 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine [ka] A mixture of 5-bromo-3-fluoropyridin-2-amine (10 g, 52.6 mmol) and 1-bromopropan-2-one (17.9 g, 131.6 mmol) in EtOH (80 mL) was heated to 80 °C for 16 h. LCMS showed that 15% of the SM remained and 50% of the DP had formed. The reaction was stopped and cooled to room temperature. The solvent was removed under vacuum, and the residue was purified by silica gel column chromatography (PE / EA = 4:1) to give 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine (5.0 g, Y: 41.7%) as a pale pink solid. ESI-MS (M+H) + :229.1, 231.1. 1 H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 1.4 Hz, 1H), 7.38 (d, J = 1.4 Hz, 1H), 6.97 (dd, J = 9.6, 1.5 Hz, 1H), 2.47 (s, 3H).

[0398] Step 2: Synthesis of 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile [ka] To a mixture of 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine (230 mg, 1.01 mmol) in DMF (10 mL) was added Zn(CN) (230 mg, 2.02 mmol) and Pd(PPh) (115 mg, 0.1 mmol), and the reaction mixture was stirred at 120 °C for 2 h. After cooling to room temperature, the mixture was diluted with water (80 mL) and 100 mL of EA. The EA layer was separated, washed once with brine and water (100 mL × 1), dried over NaSO, and concentrated to dryness. The crude material was purified by silica gel column chromatography (10–60% EA in PE). The product was obtained as an off-white solid (120 mg, Y: 68%). 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 1.2 Hz, 1H), 7.52 (dd, J = 3.0, 0.7 Hz, 1H), 6.98 (dd, J = 9.6, 1.3 Hz, 1H), 2.51 (d, J = 0.8 Hz, 3H).

[0399] Step 3: Synthesis of tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate [ka] To a suspension of 5-bromo-2-nitropyridine (5.0 g, 25.0 mmol) and tert-butyl piperazine-1-carboxylate (9.3 g, 50.0 mmol) in NMP (80 mL) was added TEA (7.5 g, 75.0 mmol), and the reaction mixture was stirred at 120 °C for 3 h. After cooling to room temperature and diluting with water, the mixture was extracted with EA. The combined organics were washed with brine and water, dried over NaSO, and concentrated to dryness. The crude was purified by silica gel column (10-100% EA in PE). The product was obtained as an off-white solid (5 g, Y: 68%). 1 H NMR (400 MHz, DMSO-d6) δ 8.24 (d, J = 3.0 Hz, 1H), 8.17 (d, J = 9.2 Hz, 1H), 7.47 (dd, J = 9.3, 3.1 Hz, 1H), 3.55 - 3.46 (m, 8H), 1.43 (s, 9H).

[0400] Step 4: Synthesis of tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate [ka] To a mixture of tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (5.5 g, 17.86 mmol) in MeOH (100 mL) was added Pd / C (1.1 g). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 16 hours. The solvent was filtered, and the filter cake was washed with MeOH (50 mL). The filtrate was concentrated to give the desired product (4.9 g, crude yield: 97%) as a purple semi-solid, which was used in the next step without further purification. ESI-MS: [M+H] + 279.2.

[0401] Step 5: Synthesis of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate [ka] To a mixture of tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (280 mg, 1.0 mmol) in THF, LDA (1 mL, 2.0 mmol, 2M in THF) was added at -78 °C. The mixture was stirred at this temperature for 30 minutes. Compound 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (150 mg, 0.9 mmol) was added. The mixture was warmed to room temperature and stirred for 16 hours. After concentration, the crude was purified by silica gel column (DCM / MeOH=10:1) to give the desired product (120 mg, Y: 29%) as a brown solid. ESI-MS: [M+H] + 454.1.

[0402] Step 6: Synthesis of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate [ka] To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate (45 mg, 0.1 mmol) in THF (5 mL) was added triphosgene (59 mg, 0.2 mmol) and pyridine (1 mL). The reaction mixture was stirred at room temperature for 1 h, and after concentration, the residue was purified by silica gel column (1-10% MeOH in DCM). The product was obtained as a white solid (20 mg, yield: 41%). ESI-MS: [M+H] + 480.1.

[0403] Step 7: Synthesis of 2-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one [ka] To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (20 mg, 0.042 mmol) in DCM (3 mL) was added TFA (0.5 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After concentration, the residue was purified by preparative HPLC (MeCN / 0.05% NH H O aqueous solution) to give 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (2 mg, 13% yield) as a white solid. ESI-MS: [M+H] + 380.2. 1H NMR (400 MHz, CD3OD) δ 9.28 (d, J = 1.3 Hz, 1H), 8.38 (d, J = 2.8 Hz, 1H), 8.25 (dd, J = 9.4, 2.6 Hz, 1H), 7.94 (dd, J = 12.0, 1.3 Hz, 1H), 7.82 (d, J = 2.1 Hz, 1H), 7.72 (d, J = 9.6 Hz, 1H), 4.58 (br s, 4H), 3.07 - 3.01 (m, 4H), 2.45 (d, J = 0.7 Hz, 3H).

[0404] Example 2. Synthesis of tert-butyl 3-(6-aminopyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate [ka] Step 1: tert-Butyl 3-(6-nitropyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a suspension of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.0 g, 4.69 mmol) and 5-bromo-2-nitropyridine (1.44 g, 7.04 mmol) in NMP (10 mL) was added TEA (947 mg, 9.38 mmol), and the reaction mixture was stirred at 110 °C for 10 h. After cooling to room temperature and diluting with water, the mixture was extracted with EA (40 mL × 2), and the combined organics were washed with brine (60 mL), dried over sodium sulfate, and concentrated to dryness. The crude was purified by silica gel column (10–100% EA in PE) to give the title product (1.4 g, yield: 93.3%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 9.2 Hz, 1H), 8.08 (d, J = 3.2 Hz, 1H), 7.15 (dd, J = 9.2, 3.2 Hz, 1H), 3.59 - 3.55 (m, 2H), 3.40 - 3.36 (m, 1H), 3.30 - 3.24 (m, 2H), 2.37 (t, J = 8.0 Hz, 1H), 2.04 - 1.98 (m, 2H), 1.83 - 1.77 (m, 2H), 1.49 (s, 9H).

[0405] Step 2: tert-Butyl 3-(6-aminopyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a mixture of tert-butyl 3-(6-nitropyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.4 g, 4.19 mmol) in MeOH / THF / EtOAc (15 mL / 15 mL / 15 mL) was added Pd / C (300 mg). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 16 hours. The solvent was filtered, and the filter cake was washed with MeOH (50 mL). The filtrate was concentrated to give the title product (1.3 g, crude) as a brown solid. 1 H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 2.8 Hz, 1H), 7.07 (dd, J = 8.8, 2.8 Hz, 1H), 6.48 (d, J = 8.8 Hz, 1H), 4.32 - 4.28 (m, 2H), 4.11 (s, 2H), 3.38 (t, J = 7.2 Hz, 1H), 3.18 (d, J = 10.4 Hz, 2H), 2.91-2.89 (m, 2H), 2.37 (t, J = 8.0 Hz, 1H), 2.06 - 1.96 (m, 2H), 1.47 (s, 9H).ESI-MS: [M+H] + 305.2.

[0406] Example 3. Synthesis of tert-butyl 3-(6-aminopyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate [ka] Step 1: tert-Butyl 3-(6-nitropyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate To a suspension of tert-butyl 3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (400 mg, 1.77 mmol) and 5-fluoro-2-nitropyridine (377 mg, 2.65 mmol) in NMP (10 mL) was added TEA (357 mg, 3.54 mmol), and the reaction mixture was stirred at 110 °C for 6 h. After cooling to room temperature and diluting with water, the mixture was extracted with EA (40 mL × 2), and the combined organics were washed with brine (60 mL), dried over sodium sulfate, and concentrated to dryness. The crude material was purified by silica gel column (10–100% EA in PE) to give tert-butyl 3-(6-nitropyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (350 mg, 56.9% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 9.2 Hz, 1H), 8.13 (d, J = 3.2 Hz, 1H), 7.19 (dd, J = 9.2, 3.2 Hz, 1H), 4.52 - 4.45 (m, 1H), 4.37 - 4.34 (m, 1H), 3.76 (d, J = 12.0 Hz, 2H), 3.31 - 3.30 (m, 2H), 2.09 - 2.01 (m, 1H), 1.95 - 1.87 (m, 2H), 1.81 - 1.77 (m, 2H), 1.64 - 1.61 (m, 1H), 1.50 (s, 9H).

[0407] Step 2: tert-Butyl 3-(6-aminopyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate To a mixture of tert-butyl 3-(6-nitropyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (350 mg, 1.00 mmol) in MeOH / THF (20 mL / 10 mL) was added Pd / C (50 mg). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 2 hours. The solvent was filtered, and the filter cake was washed with MeOH (50 mL). The filtrate was concentrated to give tert-butyl 3-(6-aminopyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (280 mg, 87.7% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 2.8 Hz, 1H), 7.12 (dd, J = 8.8, 3.0 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 4.33 - 4.31 (m, 1H), 4.21 - 4.20 (m, 1H), 4.13 - 4.11 (m, 2H), 3.37 (t, J = 9.8 Hz, 2H), 3.03 - 2.98 (m, 2H), 1.94 - 1.83 (m, 2H), 1.80 - 1.75 (m, 2H), 1.48 (s, 9H).ESI-MS: [M+H] + 319.1.

[0408] Example 4. Synthesis of tert-butyl 4-(6-aminopyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate [ka] Step 1: tert-Butyl 2,2-dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate To a mixture of 5-bromo-2-nitropyridine (300 mg, 1.5 mmol) and tert-butyl 2,2-dimethylpiperazine-1-carboxylate (214 mg, 1 mmol) in NMP (5 mL) was added TEA (303 mg, 3 mmol), and the reaction mixture was stirred at 120 °C for 24 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (40 mL). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by silica gel column chromatography (PE / EA = 6:1 to 1:1) to give the title compound (210 mg, 62.3% yield) as a brown solid. ESI-MS (M+H) + :337.3.

[0409] Step 2: tert-Butyl 4-(6-aminopyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate The compound tert-butyl 4-(6-aminopyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (900 mg, 2.67 mmol) was dissolved in MeOH (15 mL) and Pd / C (180 mg, 20%) was added. The mixture was filled with H2 three times and stirred under a H2 balloon at room temperature overnight. The mixture was filtered and the filtrate was concentrated to give the title compound (700 mg, 86% yield) as a gray solid. ESI-MS (M+H) + :307.3.

[0410] Example 5. Synthesis of tert-butyl 5-(6-nitropyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate [ka] Step 1: tert-Butyl 5-(6-nmitropyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a mixture of 5-bromo-2-nitropyridine (1.28 g, 6.33 mmol) and tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (900 mg, 4.2 mmol) in toluene (30 mL), Pd(dba) (396 mg, 0.42 mmol), Xantphos (495 mg, 0.85 mmol), and CsCO (2.7 g, 8.49 mmol) were added, and the reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (40 mL). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by silica gel column chromatography (PE / EA = 4:1 to 1:3) to give the title compound (700 mg, 50% yield) as a brown solid. ESI-MS (M+H)+:335.3.

[0411] Step 2: tert-Butyl 5-(6-aminopyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of tert-butyl 5-(6-nitropyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (700 mg, 2.09 mmol) in MeOH (15 mL) was added Pd / C (70 mg, 10%), and the mixture was filled with H2 three times and stirred under a H2 balloon at room temperature overnight. The mixture was filtered, and the filtrate was concentrated to give the title compound (600 mg, 94% yield) as a gray solid. ESI-MS (M+H) + :305.2. 1 H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.7 Hz, 1H), 6.87 - 6.79 (m, 1H), 6.49 (d, J = 8.7 Hz, 1H), 3.64 (br.s, 2H), 3.45 - 3.25 (m, 4H), 3.17 - 3.10 (m, 2H), 2.98 (br.s, 2H), 1.45 (s, 9H).

[0412] Example 6. Synthesis of tert-butyl 4-(6-amino-4-methylpyridin-3-yl)piperazine-1-carboxylate [ka] Step 1: tert-Butyl 4-(6-chloro-4-methylpyridin-3-yl)piperazine-1-carboxylate To a solution of 5-bromo-2-chloro-4-methylpyridine (3.0 g, 14.4 mmol) in toluene (20 mL) was added t-BuONa (1.8 g, 18.6 mmol), Xantphos (333 mg, 0.57 mmol), Pd(dba) (394 mg, 0.45 mmol), and tert-butyl piperazine-1-carboxylate (3.3 g, 17.3 mmol), and the mixture was stirred at 80 °C overnight. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (PE / EA = 5:1) to give the title product (2.1 g, 52%) as a pale yellow solid. ESI-MS (M+H) + :312. 1 H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.07 (s, 1H), 3.52 - 3.49 (m, 4H), 2.84 - 2.82 (m, 4H), 2.23 (s, 3H), 1.42 (s, 9H).

[0413] Step 2: tert-Butyl 4-(6-((diphenylmethylene)amino)-4-methylpyridin-3-yl)piperazine-1-carboxylate A mixture of tert-butyl 4-(6-chloro-4-methylpyridin-3-yl)piperazine-1-carboxylate (1.7 g, 5.5 mmol) in 1,4-dioxane (20 mL) was stirred overnight at 80 °C with Pd(OAc) (123 mg, 0.55 mmol), CsCO (3.6 g, 11.0 mmol), BINAP (685 mg, 1.1 mmol), and diphenylmethanimine (1.04 g, 5.7 mmol). The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (PE / EA = 5:1) to give the title product (3.5 g, yield: 60%) as a pale yellow solid. ESI-MS (M+H) + 457.3.

[0414] Step 3: tert-Butyl 4-(6-amino-4-methylpyridin-3-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-((diphenylmethylene)amino)-4-methylpyridin-3-yl)piperazine-1-carboxylate (1.64 g, 3.6 mmol) in MeOH (10 mL) was added NaOAc (887 mg, 10.8 mmol) and NH2OH.HCl (1.3 g, 18 mmol). The mixture was stirred at room temperature for 2 h. The mixture was diluted with water (20 mL), adjusted to pH = 2 with 1 M HCl, and extracted with EtOAc (50 mL x 2). The aqueous phase was adjusted to pH = 9 with NaHCO3 (aq) and extracted with ethyl acetate (2 x 100 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude product was washed with tert-butyl methyl ether (10 mL) to give the title product (770 mg, crude) as a yellow solid. ESI-MS (M+H) + 293.1. 1 H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 6.37 (s, 1H), 4.23 (s, 2H), 3.54 - 3.52 (m, 4H), 2.83 - 2.81 (m, 4H), 2.22 (s, 3H), 1.48 (s, 9H).

[0415] Example 7. Synthesis of tert-butyl (S)-4-(6-amino-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate [ka] Step 1: tert-butyl (S)-4-(6-chloro-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate To a solution of 5-bromo-2-chloro-3-fluoropyridine (4.0 g, 19.2 mmol) in toluene (20 mL) was added t-BuONa (2.4 g, 2.5 mmol), Xantphos (463 mg, 0.8 mmol), Pd(dba) (528 mg, 0.56 mmol), and tert-butyl (S)-2-methylpiperazine-1-carboxylate (4.6 g, 23.04 mmol). The mixture was stirred at 80 °C overnight. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (PE / EA = 5:1) to give the title product (5 g, 79.4%) as a pale yellow solid. ESI-MS (M+H) + 330.2. 1 H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 2.5 Hz, 1H), 6.89 (dd, J = 2.5, 0.8 Hz 1H), 4.30 (br.s, 1H), 3.90 (d, J = 13.5 Hz, 1H), 3.43 (d, J = 11.7 Hz, 1H), 3.31 - 3.15 (m, 2H), 3.03 - 3.01 (m, 1H), 2.81 - 2.79 (m, 1H), 1.42 (s, 9H), 1.20 (d, J = 6.8 Hz, 3H).

[0416] Step 2: tert-Butyl (S)-4-(6-((diphenylmethylene)amino)-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-chloro-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate (2.0 g, 6 mmol) in 1,4-dioxane (20 mL) was added Pd(OAc) (134 mg, 0.6 mmol), CsCO (3.9 g, 12.0 mmol), BINAP (747 mg, 1.2 mmol), and diphenylmethanimine (1.2 g, 6.4 mmol). The mixture was stirred at 80 °C overnight. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (PE / EA = 5:1) to give the title product (2.1 g, 55% yield) as a pale yellow solid. ESI-MS (M+H) + :475.3.

[0417] Step 3: tert-Butyl (S)-4-(6-amino-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-((diphenylmethylene)amino)-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate (1.326 g, 2.8 mmol) in MeOH (10 mL) were added NaOAc (688 mg, 8.4 mmol), NHOH.HCl (966 mg, 14 mmol), and the mixture was stirred at room temperature overnight. The mixture was diluted with water (20 mL), adjusted to pH = 2 with 1 M HCl, and extracted with EtOAc (50 mL × 2). The aqueous phase was adjusted to pH = 9 with NaHCO (aq) and extracted with ethyl acetate (2 × 100 mL). The organic phases were combined, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude product was purified by C18 flash (0.1% NH3.HO in water / CH3CN) to give the title product (943 mg, yield: 40%) as a yellow solid. ESI-MS (M+H) +: 311.3. 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 2.1 Hz, 1H), 7.01 - 6.90 (m, 1H), 4.34 (s, 3H), 3.94 (d, J = 13.5 Hz, 1H), 3.29 - 3.17 (m, 2H), 3.10 (d, J = 11.6 Hz, 1H), 2.84 (dd, J = 11.6, 3.8 Hz, 1H), 2.72 - 2.59 (m, 1H), 1.48 (s, 9H), 1.31 (d, J = 6.8 Hz, 3H).

[0418] Example 8. Synthesis of tert-butyl (S)-4-(6-amino-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate [ka] Step 1: tert-butyl (S)-4-(6-chloro-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of 5-bromo-2-chloro-3-methylpyridine (20 g, 0.097 mol), tert-butyl (S)-2-methylpiperazine-1-carboxylate (19.4 g, 0.097 mol) in toluene (400 mL), t-BuONa (12.1 g, 0.126 mol), Xantphos (2.25 g, 3.88 mmol), and Pd(dba) (2.37 g, 2.91 mmol) were added. The mixture was filled with N three times and stirred at 80 °C for 16 h. The reaction mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel column chromatography (EtOAc:PE = 1:5) to give the title compound (26 g, 82.4% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 2.9 Hz, 1H), 7.03 (t, J = 10.2 Hz, 1H), 4.36 (br.s, 1H), 3.96 (d, J = 13.4 Hz, 1H), 3.51 - 3.41 (m, ESI-MS (M+H) + :326.0.

[0419] Step 2: tert-Butyl (S)-4-(6-((diphenylmethylene)amino)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of tert-butyl (S)-4-(6-chloro-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (26 g, 0.08 mol), diphenylmethanimine (15.2 g, 0.08 mol) in 1,4-dioxane (350 mL), CsCO (52 g, 0.16 mol), BINAP (9.9 g, 0.016 mol), and Pd(OAc) (1.79 g, 0.008 mol) were added, and the mixture was filled with N three times and stirred at 100 °C for 16 h. The reaction mixture was diluted with water (400 mL) and extracted with EtOAc (400 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by silica gel column chromatography (EtOAc / PE=1:5) to give the title compound (30 g, 80% yield) as a yellow solid. 1H NMR (400 MHz, DMSO) δ 7.73 - 7.65 (m, 3H), 7.56 - 7.53 (m, 1H), 7.47 (t, J = 7.4 Hz, 2H), 7.34 - 7.25 (m, 3H), 7.16 - 7.05 (m, 3H), 4.16 (br.s, 1H), 3.75 (d, J = 13.2 Hz, 1H), 3.46 (d, J = 11.9 Hz, 1H), 3.38 (d, J = 12.1 Hz, 1H), 3.17 - 3.05 (m, 1H), 2.71 - 2.68 (m, 1H), 2.56 - 2.51 (m, 1H), 2.06 (d, J = 8.0 Hz, 3H), 1.45 - 1.38 (m, 9H), 1.21 - 1.15 (m, 3H).ESI-MS (M+H) + :471.2.

[0420] Step 3: tert-Butyl (S)-4-(6-amino-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-((diphenylmethylene)amino)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (30 g, 0.06 mol) in MeOH (400 mL) was added NaOAc (15.6 g, 0.19 mol) and hydroxylamine hydrochloride (22 g, 0.32 mol), and the mixture was stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated. The crude product was purified by C18 flash to give the title compound (14 g, 72% yield) as a yellow solid. ESI-MS (M+H) + :307.3. 1H NMR (400 MHz, DMSO-d6) δ 7.47 (d, J = 3.3 Hz, 1H), 7.03 (d, J = 2.2 Hz, 1H), 5.22 (s, 2H), 4.17 (br.s, 1H), 3.76 (d, J = 13.1 Hz, 1H), 3.29 - 3.20 (m, 1H), 3.17 - 3.04 (m, 2H), 2.61 (dd, J = 11.7, 3.8 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.03 (s, 3H), 1.41 (s, 9H), 1.22 (d, J = 6.8 Hz, 3H).

[0421] Example 9. Synthesis of tert-butyl 4-(6-amino-2-methylpyridin-3-yl)piperazine-1-carboxylate [ka] Step 1: tert-Butyl 4-(6-chloro-2-methylpyridin-3-yl)piperazine-1-carboxylate A mixture of 3-bromo-6-chloro-2-methylpyridine (6.63 g, 32.1 mmol), tert-butyl piperazine-1-carboxylate (8.57 g, 38.5 mmol), Pd(dba) (2.94 g, 3.2 mmol), Xantphos (3.7 g, 6.4 mmol), and t-BuONa (4.6 g, 48.2 mmol) in toluene (140 mL) was stirred at 80 °C for 16 h under Ar. After cooling to room temperature, the mixture was diluted with EA (100 mL), washed with brine and water, and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA = 10:1 to 5:1) to give the title product (8.0 g, yield: 80.2%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.8 Hz, 1H), 6.49 (d, J = 8.8 Hz, 1H), 3.76 - 3.60 (m, 4H), 2.89 - 2.73 (m, 4H), 2.16 (s, 3H), 1.57 (s, 9H).

[0422] Step 2: tert-Butyl 4-(6-((diphenylmethylene)amino)-2-methylpyridin-3-yl)piperazine-1-carboxylate A mixture of tert-butyl 4-(6-chloro-2-methylpyridin-3-yl)piperazine-1-carboxylate (2.5 g, 8.0 mmol), diphenylmethanimine (1.6 g, 8.8 mmol), Pd(OAc) (180 mg, 0.8 mmol), BINAP (1.0 g, 1.6 mmol), and CsCO (5.2 g, 16.0 mmol) in dioxane (50 mL) was stirred at 100 °C for 5 h under Ar. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA = 5:1 to 2:1) to give the title product (1.2 g, yield: 51.3%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.3 Hz, 2H), 7.46 - 7.29 (m, 3H), 7.26 - 7.18 (m, 3H), 7.17 - 7.12 (m, 2H), 7.01 (d, J = 8.4 Hz, 1H), 6.26 (d, J = 8.4 Hz, 1H), 3.62 - 3.33 (m, 4H), 2.84 - 2.60 (m, 4H), 2.44 (s, 3H), 1.47 (s, 9H).ESI-MS:457.5[M+H] + .

[0423] Step 3: tert-Butyl 4-(6-amino-2-methylpyridin-3-yl)piperazine-1-carboxylate A mixture of tert-butyl 4-(6-((diphenylmethylene)amino)-2-methylpyridin-3-yl)piperazine-1-carboxylate (548 mg, 1.2 mmol), NaOAc (296 mg, 3.6 mmol), and NH2OH·HCl (417 mg, 6.0 mmol) in MeOH (15 mL) was stirred at room temperature for 1 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 5:1 to 2:1) to give the title product (280 mg, yield: 83%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.8 Hz, 1H), 6.40 (d, J = 8.8 Hz, 1H), 3.63 - 3.48 (m, 4H), 2.82 - 2.66 (m, 4H), 2.41 (s, 3H), 1.48 (s, 9H).ESI-MS:293.1[M+H] + .

[0424] Example 10. Synthesis of tert-butyl 4-(6-amino-2-methoxypyridin-3-yl)piperazine-1-carboxylate [ka] Step 1: 3-Bromo-6-chloro-2-methoxypyridine To a solution of 3-bromo-2,6-dichloropyridine (554 mg, 2.0 mmol) in MeOH (10 mL) was added sodium methylate (216 mg, 4.0 mmol). The mixture was stirred at 80° C. for 5 hours. After cooling to room temperature, the mixture was diluted with water (50 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and used directly in the next step without any further purification. 1H NMR(400MHz, CDCl3) δ7.73(d,J=8.0Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 4.02 (s, 3H).

[0425] Step 2: tert-Butyl 4-(6-chloro-2-methoxypyridin-3-yl)piperazine-1-carboxylate A mixture of 3-bromo-6-chloro-2-methoxypyridine (223 mg, 1.0 mmol), tert-butyl piperazine-1-carboxylate (224 mg, 1.2 mmol), Pd(dba) (92 mg, 0.1 mmol), Xantphos (116 mg, 0.2 mmol), and t-BuONa (145 mg, 1.5 mmol) in toluene (10 mL) was stirred at 80 °C for 16 h under Ar. After cooling to room temperature, the mixture was diluted with EA (80 mL), washed with brine and water, and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA = 10:1 to 5:1) to give the title product (100 mg, yield: 30.6%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.07 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 4.01 (s, 3H), 3.66 - 3.52 (m, 4H), 3.04 - 2.94 (m, 4H), 1.48 (s, 9H).ESI-MS [M+Na] + :350.2.

[0426] Step 3: tert-Butyl 4-(6-((diphenylmethylene)amino)-2-methoxypyridin-3-yl)piperazine-1-carboxylate A mixture of tert-butyl 4-(6-chloro-2-methoxypyridin-3-yl)piperazine-1-carboxylate (100 mg, 0.3 mmol), diphenylmethanimine (58 mg, 0.32 mmol), Pd(OAc) (7 mg, 0.03 mmol), BINAP (38 mg, 0.06 mmol), and CsCO (196 mg, 0.6 mmol) in dioxane (5 mL) was stirred at 110 °C for 24 h under Ar. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA = 5:1 to 2:1) to give the title product (100 mg, yield: 69.3%) as a white solid. ESI-MS: 473.2 [M+H] + .

[0427] Step 4: tert-Butyl 4-(6-amino-2-methoxypyridin-3-yl)piperazine-1-carboxylate A mixture of tert-butyl 4-(6-((diphenylmethylene)amino)-2-methoxypyridin-3-yl)piperazine-1-carboxylate (577 mg, 1.2 mmol), NaOAc (296 mg, 3.6 mmol), and NH2OH·HCl (417 mg, 6.0 mmol) in MeOH (15 mL) was stirred at room temperature for 1 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 5:1 to 2:1) to give the title product (300 mg, yield: 83%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.19 - 6.94 (m, 1H), 6.21 - 5.93 (m, 1H), 4.36 (s, 2H), 3.91 (s, 3H), 3.64 - 3.47 (m, 4H), 2.97 - 2.79 (m, 4H), 1.47 (s, 9H).ESI-MS: [M+H] + 309.1.

[0428] Example 11. Synthesis of tert-butyl 4-(6-amino-5-fluoropyridin-3-yl)piperazine-1-carboxylate [ka] Step 1: tert-Butyl 4-(6-chloro-5-fluoropyridin-3-yl)piperazine-1-carboxylate To a mixture of 5-bromo-2-chloro-3-fluoropyridine (15 g, 71.5 mmol), tert-butyl piperazine-1-carboxylate (13.3 g, 71.5 mmol) in toluene (250 mL), t-BuONa (8.8 g, 92.2 mmol), Xantphos (1.65 g, 2.85 mmol), and Pd(dba) (1.95 g, 2.3 mmol) were added, and the mixture was filled with N three times and stirred at 100 °C for 16 h. The reaction mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel chromatography eluting with (EtOAc:PE = 3:1) to give the title compound (14.7 g, 65.8% yield) as a gray solid. ESI-MS(M+H)+:316.0.

[0429] Step 2: tert-Butyl 4-(6-((diphenylmethylene)amino)-5-fluoropyridin-3-yl)piperazine-1-carboxylate To a mixture of tert-butyl 4-(6-chloro-5-fluoropyridin-3-yl)piperazine-1-carboxylate (10.4 g, 33 mmol), diphenylmethanimine (6.27 g, 36 mmol) in 1,4-dioxane (150 mL), CsCO (21.5 g, 66 mol), BINAP (3.0 g, 5.0 mmol), and Pd(OAc) (370 mg, 1.65 mmol) were added. The mixture was filled with N three times and stirred at 100 °C for 24 h. The reaction mixture was diluted with water (400 mL) and extracted with EtOAc (400 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by silica gel column chromatography eluting with (EtOAc / PE = 3:1) to give the title compound (10.2 g, 67% yield) as a brown solid. ESI-MS(M+H)+:461.2.

[0430] Step 3: tert-Butyl 4-(6-amino-5-fluoropyridin-3-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-((diphenylmethylene)amino)-5-fluoropyridin-3-yl)piperazine-1-carboxylate (20.4 g, 44.3 mmol) in MeOH (300 mL) were added NaOAc (10.9 mg, 133 mmol) and hydroxylamine hydrochloride (15.2 g, 221 mmol) at room temperature, and the mixture was stirred at room temperature for 2 hours. The mixture was filtered, and the filtrate was concentrated. The crude was purified by silica gel column chromatography (EtOAc / PE=3:1) to give the title compound (8.4 g, 65.2% yield) as a gray solid. ESI-MS(M+H)+:297.1.1H NMR (400 MHz, DMSO-d6) δ 7.50 (d, J = 1.7 Hz, 1H), 7.22 (dd, J = 13.4, 2.4 Hz, 1H), 5.63 (s, 2H), 3.48 - 3.38 (m, 4H), 2.96 - 2.84 (m, 4H), 1.41 (s, 9H).

[0431] Example 12. Synthesis of tert-butyl 4-(6-amino-4-methoxypyridin-3-yl)piperazine-1-carboxylate [ka] Step 1: tert-Butyl 4-(6-chloro-4-methoxypyridin-3-yl)piperazine-1-carboxylate To a mixture of 5-bromo-2-chloro-4-methoxypyridine (6 g, 27.1 mmol), tert-butyl piperazine-1-carboxylate (6 g, 32.5 mmol) in toluene (100 mL) was added t-BuONa (5.2 g, 54.2 mmol), Xantphos (3.1 g, 5.42 mmol), and Pd(dba) (2.5 g, 2.71 mmol). The mixture was filled with N three times and stirred at 100 °C for 16 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel column chromatography (EtOAc:PE = 3:1) to give the title compound (1.4 g, 16% yield) as a gray solid. ESI-MS (M+H) + :328.0.

[0432] Step 2: tert-Butyl 4-(6-((diphenylmethylene)amino)-4-methoxypyridin-3-yl)piperazine-1-carboxylate To a mixture of tert-butyl 4-(6-chloro-5-fluoropyridin-3-yl)piperazine-1-carboxylate (1.4 g, 4.28 mmol), diphenylmethanimine (800 mg, 4.50 mmol) in 1,4-dioxane (40 mL) was added CsCO (2.78 g, 8.56 mol), BINAP (532 mg, 0.856 mmol), and Pd(OAc) (96 mg, 0.428 mmol). The mixture was filled with N three times and stirred at 100 °C for 16 h. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel column chromatography eluting with (EtOAc / PE=4:1) to give the title compound (800 mg, 40% yield) as a brown solid. ESI-MS (M+H)+: 473.1.

[0433] Step 3: tert-Butyl 4-(6-amino-4-methoxypyridin-3-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-((diphenylmethylene)amino)-4-methoxypyridin-3-yl)piperazine-1-carboxylate (800 mg, 1.67 mmol) in MeOH (20 mL) were added NaOAc (412 mg, 5.02 mmol) and hydroxylamine hydrochloride (578 mg, 8.37 mmol) at room temperature, and the mixture was stirred at room temperature for 1 h. The mixture was diluted with water (20 mL), adjusted to pH = 2 with 1 M HCl, and extracted with EtOAc (50 mL × 2). The aqueous phase was adjusted to pH = 9 with NaHCO3 (aq) and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated to give the title compound (400 mg, 77.8% yield) as a gray solid. ESI-MS (M+H): 309.1. 1H NMR(400MHz, CDCl3) δ 7.57 (s, 1H), 6.02 (s, 1H), 4.35 (s, 2H), 3.85 (s, 3H), 3.59 - 3.56 (m, 4H), 2.94 - 2.90 (m, 4H), 1.48 (s, 9H).

[0434] Example 13. Synthesis of tert-butyl 4-(6-amino-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate [ka] Step 1: tert-butyl 4-(6-chloro-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate To a mixture of 5-bromo-2-chloro-3-methylpyridine (5 g, 25.9 mmol), tert-butyl 2,2-dimethylpiperazine-1-carboxylate (5.32 g, 23.3 mmol) in toluene (100 mL), t-BuONa (5 g, 51.8 mmol), Xantphos (3 g, 5.18 mmol), and Pd(dba) (2.38 g, 2.5 mmol) were added. The mixture was filled with N three times and stirred at 80 °C for 16 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel chromatography eluting with (EtOAc:PE = 6:1) to give the title compound (4.5 g, 51% yield) as a gray solid. ESI-MS (M+H) + :340.2. 1 H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 3.0 Hz, 1H), 6.85 (d, J = 2.8 Hz, 1H), 3.87 - 3.75 (m, 2H), 3.42 - 3.33 (m, 2H), 3.30 (s, 2H), 2.33 (s, 3H), 1.49 (s, 9H), 1.42 (s, 6H).

[0435] Step 2: tert-butyl 4-(6-((diphenylmethylene)amino)-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate To a mixture of tert-butyl 4-(6-chloro-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (4.5 g, 13.27 mmol), diphenylmethanimine (2.52 g, 13.93 mmol) in 1,4-dioxane (100 mL) was added CsCO (8.62 g, 26.54 mol), BINAP (1.65 g, 2.65 mmol), and Pd(OAc) (297 mg, 1.32 mmol). The mixture was filled with N three times and stirred at 100 °C for 16 h. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel column chromatography (EtOAc / PE=6:1) to give the title compound (4 g, 62% yield) as a brown solid. ESI-MS (M+H) + :473.1.

[0436] Step 3: tert-Butyl 4-(6-amino-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate To a solution of tert-butyl 4-(6-((diphenylmethylene)amino)-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (4 g, 8.26 mmol) in MeOH (100 mL) were added NaOAc (2 g, 24.79 mmol) and hydroxylamine hydrochloride (2.8 g, 41.32 mmol) at room temperature, and the mixture was stirred at room temperature for 1 h. The mixture was diluted with water (20 mL), adjusted to pH = 2 with 1 M HCl, and extracted with EtOAc (50 mL × 2). The aqueous phase was adjusted to pH = 9 with NaHCO3 (aq) and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated to give the title compound (1.5 g, 57.7% yield) as a gray solid. ESI-MS (M+H): 321.0. 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 2.6 Hz, 1H), 4.09 (s, 2H), 3.69 - 3.65 (m, 2H), 3.18 - 3.13 (m, 2H), 2.97 (s, 2H), 2.13 (s, 3H), 1.49 (s, 9H), 1.44 (s, 6H).

[0437] Example 14. Synthesis of tert-butyl 4-(6-amino-5-methoxypyridin-3-yl)piperazine-1-carboxylate [ka] Step 1: tert-Butyl 4-(5-methoxy-6-nitropyridin-3-yl)piperazine-1-carboxylate To a mixture of 5-bromo-3-methoxy-2-nitropyridine (3 g, 12.93 mmol) and tert-butyl piperazine-1-carboxylate (3.61 g, 19.39 mmol) in toluene (30 mL) was added Pd(dba) (1.18 g, 1.29 mmol), Xantphos (1.50 g, 2.58 mmol), and CsCO (8.43 g, 25.86 mmol). The reaction mixture was stirred at 100 °C for 4 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (40 mL). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by silica gel column chromatography (PE / EA = 3:1 to 1:1) to give the title compound (600 mg, 13.7% yield) as a brown solid. ESI-MS (M+H) + :339.1. 1 H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 2.4 Hz, 1H), 6.69 (d, J = 2.4 Hz, 1H), 3.98 (s, 3H), 3.66 - 3.63 (m, 4H), 3.44 - 3.41 (m, 4H), 1.49 (s, 9H).

[0438] Step 2: tert-Butyl 4-(6-amino-5-methoxypyridin-3-yl)piperazine-1-carboxylate To a solution of tert-butyl 5-(6-nitropyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (600 mg, 1.77 mmol) in MeOH (15 mL) was added Pd / C (60 mg, 10%). The mixture was filled with H2 three times and stirred under a H2 balloon at room temperature overnight. The mixture was filtered, and the filtrate was concentrated to give the title compound (470 mg, 86% yield) as a gray solid. ESI-MS (M+H) + :309.1. 1 H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 2.4 Hz, 1H), 6.70 (d, J = 2.4 Hz, 1H), 4.43 (s, 2H), 3.84 (s, 3H), 3.60 - 3.56 (m, 4H), 3.01 - 2.94 (m, 4H), 1.48 (s, 9H).

[0439] Example 15. Synthesis of 2,7-dimethylpyrazolo[1,5-a]pyridine-5-carbonitrile [ka] Step 1: Preparation of 1-(4-bromo-6-methylpyridin-2-yl)propan-2-one To a solution of 4-bromo-2,6-dimethylpyridine (25 g, 135 mmol) in dry THF (400 mL), LDA (1.0 M, 162 mL, 162 mmol) was added dropwise at −65° C., and the reaction mixture was stirred at this temperature for 4 hours. N-Methoxy-N-methylacetamide (6.95 g, 67.5 mmol) in dry THF (100 mL) was added dropwise at −65° C., and the reaction mixture was stirred at this temperature for 1 hour. TLC (PE / EA=5:1) showed the reaction was complete. The mixture was diluted with water (30 mL) and extracted with EtOAc (100 mL×2). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by column chromatography (PE / EA=5:1) to give 1-(4-bromo-6-methylpyridin-2-yl)propan-2-one (16 g, Y: 95%) as a yellow oil. H NMR (400 MHz, CDCl) δ 7.25 (s, 1H), 7.21 (s, 1H), 3.86 (s, 2H), 2.51 (s, 3H), 2.24 (s, 3H).

[0440] Step 2: Preparation of (Z)-1-(4-bromo-6-methylpyridin-2-yl)propan-2-one oxime To a solution of 1-(4-bromo-6-methylpyridin-2-yl)propan-2-one (14 g, 61.9 mmol) in MeOH (350 mL), NH2OH.HCl (12.8 g, 185.7 mmol) and NaOH (7.4 g, 185.7 mmol) were added, and the mixture was stirred at 60 °C for 16 h. LCMS showed the reaction was complete. The mixture was concentrated in vacuo. The residue was diluted with water (100 mL) and extracted with EtOAc (100 mL × 2). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by column chromatography (PE / EA = 5:1) to give (Z)-1-(4-bromo-6-methylpyridin-2-yl)propan-2-one oxime (12.5 g, 83.3% yield) as a yellow solid. ESI-MS (M+H) +:245.0.

[0441] Step 3: Preparation of 5-bromo-2,7-dimethylpyrazolo[1,5-a]pyridine To a solution of (Z)-1-(4-bromo-6-methylpyridin-2-yl)propan-2-one oxime (4.0 g, 16.5 mmol) and N1,N1,N6,N6-tetramethylhexane-1,6-diamine (4 mL, 19.8 mmol) in DCM (140 mL) was added TsCl (4.0 g, 19.8 mmol) in DCM (20 mL) dropwise at 0 °C, and the reaction mixture was warmed to room temperature and stirred at room temperature for 16 h. TLC (PE / EA = 5:1) showed the reaction was complete. The mixture was diluted with water (100 mL) and extracted with DCM (100 mL × 2). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by column chromatography (PE / EA = 5:1) to give 5-bromo-2,7-dimethylpyrazolo[1,5-a]pyridine (1.8 g, 48.6% yield) as a yellow solid. ESI-MS (M+H) +: 225.2. 1H NMR (400 MHz, DMSO-d6) δ 7.78 (d, J = 1.4 Hz, 1H), 6.90 (d, J = 1.4 Hz, 1H), 6.41 (s, 1H), 2.62 (s, 3H), 2.41 (s, 3H).

[0442] Step 4: Preparation of 2,7-dimethylpyrazolo[1,5-a]pyridine-5-carbonitrile To a solution of 5-bromo-2,7-dimethylpyrazolo[1,5-a]pyridine (2.0 g, 8.93 mmol) and Zn(CN) (2.61 g, 22.32 mmol) in dry DMF (50 mL) was added Pd(PPh) (1.03 g, 0.89 mmol), and the mixture was backfilled with Ar three times and stirred at 130 °C for 2 h. TLC (PE / EA = 5:1) showed the reaction was complete. The mixture was added with water (40 mL) and extracted with EA (50 mL * 2). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 5:1) to give 2,7-dimethylpyrazolo[1,5-a]pyridine-5-carbonitrile (1.4 g, 91.5% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 6.67 (s, 1H), 6.55 (s, 1H), 2.75 (s, 3H), 2.55 (s, 3H).

[0443] Example 16. Synthesis of tert-butyl (S)-4-(6-aminopyridin-3-yl)-2-methylpiperazine-1-carboxylate [ka] Step 1: Preparation of tert-butyl (S)-2-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate To a mixture of tert-butyl (S)-2-methylpiperazine-1-carboxylate (5 g, 0.025 mol), 5-bromo-2-nitropyridine (7.6 g, 0.038 mol) in NMP (40 mL) was added TEA (7.57 g, 0.075 mol), and the mixture was stirred at 120° C. for 16 hours. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (80 mL×3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The crude was purified by silica gel chromatography eluting with (EtOAc:PE=1:1) to give the title compound (6 g, 74.5% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 3.0 Hz, 1H), 8.16 (d, J = 9.2 Hz, 1H), 7.46 - 7.38 (m, 1H), 4.22 - 4.12 (m, 1H), 3.93 - 3.75 (m, 3H), 3.42 - 3.41 (m, 1H), 3.33 - 3.21 (m, 1H), 3.18 - 3.10 (m, 1H), 1.42 (s, 9H), 1.11 (d, J = 6.6 Hz, 3H).ESI-MS (M+H) +:323.0

[0444] Step 2: Preparation of tert-butyl (S)-4-(6-aminopyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of tert-butyl (S)-2-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (4 g, 0.012 mol) in THF (200 mL) was added Pd / C (400 mg, 10%), and the mixture was charged with H three times and stirred at room temperature overnight. The mixture was filtered, and the filtrate was concentrated to give the title compound (3.5 g, 96.4% yield) as a yellow solid. ESI-MS:(M+H)+:293.1. 1H NMR (400 MHz, DMSO-d6) δ 7.59 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 8.8, 2.6 Hz, 1H), 6.42 (d, J = 8.8 Hz, 1H), 5.43 (s, 2H), 4.17 - 4,16 (m, 1H), 3.77 - 3.76 (m, 1H), 3.24 - 3.23 (m, 1H), 3.16 - 3.06 (m, 2H), 2.62 - 2.61 (m, 1H), 2.49 - 2.40 (m, 1H), 1.41 (s, 9H), 1.22 (d, J = 6.6 Hz, 3H).

[0445] Example 17. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 100) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate To a mixture of diisopropylamine (0.6 mL, 4.4 mmol) in dry THF (15 mL), n-BuLi (3 mL, 4.8 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (1.12 g, 4.0 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (350 mg, 2.0 mmol) in dry THF (10 mL) was added to the mixture at −40° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 1:1 to 0:1) and then slurried with MeOH (30 mL) to give the title product (600 mg, yield: 44.4%, 3 batches) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 8.01 (d, J = 2.8 Hz, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.36 - 7.31 (m, 2H), 7.21 (d, J = 8.8 Hz, 1H), 3.62 - 3.58 (m, 4H), 3.15 - 3.12 (m, 4H), 2.50 (s, 3H), 1.49 (s, 9H).ESI-MS: [M+H] + :454.3.

[0446] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate (600 mg, 1.32 mmol) in THF (60 mL) and pyridine (6 mL) was added triphosgene (1.18 g, 3.97 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was diluted with MeOH (40 mL) and stirred at room temperature for 1 hour. The precipitate was filtered and dried in vacuo to give the title product (600 mg, yield: 97%). 1 H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 8.48 (d, J = 2.4 Hz, 1H), 7.95 - 7.90 (m, 2H), 7.66 (d, J = 9.6 Hz, 1H), 7.48 (d, J = 2.0 Hz, 1H), 3.67 - 3.63 (m, 4H), 3.29 - 3.26 (m, 4H), 2.50 (s, 3H), 1.50 (s, 9H).ESI-MS: [M+H] + :480.0.

[0447] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (1.25 g, 2.61 mmol) in 15 mL of EtOAc was added 3 M HCl in 15 mL of EtOAc at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered and lyophilized to give the title product (1.0 g, 86.2% yield) as the HCl salt as a yellow solid. 1H NMR (400 MHz, MeOD-d4) δ 9.66 (s, 1H), 8.66 (d, J = 11.2 Hz, 1H), 8.60 (d, J = 2.4 Hz, 1H), 8.41 (dd, J = 9.6, 2.8 Hz, 1H), 8.25 (s, 1H), 7.91 (d, J = 9.6 Hz, 1H), 3.71 - 3.67 (m, 4H), 3.49 - 3.46 (m, 4H), 2.62 (s, 3H).ESI-MS: [M+H] + 380.2.

[0448] Example 18. Synthesis of (S)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one HCl (Compound 101) [ka] Step 1: tert-butyl (S)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of tert-butyl (S)-4-(6-aminopyridin-3-yl)-2-methylpiperazine-1-carboxylate (700 mg, 2.40 mmol) in THF (15 mL) was added LDA (2.8 mL, 1 M in THF) under N2 at -78 °C. The resulting mixture was stirred at 0 °C for 1 hour, cooled to -78 °C, and 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (140 mg, 0.80 mmol) was added. The mixture was stirred at room temperature overnight. After dilution with water, the mixture was extracted with EtOAc (40 mL x 3). The organic layer was washed with brine and concentrated. The residue was purified by silica gel column chromatography (DCM:MeOH = 20:1) to give the title product (130 mg, yield: 35%) as a yellow solid. ESI-MS (M+H) + :468.1 1H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 7.97 (d, J = 2.9 Hz, 1H), 7.46 (d, J = 2.3 Hz, 1H), 7.38 - 7.33 (m, 1H), 7.29 (dd, J = 8.9, 3.0 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 4.38 (br s, 1H), 3.98 (d, J = 13.0 Hz, 1H), 3.47 (d, J = 11.4 Hz, 1H), 3.36 - 3.22 (m, 2H), 2.97 (dd, J = 11.9, 3.7 Hz, 1H), 2.79 - 2.76 (m, 1H), 2.49 (s, 3H), 1.33 (d, J = 6.7 Hz, 3H).

[0449] Step 2: tert-Butyl (S)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a mixture of tert-butyl (S)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2-methylpiperazine-1-carboxylate (120 mg, 0.26 mmol) in THF (5 mL) was added triphosgene (193 mg, 0.65 mmol) and pyridine (1 mL). The resulting mixture was stirred at room temperature for 1 hour. The mixture was quenched with water and extracted with EtOAc (40 mL x 3). The organic layer was washed with brine. The organic layer was concentrated and purified by silica gel column chromatography (DCM:MeOH = 20:1) to give the title product (120 mg, yield: 94%) as a yellow solid. ESI-MS (M+H) + :494.1

[0450] Step 3: (S)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one HCl To a solution of tert-butyl (S)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (110 mg, 0.22 mmol) in DCM (10 mL) was added HCl in dioxane (1 mL) at 0° C. The mixture was stirred at room temperature for 1 h. After concentration, the residue was stirred with EtOAc. The precipitate was filtered and the solid was dried to give the title product (55.68 mg, yield: 64%) as a yellow solid. ESI-MS (M+H) + :394.4 1 H NMR (400 MHz, MeOD) δ 9.66 (s, 1H), 8.66 (d, J = 11.0 Hz, 1H), 8.60 (d, J = 2.7 Hz, 1H), 8.43 (dd, J = 9.6, 2.8 Hz, 1H), 8.25 (s, 1H), 7.91 (d, J = 9.5 Hz, 1H), 4.06 (dd, J = 17.7, 14.2 Hz, 2H), 3.64 - 3.57 (m, 2H), 3.46 - 3.32 (m, 2H), 3.09 (dd, J = 13.3, 10.7 Hz, 1H), 2.63 (s, 3H), 1.47 (d, J = 6.6 Hz, 1H).

[0451] Example 19. Synthesis of (R)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-oneformic acid (Compound 102) [ka] Step 1: tert-Butyl (R)-2-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate To a suspension of 5-bromo-2-nitropyridine (2.0 g, 10.0 mmol) and tert-butyl (R)-2-methylpiperazine-1-carboxylate (2.4 g, 12.0 mmol) in NMP (50 mL) was added TEA (3.0 g, 30.0 mmol), and the reaction mixture was stirred at 120 °C for 16 h. After cooling to room temperature, the mixture was diluted with water and extracted with EA. The organic layer was washed with brine, dried over Na2SO4, and concentrated. The crude was purified by silica gel column (10-100% EA in PE). The product was obtained as an off-white solid (2.5 g, yield: 77%). ESI-MS: [M+H] + 323.1

[0452] Step 2: tert-Butyl (R)-4-(6-aminopyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of tert-butyl (R)-2-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (2.5 g, 7.76 mmol) in MeOH (100 mL) was added Pd / C (250 mg). The reaction mixture was stirred under hydrogen (balloon pressure) at room temperature for 16 hours. The mixture was filtered and washed with MeOH (50 mL). The filtrate was concentrated to give the desired product (2 g, crude yield: 89%) as a purple semi-solid, which was used in the next step without further purification. ESI-MS: [M+H] + 293.3

[0453] Step 3: tert-Butyl (R)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of N,N-diisopropylamine (0.15 mL, 1 mmol) in dry THF (5 mL), n-BuLi (0.7 mL, 1.6 M in hexane, 1.1 mmol) was added at −78° C., and the mixture was stirred at −70° C. for 40 min. tert-Butyl (R)-4-(6-aminopyridin-3-yl)-2-methylpiperazine-1-carboxylate (293 mg, 1.0 mmol) was then added, and the resulting mixture was stirred at room temperature for 1 h. After cooling to −78° C., 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (100 mg, 0.57 mmol) was added, and the mixture was warmed to room temperature and stirred for an additional 16 h. After dilution with water (20 mL), the mixture was extracted with EA (50 mL × 2). The combined organics were washed with brine and dried over Na2SO4. After concentration, the crude was purified on silica gel (PE:EA=1:2) to give the product (70 mg, yield: 26%). ESI-MS: [M+H] + 468.4

[0454] Step 4: tert-Butyl (R)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (R)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2-methylpiperazine-1-carboxylate (70 mg, 0.15 mmol) in THF (8 mL) was added triphosgene (120 mg, 0.75 mmol), the reaction mixture was stirred for 5 min, and pyridine (1.0 mL) was added. The mixture was stirred for 1 h. After concentration under reduced pressure, the residue was purified by silica gel column (1-10% MeOH in DCM). The product was obtained as a white solid (40 mg, yield: 53%). ESI-MS: [M+H] + 494.4

[0455] Step 5: (R)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-oneformic acid To a solution of tert-butyl (R)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (40 mg, 0.08 mmol) in DCM (3 mL) was added TFA (0.5 mL) at 0° C. The reaction mixture was warmed to room temperature and stirred for 1 h. After concentration, the residue was purified by preparative HPLC (MeCN / 0.05% formic acid in water) to give the title product (3.1 mg, yield: 10%) as a white solid. ESI-MS: [M+H] + 394.3. 1 H NMR (400 MHz, MeOD) δ 9.28 (d, J = 1.0 Hz, 1H), 8.50 (s, 2H), 8.41 (d, J = 2.6 Hz, 1H), 8.27 (dd, J = 9.6, 2.7 Hz, 1H), 7.91 (d, J = 12.0 Hz, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.74 (d, J = 9.6 Hz, 1H), 3.97 - 3.84 (m, 2H), 3.53 - 3.43 (m, 2H), 3.26 - 3.24 (m, 1H), 3.13 - 3.10 (m, 1H), 2.92 - 2.84 (m, 1H), 2.45 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H).

[0456] Example 20. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 103) [ka] To a solution of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (20 mg, 0.048 mmol), HCHO (0.5 mL), and HOAc (0.1 mL) was added NaBHCN (10 mg, 0.144 mmol) in MeOH (5 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by preparative HPLC (MeCN / 0.05% NHHO aqueous solution) to give the title product (4.8 mg, yield: 25%) as a yellow solid. ESI-MS (M+H) + :394.3. 1 H NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 1.3 Hz, 1H), 8.35 (dd, J = 9.6, 2.9 Hz, 1H), 8.28 (d, J = 2.8 Hz, 1H), 8.03 (d, J = 2.3 Hz, 1H), 7.82 (dd, J = 12.4, 1.3 Hz, 1H), 7.72 (d, J = 9.5 Hz, 1H), 3.29 (s, 8H), 2.38 (s, 3H), 2.25 (s, 3H).

[0457] Example 21. Synthesis of 7-(1,4-diazepan-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 104) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-1,4-diazepane-1-carboxylate To a three-neck flask, DIPA (220 mg, 2.2 mmol) and THF (6 mL) were added, and the mixture was cooled to -60 °C. Then, 1.6 M n-BuLi (1.5 mL, 2.4 mmol) was added dropwise under N2 and stirred at this temperature for 1 hour. tert-Butyl 4-(6-aminopyridin-3-yl)-1,4-diazepane-1-carboxylate (584 mg, 2 mmol) in THF (2 mL) was added at -60 °C, and the mixture was stirred at room temperature for 1.5 hours. The mixture was cooled again to -60 °C. Then, 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in THF (5 mL) was slowly added. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (160 mg, 34% yield) as a gray solid. ESI-MS (M+H) + :468.3.

[0458] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-1,4-diazepane-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-1,4-diazepane-1-carboxylate (135 mg, 0.29 mmol) dissolved in THF (15 mL), pyridine (1 mL) and triphosgene (301 mg, 1.02 mmol) were added at 0° C., and the mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (80 mg, 56% yield) as a yellow solid. ESI-MS (M+H) + :494.3.

[0459] Step 3: 7-(1,4-diazepan-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride A solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-1,4-diazepane-1-carboxylate (80 mg, 0.62 mmol) in HCl / EA (3 mL) was stirred at room temperature for 2 hours. The mixture was filtered, and the filter cake was washed with EtOAc (1 mL) and dried to give the title compound (50 mg, 78.3% yield) as a yellow solid. ESI-MS (M+H) + :394.3. 1 H NMR (400 MHz, DMSO-d6) δ 9.35 (s, 2H), 9.24 (s, 1H), 8.13 (s, 1H), 8.08 (s, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 10.6 Hz, 1H), 7.43 (d, J = 8.8 Hz, 1H), 3.85 (br.s, 2H), 3.63 (br.s, 2H), 3.26 (br.s, 2H), 3.15 (br.s, 2H), 2.38 (s, 3H), 2.14 (br s, 2H).

[0460] Example 22. Synthesis of 7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 105) [ka] Step 1: tert-butyl 3-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (10 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 3-(6-aminopyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (608 mg, 2.0 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1.0 mmol) in dry THF (5 mL) was added to the mixture at −40° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 1:1 to 0:1) to give the title product (170 mg, yield: 35.5%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 9.15 (s, 1H), 8.07 (s, 1H), 7.75 (s, 2H), 7.16 (s, 2H), 7.06 (d, J = 10.9 Hz, 1H), 4.47 - 4.34 (m, 2H), 3.43 (d, J = 10.4 Hz, 2H), 3.11 - 3.02 (m, 2H), 2.50 (s, 3H), 2.04 - 1.99 (m, 2H), 1.87 (m, 2H), 1.49 (s, 9H).

[0461] Step 2: tert-Butyl 3-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (170 mg, 0.35 mmol) in THF (16 mL) and pyridine (2 mL) was added triphosgene (315 mg, 1.05 mmol). The reaction mixture was stirred at room temperature for 1 hour, and the mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 1:1 to 0:1) to give the title product (90 mg, yield: 50%) as a brown solid. 1 H NMR (400 MHz, CDCl3) δ 8.84 (s, 1H), 8.07 (d, J = 2.8 Hz, 1H), 8.00 (dd, J = 11.2, 5.2 Hz, 2H), 7.28 (s, 1H), 6.82 (d, J = 9.2 Hz, 1H), 4.44 - 4.42 (m, 2H), 3.48 (d, J = 10.4 Hz, 2H), 3.15 - 3.12 (m, 2H), 2.47 (s, 3H), 2.03 - 2.01 (m, 2H), 1.85 - 1.83 (m, 2H), 1.49 (s, 9H).ESI-MS: [M+H] + 506.2.

[0462] Step 3: 7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 3-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (90 mg, 0.18 mmol) in 2 mL of EtOAc was added 3 M HCl / EtOAc (2 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered, and the solid was dried by lyophilization to give the title product (40 mg, yield: 51.3%) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.61 - 9.52 (m, 2H), 9.22 (d, J = 4.8 Hz, 1H), 8.25 (d, J = 2.4 Hz, 1H), 8.08 (s, 1H), 7.76 (dd, J = 9.0, 2.8 Hz, 1H), 7.57 (dd, J = 9.1, 2.8 Hz, 1H), 7.45 - 7.41 (m, 1H), 4.18 (br.s, 2H), 3.81 (d, J = 12.0 Hz, 2H), 3.30 - 3.26 (m, 2H), 2.38 (s, 3H), 2.04 - 1.95 (m, 4H).ESI-MS: [M+H] + :406.1.

[0463] Example 23. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 106) [ka] Step 1: tert-Butyl 5-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of DIPA (220 mg, 2.2 mmol) and THF (6 mL) was added n-BuLi (2.4 mmol, 1.5 mL, 1.6 M) under N at −60° C. The mixture was stirred for 1 hour, and then tert-butyl 5-(6-aminopyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (608 mg, 2 mmol) in THF (5 mL) was added. The mixture was warmed to room temperature and stirred at room temperature for 1.5 hours. The mixture was cooled again to −60° C. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in THF (5 mL) was slowly added. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (120 mg, 25% yield) as a gray solid. ESI-MS (M+H) + :480.2.

[0464] Step 2: tert-Butyl 5-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of tert-butyl 5-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (120 mg, 0.25 mmol) in THF (8 mL) and pyridine (1 mL) was added triphosgene (222 mg, 0.75 mmol), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by preparative TLC (EtOAc:PE = 1:3) to give the title compound (50 mg, 47.6% yield) as a yellow solid. ESI-MS (M+H)+ :506.3.

[0465] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride A solution of tert-butyl 5-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (50 mg, 0.099 mmol) in 4M HCl / EA (2 mL) was stirred at room temperature for 1 hour. The precipitate was filtered, washed with EtOAc (1 mL), and dried under vacuum to give the title compound (30 mg, 24.4% yield) as a yellow solid. ESI-MS (M+H) + :406.1. 1 H NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.26 (s, 1H), 8.10 (s, 1H), 7.94 (d, J = 2.5 Hz, 1H), 7.72 (d, J = 8.9 Hz, 1H), 7.48 (d, J = 10.5 Hz, 1H), 7.27 - 7.20 (m, 1H), 3.57 (br.s, 2H), 3.48 - 3.46 (m, 6H), 3.18 (d, J = 2.9 Hz, 2H), 3.14 - 3.06 (m, 2H), 2.38 (s, 3H).

[0466] Example 24. Synthesis of 7-((3S,5R)-3,5-dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 107) [ka] Step 1: tert-butyl (2S,6R)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2,6-dimethylpiperazine-1-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (10 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. Then, cis tert-butyl-4-(6-aminopyridin-3-yl)-2,6-dimethylpiperazine-1-carboxylate (612 mg, 2.0 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1.0 mmol) in dry THF (5 mL) was added at −40° C., and the mixture was warmed to room temperature and stirred for 16 hours. The mixture was diluted with water (10 mL) and extracted with EtOAc (20 mL×2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column C18 to give the title product (100 mg, yield: 20.8%) as a yellow solid. ESI-MS: [M+H] + 482.3

[0467] Step 2: tert-Butyl (2S,6R)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,6-dimethylpiperazine-1-carboxylate To a solution of cis tert-butyl-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2,6-dimethylpiperazine-1-carboxylate (100 mg, 0.208 mmol) in THF (18 mL) and pyridine (0.8 mL) was added triphosgene (185 mg, 0.624 mmol). The reaction mixture was stirred at room temperature for 1 h, and the mixture was diluted with water (10 mL) and extracted with EtOAc (20 mL × 2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous FA / CHCN) to give the title product (50 mg, 47.6%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 1.3 Hz, 1H), 8.51 (d, J = 2.7 Hz, 1H), 7.95 (dd, J = 11.6, 1.3 Hz, 1H), 7.90 (dd, J = 9.6, 2.9 Hz, 1H), 7.67 (d, J = 9.5 Hz, 1H), 7.48 (d, J = 2.9 Hz, 1H), 4.38 - 4.33 (m, 2H), 3.47 (d, J = 12.1 Hz, 2H), 3.08 (dd, J = 12.1, 4.5 Hz, 2H), 2.50 (s, 3H), 1.51 (s, 9H), 1.38 (d, J = 6.4 Hz, 6H).ESI-MS: [M+H] + :508.1

[0468] Step 3: 7-((3S,5R)-3,5-Dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl (2S,6R)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,6-dimethylpiperazine-1-carboxylate (50 mg, 0.099 mmol) in EtOAc (2 mL) was added 3 M HCl / EtOAc (3 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered, and the solid was dried by lyophilization to give the title product (25 mg, yield: 57.3%) as a yellow solid. 1 H NMR (400 MHz, MeOD-d4) δ 9.66 (s, 1H), 8.67 (d, J = 11.0 Hz, 1H), 8.58 (s, 1H), 8.42 (d, J = 11.8 Hz, 1H), 8.23 ​​(s, 1H), 7.89 (d, J = 9.5 ESI-MS: [M+H] + 408.2.

[0469] Example 25. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 108) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)piperazine-1-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (10 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. Then, tert-butyl 4-(6-amino-5-methylpyridin-3-yl)piperazine-1-carboxylate (600 mg, 2.0 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1.0 mmol) in dry THF (5 mL) was added to the mixture at −40° C., and the mixture was warmed to room temperature and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 1:1 to 0:1) to give the title product (60 mg, yield: 22.5%) as a yellow solid. ESI-MS: [M+H] + :468.3

[0470] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)piperazine-1-carboxylate (60 mg, 0.121 mmol) in THF (6 mL) and pyridine (0.6 mL) was added triphosgene (108 mg, 0.363 mmol). The reaction mixture was stirred at room temperature for 1 hour, and the mixture was diluted with water (10 mL) and extracted with EtOAc (20 mL × 2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous FA / CH3CN) to give the title product (30 mg, 47.6%). 1H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 1.3 Hz, 1H), 8.41 (d, J = 2.8 Hz, 1H), 7.97 (dd, J = 11.6, 1.3 Hz, 1H), 7.76 (dd, J = 2.7, 0.9 Hz, 1H), 7.48 s, 1H), 3.66 - 3.61 (m, 4H), 3.28 - 3.22 (m, 4H), 2.69 (s, 3H), 2.51 (s, 3H), 1.50 (s, 9H).ESI-MS: [M+H] + :494.3.

[0471] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (30 mg, 0.061 mmol) in EtOAc (0.5 mL) was added 3M HCl / EtOAc (1 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered and dried by lyophilization to give the title product (18 mg, yield: 69.2%) as a yellow solid. 1 H NMR (400 MHz, MeOD-d4) δ 9.68 (s, 1H), 8.66 (d, J = 10.8 Hz, 1H), 8.49 (d, J = 2.8 Hz, 1H), 8.31 - 8.27 (m, 2H), 3.69 - 3.65 (m, 4H), 3.49 - 3.45 (m, 4H), 2.75 (s, 3H), 2.63 (s, 3H).ESI-MS: [M+H] + :394.2.

[0472] Example 26. Synthesis of 7-(3,3-dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 109) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate To a solution of diisopropylamine (220 mg, 2.2 mmol) in THF (6 mL) was added n-BuLi (1.5 mL, 1.6 M) under N2 at -60 °C. The mixture was stirred for 1 hour, and then tert-butyl 4-(6-aminopyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (612 mg, 2 mmol) in THF (5 mL) was added at -60 °C. The mixture was warmed to room temperature and stirred at room temperature for 1.5 hours. The mixture was cooled again to -60 °C. Then 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in THF (5 mL) was added. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (220 mg, 45.7% yield) as a gray solid. ESI-MS (M+H) + :482.3. 1 H NMR (400 MHz, CDCl3): δ 8.64 (s, 1H), 7.83 (s, 1H), 7.47 (s, 1H), 7.36 (d, J = 10.9 Hz, 1H), 7.23 (s, 1H), 7.16 - 7.05 (m, 1H), 3.81 (d, J = 4.9 Hz, 2H), 3.49 (s, 2H), 3.40 (br s, 2H), 2.48 (s, 3H), 1.50 (s, 9H), 1.44 (s, 6H).

[0473] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,2-dimethylpiperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (220 mg, 0.46 mmol) in THF (6 mL) and pyridine (1 mL) was added triphosgene (407 mg, 1.37 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL x 3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (150 mg, 64.6% yield) as a yellow solid. ESI-MS (M+H) + :508.7. 1 H NMR (400 MHz, CDCl3): δ 9.20 (s, 1H), 8.36 (s, 1H), 7.93 (d, J = 11.7 Hz, 1H), 7.77 (d, J = 9.3 Hz, 1H), 7.67 (d, J = 9.5 Hz, 1H), 7.47 (s, 1H), 3.90 (br.s, 2H), 3.52 (br.s, 2H), 3.45 (s, 2H), 2.50 (s, 3H), 1.47 (s, 15H).

[0474] Step 3: 7-(3,3-dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one A solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,2-dimethylpiperazine-1-carboxylate (140 mg) in 4M HCl / EA (5 mL) was stirred at room temperature for 1 hour. The precipitate was filtered, and the filter cake was further purified by preparative HPLC to give the title compound (30 mg, 24.4% yield) as a yellow solid. ESI-MS (M+H) + :408.1. 1 H NMR (400 MHz, CDCl3): δ 9.22 (s, 1H), 8.46 (s, 1H), 7.95 - 7.89 (m, 2H), 7.64 (d, J = 9.6 Hz, 1H), 7.48 (s, 1H), 3.25 - 3.17 (m, 2H), 3.17 - 3.10 (m, 2H), 3.02 (s, 2H), 2.50 (s, 3H), 1.26 (s, 6H).

[0475] Example 27. Synthesis of 9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 110) [ka] Step 1: tert-butyl 4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate To a solution of diisopropylamine (606 mg, 6 mmol) and THF (10 mL), n-BuLi (6.4 mmol, 1.6 M, 4 mL) was added under N2 at -60 °C, and the mixture was stirred for 1 hour. tert-Butyl 4-(6-amino-5-fluoropyridin-3-yl)piperazine-1-carboxylate (1.34 g, 4.5 mmol) in THF (10 mL) was added at -60 °C, and the mixture was warmed to room temperature and stirred for 1.5 hours. The mixture was cooled again to -60 °C. Then, 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (525 mg, 3 mmol) in THF (15 mL) was slowly added. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL x 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (300 mg, 21.2% yield) as a gray solid. ESI-MS (M+H) + :472.1. Step 2: tert-Butyl 4-(9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate (300 mg, 0.64 mmol) in THF (15 mL) and pyridine (1.5 mL) was added triphosgene (1.2 g, 2.22 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by preparative HPLC (0.05% aqueous FA / CHCN) to give the title compound (130 mg, 41.1% yield) as a yellow solid. ESI-MS (M+H) + :498.1.

[0476] Step 3: 9-Fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride A solution of tert-butyl 4-(9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (130 mg, 0.26 mmol) in 3M HCl / EtOAc (5 mL) was stirred at room temperature for 1 hour. The mixture was filtered. The solid was washed with EtOAc (1 mL) and dried under vacuum to give the title compound (105 mg, 94.6% yield) as a yellow solid. ESI-MS (M+H) + :398.1. 1 H NMR(400MHz,MeOD-d4) δ 9.67 (d, J = 0.9 Hz, 1H), 8.65 (dd, J = 10.9, 1.1 Hz, 1H), 8.44 (d, J = 2.0 Hz, 1H), 8.35 (dd, J = 11.3, 2.6 Hz, 1H), 8.24 (dd, J = 2.1, 1.1 Hz, 1H), 3.72 - 3.65 (m, 4H), 3.50 - 3.43 (m, 4H), 2.62 (d, J = 0.9 Hz, 3H).

[0477] Example 28. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 111) [ka] Step 1: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate A mixture of 7-bromo-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (100 mg, 0.268 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (124 mg, 0.402 mol), KCO (111 mg, 0.804 mol), and Pd(dppf)Cl (22 mg, 0.027 mmol) in 1,4-dioxane / HO (15 mL / 3 mL) was stirred at 95 °C for 3 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (30 mL × 3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The crude product was purified by preparative HPLC (0.05% FA in water / CH3CN) to give the title compound (40 mg, 31.3% yield) as a yellow solid. ESI-MS (M+H) + :477.1.

[0478] Step 2: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (30 mg, 0.063 mmol) in 2 mL of EtOAc was added 3M HCl / EtOAc (2 mL) at room temperature. The reaction mixture was stirred for 1 hour. The precipitate was filtered and dried under vacuum to give the title product (6 mg, yield: 25.3%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.70 - 9.65 (m, 1H), 9.36 (s, 2H), 8.89 (s, 1H), 8.60 (d, J = 9.2 Hz, 1H), 8.26 - 8.15 (m, 2H), 7.83 (d, J = 9.0 Hz, 1H), 6.61 (s, 1H), 3.85 (s, 2H), 3.40 - 3.33 (m, 2H), 2.79 (br.s, 2H), 2.48 (s, 3H).ESI-MS: [M+H] + =377.1.

[0479] Example 29. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(pyrrolidin-3-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 112) [ka] Step 1: tert-butyl 3-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)pyrrolidine-1-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (20 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 3-(6-aminopyridin-3-yl)pyrrolidine-1-carboxylate (512 mg, 2 mmol) in dry THF (7 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in dry THF (10 mL) was added to the mixture at −65° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (20 mL) and extracted with EtOAc (15 mL×2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by C18-flash (0.05% aqueous NH3.H2O / CH3CN) to give the title product (60 mg, yield: 13.7%) as a yellow solid. ESI-MS: [M+H] + =439.1.

[0480] Step 2: tert-Butyl 3-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)pyrrolidine-1-carboxylate To a solution of tert-butyl 3-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)pyrrolidine-1-carboxylate (60 mg, 0.14 mmol) in THF (5 mL) and pyridine (1 mL) was added triphosgene (125 mg, 0.42 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (15 mL) and extracted with EtOAc (15 mL x 2). The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous NH3.HO / CH3CN) to give the title product (4 mg, 6.3%). ESI-MS: [M+H] + =465.1.

[0481] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(pyrrolidin-3-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 3-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)pyrrolidine-1-carboxylate (4 mg, 0.009 mmol) in EtOAc (2 mL) was added 3M HCl / EtOAc (3 mL) at room temperature. The reaction mixture was stirred for 1 hour. The precipitate was filtered and dried under vacuum to give the title product (0.9 mg, yield: 29%) as a white solid. 1 H NMR (400 MHz, MeOD-d4) δ 9.72 (s, 1H), 9.12 (s, 1H), 8.69 (d, J = 10.8 Hz, 1H), 8.46 (d, J = 7.0 Hz, 1H), 8.25 (s, 1H), 7.94 (d, J = 7.4 3.86 (br.s, 2H), 3.66 (br.s, 1H), 3.40 - 3.35 (m, 3H), 2.63 (s, 3H), 1.34 - 1.27 (m, 1H). + 365.1.

[0482] Example 30. Synthesis of (2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 113) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylindolizine-6-carboximidamido)pyridin-3-yl)piperidine-1-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (20 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate (556 mg, 2 mmol) in dry THF (7 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in dry THF (10 mL) was added to the mixture at −65° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (20 mL) and extracted with EtOAc (15 mL×2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by C18 flash to give the title product (150 mg, yield: 33.3%) as a yellow solid. 1 H NMR (400 MHz, DMSO-D6) δ 9.04 (d, J = 1.1 Hz, 1H), 8.24 (d, J = 2.3 Hz, 1H), 7.94 (d, J = 2.5 Hz, 1H), 7.70 - 7.62 (m, 2H), 7.09 (d, J = 8.4 Hz, 1H), 4.14 - 4.02 (m, 2H), 2.89 - 2.65 (m, 3H), 2.37 (s, 3H), 1.77 - 1.74 (m, 2H), 1.57 - 1.51 (m, 2H), 1.41 (s, 9H).ESI-MS: [M+H] + =453.2.

[0483] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperidine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylindolizine-6-carboximidamido)pyridin-3-yl)piperidine-1-carboxylate (150 mg, 0.33 mmol) in THF (5 mL) and pyridine (1 mL) was added triphosgene (294 mg, 0.99 mmol). The reaction mixture was stirred at room temperature for 1 hour, and the mixture was diluted with water (15 mL) and extracted with EtOAc (15 mL x 2). The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title product (60 mg, yield: 38%) as a yellow solid. ESI-MS: [M+H] + =479.1.

[0484] Step 3: (2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperidine-1-carboxylate (60 mg, 0.125 mmol) in EtOAc (2 mL) was added 3M HCl / EtOAc (5 mL) at room temperature. The reaction mixture was stirred for 1 hour. The precipitate was filtered, and the solid was dried under vacuum to give the title product (15 mg, yield: 32%) as a white solid. H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 1H), 9.17 (s, 2H), 8.85 (s, 1H), 8.32 - 8.29 (m, 3H), 7.86 (d, J = 9.0 Hz, 1H), 3.41 - 3.39 (m, 2H), 3.19 (br.s, 1H), 3.02 (br.s, 2H), 2.10 - 1.94 (m, 4H).ESI-MS: [M+H] + 379.2.

[0485] Example 31. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 114) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methoxypyridin-3-yl)piperazine-1-carboxylate To a solution of diisopropylamine (110 mg, 1.1 mmol) in THF (6 mL) was added n-BuLi (0.75 mL, 1.6 M) under N2 at -60 °C, and the mixture was stirred for 1 hour. tert-Butyl 4-(6-amino-5-methoxypyridin-3-yl)piperazine-1-carboxylate (308 mg, 1 mmol) in THF (5 mL) was added, and the mixture was warmed to room temperature and stirred for 1.5 hours. The mixture was cooled again to -60 °C. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (88 mg, 0.5 mmol) in THF (5 mL) was added slowly. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (45 mg, 21.3% yield) as a grey solid. ESI-MS (M+H) + :484.3.

[0486] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methoxy-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methoxypyridin-3-yl)piperazine-1-carboxylate (45 mg, 0.09 mmol) in THF (8 mL) and pyridine (1 mL) was added triphosgene (83 mg, 0.75 mmol), and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was suspended in MeOH, stirred for 1 h, and the precipitate was filtered to give the title compound (15 mg, 32% yield) as a yellow solid. ESI-MS (M+H) + :510.1.

[0487] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride A solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methoxy-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (15 mg, 0.029 mmol) in 3M HCl / EA (2 mL) was stirred at room temperature for 1 hour. The precipitate was filtered and the solid was dried to give the title compound (9 mg, 81.8% yield) as a yellow solid. ESI-MS (M+H) + :410.2. 1 H NMR (400 MHz, MeOD-d4) δ 9.66 (s, 1H), 8.68 (d, J = 10.8 Hz, 1H), 8.24 (s, 2H), 7.77 (d, J = 2.1 Hz, 1H), 4.17 (s, 3H), 3.69 - 3.65 (m, 4H), 3.49 - 3.46 (m, 4H), 2.62 (s, 3H).

[0488] Example 32. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 115) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-4-methylpyridin-3-yl)piperazine-1-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (10 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. Then, tert-butyl 4-(6-amino-4-methylpyridin-3-yl)piperazine-1-carboxylate (438 mg, 1.5 mmol) was added, and the mixture was warmed to room temperature and stirred at room temperature for 1.5 hours. The mixture was cooled again to −60° C. Then, 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1.0 mmol) in THF (5 mL) was added, and the mixture was warmed to room temperature and stirred overnight. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL×3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (150 mg, 51.2% yield) as a gray solid. ESI-MS (M+H) + :468.2.

[0489] Step 2: tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-4-methylpyridin-3-yl)piperazine-1-carboxylate (70 mg, 0.15 mmol) in THF (15 mL) and pyridine (1 mL) was added triphosgene (134 mg, 0.45 mmol) at 0° C., and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C column chromatography to give the title compound (18 mg, 24.3% yield) as a yellow solid. ESI-MS (M+H) + :494.1.

[0490] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride A solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (18 mg, 0.04 mmol) in HCl / EA (3 mL) was stirred at room temperature for 1 hour. The mixture was filtered and the solid was dried under vacuum to give the title compound (10 mg, 62.5%) as a yellow solid. ESI-MS (M+H) + :394.2. 1 H NMR (400 MHz, MeOD-d4) δ 9.64 (s, 1H), 8.73 (s, 1H), 8.63 (d, J = 11.0 Hz, 1H), 8.20 (s, 1H), 7.80 (s, 1H), 3.51 - 3.47 (m, 4H), 3.39 - 3.36 (m, 4H), 2.66 (s, 3H), 2.61 (s, 3H).

[0491] Example 33. Synthesis of (S)-9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 116) [ka] Step 1: tert-butyl (S)-4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of diisopropylamine (0.3 mL, 2.2 mmol) in dry THF (10 mL), n-BuLi (1.5 mL, 2.4 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour, and then tert-butyl (S)-4-(6-amino-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate (465 mg, 1.56 mmol) in THF (2 mL) was added, and the mixture was warmed to room temperature and stirred for 1.5 hours. The mixture was cooled again to −60° C. Then, 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in THF (5 mL) was slowly added, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL×3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (150 mg, 30% yield) as a gray solid. ESI-MS (M+H) + :486.3. 1H NMR (400 MHz, CDCl3): δ 8.65 (d, J = 1.3 Hz, 1H), 7.78 (d, J = 2.6 Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 7.33 (dd, J = 11.1, 1.3 Hz, 1H), 7.04 (dd, J = 12.4, 2.6 Hz, 1H), 4.44 - 4.34 (m, 1H), 3.98 (d, J = 13.8 Hz, 1H), 3.48 (d, J = 11.9 Hz, 1H), 3.38 - 3.21 (m, 2H), 3.02 - 3.00 (m, 1H), 2.83 - 2.80 (m, 1H), 2.50 (s, 3H), 1.49 (s, 9H), 1.31 (d, J = 6.7 Hz, 3H).

[0492] Step 2: tert-Butyl (S)-4-(9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2-methylpiperazine-1-carboxylate (1.0 g, 2.06 mmol) in THF (100 mL) was added triphosgene (1.83 g, 6.18 mmol) and pyridine (10 mL) at 0° C. The mixture was stirred at 0° C. for 20 minutes. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL×3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by preparative HPLC (0.05% aqueous HCl / CHCN) to give the title compound (550 mg, yield: 52.6%) as a yellow solid. ESI-MS (M+H) + :512.0. 1H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 1.2 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 7.97 (dd, J = 11.6, 1.2 Hz, 1H), 7.63 (dd, J = 10.5, 2.6 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 4.44 - 4.40 (m, 1H), 4.04 (d, J = 13.6 Hz, 1H), 3.59 (d, J = 12.0 Hz, 1H), 3.44 - 3.40 (m, 1H), 3.36 - 3.29 (m, 1H), 3.21 - 3.16 (m, 1H), 3.03 - 2.96 (m, 1H), 2.51 (s, 3H), 1.50 (s, 9H), 1.30 (d, J = 6.8 Hz, 3H).

[0493] Step 3: (S)-9-Fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one. To a solution of tert-butyl (S)-4-(9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (1.1 g, 2.15 mmol) in EtOAc (10 mL) was added 3 M HCl / EtOAc (15 mL) at room temperature. The reaction mixture was stirred for 1 hour. The mixture was concentrated in vacuo, and the residue was purified by preparative HPLC (0.05% aqueous NHOH / CHCN) to give the title compound (520 mg, 58%) as a yellow solid. ESI-MS (M+H) + :412.1. 1H NMR (400 MHz, DMSO-d6 ) δ 9.43 (d, J = 1.1 Hz, 1H), 8.43 (dd, J = 12.4, 2.5 Hz, 1H), 8.10 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.78 (dd, J = 12.3, 1.0 Hz, 1H), 3.70 - 3.65 (m, 2H), 3.02 - 2.99 (m, 1H), 2.81 - 2.66 (m, 3H), 2.39 (s), 2.37 - 2.33 (m, 1H), 1.06 (d, J = 6.0 Hz, 3H).

[0494] Example 34. Synthesis of (S)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 117) [ka] Step 1: tert-butyl (S)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of diisopropylamine (0.9 mL, 6.6 mmol) in dry THF (25 mL), n-BuLi (4.5 mL, 7.2 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl (S)-4-(6-amino-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (1.38 g, 4.5 mmol) in dry THF (7 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (525 mg, 3.0 mmol) in dry THF (10 mL) was added to the mixture at −65° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (40 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by C18 flash to give the title product (600 mg, yield: 41.5%) as a yellow solid. 1 H NMR (400 MHz, MeOD-d4) δ 8.83 (s, 1H), 7.88 (d, J = 2.6 Hz, 1H), 7.79 (d, J = 2.1 Hz, 1H), 7.65 (d, J = 11.7 Hz, 1H), 7.32 (d, J = 2.6 Hz, 1H), 4.35 (br.s, 1H), 3.95 (d, J = 13.3 Hz, 1H), 3.56 (d, J = 11.5 Hz, 1H), 3.49 - 3.42 (m, 1H), 3.25 (d, J = 3.5 Hz, 1H), 2.89 - 2.86 (m, 1H), 2.71 - 2.68 (m, 1H), 2.45 (s, 3H), 2.38 (s, 3H), 1.50 (s, 9H), 1.33 (d, J = 6.7 Hz, 3H).ESI-MS: [M+H] + =482.1.

[0495] Step 2: tert-Butyl (S)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (600 mg, 1.25 mmol) in THF (50 mL) and pyridine (10 mL) was added triphosgene (1.11 g, 3.74 mmol). The reaction mixture was stirred at 0° C. for 15 min. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was mixed with MeOH (40 mL) and stirred at room temperature for 1 h. The precipitate was filtered and dried in vacuo to give the title product (310 mg, yield: 49%) as a yellow solid. ESI-MS: [M+H] + = 508.2.

[0496] Step 3: (S)-2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl (S)-4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (80 mg, 0.157 mmol) in EtOAc (2 mL) was added 3 M HCl / EtOAc (5 mL) at room temperature. The reaction mixture was stirred for 1 hour. The precipitate was filtered and dried under vacuum to give the title product (50 mg, yield: 64%) as a yellow solid. 1H NMR (400 MHz, MeOD-d4) δ 9.68 (s, 1H), 8.68 (dd, J = 10.9, 0.9 Hz, 1H), 8.50 (d, J = 2.7 Hz, 1H), 8.31 - 8.24 (m, 2H), 4.03 - 3.98 (m, 2H), 3.59 - 3.56 (m, 2H), 3.38 - 3.36 (m, 1H), 3.26 - 3.20 (m, 1H), 3.02 - 3.00 (m, 1H), 2.76 (s, 3H), 2.62 (s, 3H), 1.45 (d, J = 6.7 Hz, 3H).ESI-MS: [M+H] + 408.0.

[0497] Example 35. Synthesis of 7-(3,9-diazabicyclo[3.3.1]nonan-3-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 118) [ka] Step 1: tert-butyl 3-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)3,9-diazabicyclo[3.3.1]nonane-9-carboxylate To a mixture of diisopropylamine (184 mg, 1.06 mmol) in dry THF (10 mL), n-BuLi (0.81 mL, 1.30 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 3-(6-aminopyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (280 mg, 0.88 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (100 mg, 0.59 mmol) in dry THF (5 mL) was added to the mixture at −40° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous HCl / CHCN) to give the title product (20 mg, yield: 7.1%) as a yellow solid. ESI-MS: [M+H] + :494.2.

[0498] Step 2: tert-Butyl 3-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate To a solution of tert-butyl 3-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (20 mg, 0.041 mmol) in THF (4 mL) and pyridine (0.4 mL) was added triphosgene (36 mg, 0.122 mmol). The reaction mixture was stirred at room temperature for 1 hour, and the mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous HCl / CH3CN) to give the title product (18 mg, yield: 85.7%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 1.2 Hz, 1H), 8.46 (d, J = 2.8 Hz, 1H), 7.96 - 7.92 (m, 2H), 7.67 (d, J = 9.4 Hz, 1H), 7.48 (d, J = 2.8 Hz, 1H), 4.49 - 4.48 (m, 1H), 4.38 - 4.33 (m, 1H), 3.72 - 3.69 (m, 1H), 3.63 (d, J = 11.6 Hz, 1H), 3.24 (d, J = 11.6 Hz, 2H), 2.50 (s, 3H), 2.29 - 2.19 (m, 2H), 1.97 - 1.88 (m, 2H), 1.83 - 1.78 (m, 2H), 1.51 (s, 9H).ESI-MS: [M+H] + :520.0.

[0499] Step 3: 7-(3,9-diazabicyclo[3.3.1]nonan-3-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 3-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (18 mg, 0.0347 mmol) in EtOAc (0.5 mL) was added 3M HCl / EtOAc (1 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered and dried under vacuum to give the title product (8.08 mg, yield: 50.9%) as a yellow solid. 1 H NMR (400 MHz, MeOD-d4) δ 9.66 (s, 1H), 8.67 (d, J = 10.8 Hz, 1H), 8.55 (s, 1H), 8.47 (d, J = 10.8 Hz, 1H), 8.24 (s, 1H), 7.91 (d, J = 8.8 Hz, 1H), 4.16 (d, J = 12.8 Hz, 2H), 3.92 - 3.86 (m, 2H), 3.54 (d, J = 12.4 Hz, 2H), 2.63 (s, 3H), 2.41 - 2.33 (m, 1H), 2.21 - 2.23 (m, 4H), 1.74 - 1.65 (m, 1H).ESI-MS: [M+H] + :420.1.

[0500] Example 36. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 119) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-4-methoxypyridin-3-yl)piperazine-1-carboxylate To a mixture of diisopropylamine (121 mg, 1.2 mmol) in dry THF (5 mL), n-BuLi (0.9 mL, 1.44 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. Then, tert-butyl 4-(6-amino-4-methoxypyridin-3-yl)piperazine-1-carboxylate (308 mg, 1 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (110 mg, 0.66 mmol) in dry THF (5 mL) was added to the mixture at −40° C., warmed to room temperature, and stirred for 16 hours. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine, dried over Na2SO4 and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (70 mg, 21.2% yield) as a grey solid. 1 H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 7.82 (s, 1H), 7.46 (s, 1H), 7.36 - 7.32 (m, 1H), 6.79 (s, 1H), 3.94 (s, 3H), 3.64 - 3.59 (m, 4H), 3.07 - 3.00 (m, 4H), 2.50 (s, 3H), 1.49 (s, 9H).

[0501] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methoxy-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-4-methoxypyridin-3-yl)piperazine-1-carboxylate (70 mg, 0.15 mmol) in THF (8 mL) and pyridine (1 mL) was added triphosgene (1.2 g, 2.22 mmol), and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was suspended in MeOH and stirred for 1 h. The precipitate was filtered, and the solid was dried to give the title compound (30 mg, 41% yield) as a yellow solid. ESI-MS (M+H): 510.2.

[0502] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one. A solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-8-methoxy-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (30 mg, 0.05 mmol) in 3M HCl / EtOAc (4 mL) was stirred at room temperature for 1 hour. The mixture was filtered and the solid was dried under vacuum to give the title compound (9 mg, 45% yield) as a yellow solid. ESI-MS (M+H) + :410.0. 1 H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 2H), 9.56 (s, 1H), 8.34 (s, 1H), 8.18 (s, 1H), 8.08 (d, J = 11.8 Hz, 1H), 7.21 (s, 1H), 4.15 (s, 3H), 3.38 (br.s, 4H), 3.25 (br.s, 4H), 2.46 (s, 3H).

[0503] Example 37. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-oneformic acid (Compound 120) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-2-methoxypyridin-3-yl)piperazine-1-carboxylate To a mixture of diisopropylamine (79 mg, 0.78 mmol) in dry THF (15 mL), n-BuLi (0.53 mL, 0.85 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 4-(6-amino-2-methoxypyridin-3-yl)piperazine-1-carboxylate (200 mg, 0.65 mmol) in dry THF (2 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (80 mg, 0.45 mmol) in dry THF (5 mL) was added to the mixture at −65° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by C18 column to give the title product (20 mg, yield: 6.4%) as a white solid. ESI-MS: [M+H] + 484.2.

[0504] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methoxy-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-2-methoxypyridin-3-yl)piperazine-1-carboxylate (150 mg, 0.31 mmol) in THF (10 mL) and pyridine solution (2 mL) was added triphosgene (276 mg, 0.93 mmol). The reaction mixture was stirred at room temperature for 1 hour, and the mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was mixed with MeOH (40 mL) and stirred at room temperature for 1 hour. The precipitate was filtered and dried in vacuo to give the title product (20 mg, yield: 12.6%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 8.08 - 7.96 (m, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.26 - 7.17 (m, 1H), 6.85 (d, J = 9.3 Hz, 1H), 4.04 (s, 3H), 3.65 - 3.57 (m, 4H), 3.12 - 3.02 (m, 4H), 2.47 (s, 3H), 1.50 (s, 9H).ESI-MS: [M+H] + 510.2.

[0505] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-oneformic acid. To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methoxy-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (20 mg, 0.039 mmol) in EtOAc (1 mL) was added 3M HCl / EtOAc (2 mL) at room temperature. The reaction mixture was stirred for 2 hours. After concentration, the residue was purified by preparative HPLC to give the title product (10 mg, yield: 60%) as a yellow solid. 1H NMR (400 MHz, MeOD-d4) δ 1 H NMR (400 MHz, MeOD) δ 9.23 (s, 1H), 8.47 (s, 1H, HCO2H), 8.07 (s, 1H), 7.51 (dd, J = 20.0, 8.2 Hz, 2H), 7.28 - 7.25 (m, 1H), 4.06 (s, 3H), 3.40 (br s, 8H), 2.45 (s, 3H).ESI-MS: [M+H] + :410.0.

[0506] Example 38. Synthesis of (S)-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-fluoro-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 121) [ka] Step 1: tert-butyl (S)-4-(6-(2,8-dimethylimidazo[1,2-a]pyridine-6-carboximidamido)-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of diisopropylamine (0.9 mL, 5.4 mmol) in dry THF (20 mL), n-BuLi (4.2 mL, 6.6 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl (S)-4-(6-amino-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate (1.40 g, 4.5 mmol) in dry THF (10 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 2,8-Dimethylimidazo[1,2-a]pyridine-6-carbonitrile (513 mg, 3.0 mmol) in dry THF (10 mL) was added to the mixture at −40° C. The mixture was warmed to room temperature and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 1:1 to 0:1) to give the title product (133 mg, yield: 10%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 7.78 (d, J = 2.6 Hz, 1H), 7.40 (s, 1H), 7.36 (s, 1H), 7.06 - 7.01 (m, 1H), 4.42 - 4.34 (m, 1H), 3.98 - 3.96 (m, 1H), 3.47 - 3.43 (m, 1H), 3.31 - 3.23 (m, 2H), 3.00 - 2.96 (m, 1H), 2.85 - 2.77 (m, 1H), 2.65 (s, 3H), 2.49 (s, 3H), 1.49 (s, 9H), 1.31 (d, J = 6.8 Hz, 3H).

[0507] Step 2: tert-Butyl (S)-4-(2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-fluoro-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-(2,8-dimethylimidazo[1,2-a]pyridine-6-carboximidamido)-5-fluoropyridin-3-yl)-2-methylpiperazine-1-carboxylate (400 mg, 0.83 mmol) in THF (40 mL) and pyridine (4 mL) was added triphosgene (738 mg, 2.50 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 10 min. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous FA / CH3CN) to give the title product (200 mg, 47.5%) as a yellow solid. ESI-MS: [M+H] + 508.2.

[0508] Step 3: (S)-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-fluoro-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl (S)-4-(2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-fluoro-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (200 mg, 0.39 mmol) in EtOAc (10 mL) was added 3 M HCl / EtOAc (10 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered and dried under vacuum to give the title product (130 mg, yield: 74.5%) as a yellow solid. 1H NMR (400 MHz, MeOD-d4) δ 9.62 (s, 1H), 8.68 (s, 1H), 8.43 (d, J = 2.0 Hz, 1H), 8.38 - 8.31 (m, 1H), 8.12 (d, J = 1.0 Hz, 1H), 4.09 - 3.96 (m, 2H), 3.64 - 3.54 (m, 2H), 3.44 - 3.32 (m, 2H), 3.09 - 3.05 (m, 1H), 2.73 (s, 3H), 2.61 (s, 3H), 1.46 (d, J = 6.4 Hz, 3H).ESI-MS: [M+H] + 408.2.

[0509] Example 39. Synthesis of 2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 122) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-2-methylpyridin-3-yl)piperazine-1-carboxylate To a mixture of diisopropylamine (300 mg, 3.0 mmol) in dry THF (15 mL), n-BuLi (2.0 mL, 3.2 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour, and tert-butyl 4-(6-amino-2-methylpyridin-3-yl)piperazine-1-carboxylate (730 mg, 2.5 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (297 mg, 1.7 mmol) in dry THF (10 mL) was added to the mixture at −65° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by C18 column to give the title product (150 mg, yield: 12.6%) as a white solid. ESI-MS: [M+H] + :468.2.

[0510] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-2-methylpyridin-3-yl)piperazine-1-carboxylate (100 mg, 0.21 mmol) in THF (10 mL) and pyridine (2 mL) was added triphosgene (187 mg, 0.63 mmol). The reaction mixture was stirred at room temperature for 1 hour, and the mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was diluted with MeOH (40 mL) and stirred at room temperature for 1 hour. The precipitate was filtered, and the solid was dried in vacuo to give the title product (60 mg, 57.9%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 1.2 Hz, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.40 - 7.33 (m, 2H), 7.09 (d, J = 8.5 Hz, 1H), 3.65 - 3.52 (m, 4H), 2.90 - 2.81 (m, 4H), 2.52 (s, 3H), 2.49 (s, 3H), 1.49 (s, 9H).ESI-MS: [M+H] + 494.2.2.

[0511] Step 3: 2-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-6-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (20 mg, 0.041 mmol) in EtOAc (1 mL) was added 3M HCl / EtOAc (2 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered, and the solid was dried under vacuum to give the title product (5 mg, yield: 33%) as a yellow solid. 1 H NMR (400 MHz, MeOD-d4) δ 9.62 (s, 1H), 8.62 (d, J = 11.8 Hz, 1H), 8.27 - 8.20 (m, 2H), 7.72 (d, J = 9.2 Hz, 1H), 3.48 - 3.46 (m, 4H), 3.37 - 3.35 (m, 4H), 3.03 (s, 3H), 2.62 (s, 3H).ESI-MS: [M+H] + 394.0.

[0512] Example 40. Synthesis of (S)-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 123) [ka] Step 1: tert-butyl (S)-4-(6-(2,8-dimethylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate To a mixture of diisopropylamine (303 mg, 3.0 mmol) in dry THF (10 mL), n-BuLi (2.6 mL, 4.2 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl (S)-4-(6-amino-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (612 mg, 2.0 mmol) in dry THF (5 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 2,8-Dimethylimidazo[1,2-a]pyridine-6-carbonitrile (171 mg, 1.0 mmol) in dry THF (5 mL) was added to the mixture at −40° C., warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA = 1:1 to 0:1) to give the title product (90 mg, yield: 18%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 7.83 (d, J = 2.9 Hz, 1H), 7.42 - 7.40 m, 2H), 7.15 (d, J = 2.5 Hz, 1H), 4.40 - 4.33 (m, 1H), 3.97 (d, J = 13.4 Hz, 1H), 3.45 (d, J = 10.1 Hz, 1H), 3.34 - 3.22 (m, 2H), 2.93 (dd, J = 11.8, 3.8 Hz, 1H), 2.78 - 2.72 (m, 1H), 2.65 (s, 3H), 2.50 (s, 3H), 2.49 (s, 3H), 1.49 (s, 9H), 1.33 (d, J = 6.8 Hz, 3H).ESI-MS: [M+H] + 478.1.

[0513] Step 2: tert-Butyl (S)-4-(2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-(2,8-dimethylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (90 mg, 0.18 mmol) in THF (10 mL) and pyridine (1 mL) was added triphosgene (162 mg, 0.55 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was diluted with MeOH (10 mL) and stirred at room temperature for 1 hour. The precipitate was filtered and dried in vacuo to give the title product (70 mg, yield: 73.7%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.25 (d, J = 0.9 Hz, 1H), 8.39 (d, J = 2.7 Hz, 1H), 8.05 (s, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.42 (s, 1H), 4.45 - 4.40 (m, 1H), 4.05 - 4.00 (m, 1H), 3.60 - 3.56 (m, 1H), 3.44 - 3.41 (m, 1H), 3.31 - 3.27 (m, 1H), 3.08 (dd, J = 12.0, 4.0 Hz, 1H), 2.92 - 2.86 (m, 1H), 2.71 (s, 3H), 2.67 (s, 3H), 2.50 (s, 3H), 1.50 (s, 9H), 1.31 (d, J = 6.8 Hz, 3H).ESI-MS: [M+H] + 504.2.

[0514] Step 3: (S)-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To a solution of tert-butyl (S)-4-(2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (70 mg, 0.139 mmol) in EtOAc (4 mL) was added 3 M HCl / EtOAc (2 mL) at room temperature. The reaction mixture was stirred for 2 hours. The precipitate was filtered and dried under vacuum to give the title product (43 mg, yield: 70.5%) as a yellow solid. 1H NMR (400 MHz, MeOD-d4) δ 9.64 (s, 1H), 8.71 (s, 1H), 8.49 (d, J = 2.8 Hz, 1H), 8.26 (s, 1H), 8.13 (s, 1H), 4.03 (dd, J = 10.6, 7.4 Hz, 2H), 3.61 - 3.57 (m, 2H), 3.42 - 3.36 (m, 1H), 3.25 - 3.18 (m, 1H), 3.02 - 2.96 (m, 1H), 2.76 (s, 3H), 2.73 (s, 3H), 2.61 (s, 3H), 1.45 (d, J = 6.8 Hz, 3H).ESI-MS: [M+H] + 404.1.

[0515] Example 41. Synthesis of (S)-7-(3,4-dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 124) [ka] To a mixture of (S)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (40 mg, 0.09 mmol) in MeOH (5 mL) was added polyoxymethylene (15 mg, 0.45 mmol) and AcOH (catalytic) at room temperature. The mixture was stirred at this temperature for 0.5 hours, and NaBH(OAc)3 (19 mg, 0.27 mmol) was added. The mixture was stirred for 16 hours. The mixture was diluted with water (10 mL) and extracted with DCM (10 mL × 2). The combined organic layer was washed with brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (0.05% aqueous NH3.H2O / CH3CN) to give the title product (30 mg, yield: 78.9%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.43 (d, J = 1.1 Hz, 1H), 8.27 (s, 1H), 8.17 (d, J = 2.4 Hz, 1H), 8.03 (d, J = 2.2 Hz, 1H), 7.85 (d, J = 12.3 Hz, 1H), 3.67 (t, J = 10.5 Hz, 2H), 2.89 (t, J = 9.6 Hz, 2H), 2.61 (s, 3H), 2.53 (d, J = 8.9 Hz, 1H), 2.38 (s, 3H), 2.29 (dd, J = 17.8, 7.2 Hz, 1H), 2.24 (s, 3H), 2.18 (d, J = 6.3 Hz, 1H), 1.09 (d, J = 6.2 Hz, 3H).ESI-MS: [M+H] + =422.0.

[0516] Example 42. Synthesis of 7-(3,3-dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 125) [ka] Step 1: tert-butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate To a mixture of diisopropylamine (666 mg, 6.6 mmol) in dry THF (15 mL), n-BuLi (4.5 mL, 7.2 mmol, 1.6 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour. tert-Butyl 4-(6-amino-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (1.5 g, 4.5 mmol) in THF (20 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (525 mg, 3 mmol) in dry THF (5 mL) was added to the mixture at −40° C., warmed to room temperature, and stirred for 16 hours. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL×3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (400 mg, 30% yield) as a gray solid. ESI-MS (M+H) + :496.3. 1 H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 1.1 Hz, 1H), 7.72 (d, J = 3.0 Hz, 1H), 7.48 - 7.45 (m, 2H), 6.98 (d, J = 2.9 Hz, 1H), 3.82 - 3.77 (m, 2H), 3.41 - 3.36 (m, 2H), 3.27 (s, 2H), 2.49 (s, 3H), 2.48 (s, 3H), 1.50 (s, 9H), 1.44 (s, 6H).

[0517] Step 2: tert-Butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,2-dimethylpiperazine-1-carboxylate tert-Butyl 4-(6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)-5-methylpyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (400 mg, 0.808 mmol) was dissolved in THF (20 mL) and pyridine (2 mL), and triphosgene (1.2 g, 2.22 mmol) was added at 0° C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was suspended in MeOH and stirred for 1 hour. The precipitate was filtered to give the title compound (300 mg, 71% yield) as a yellow solid. ESI-MS (M+H) + :522.3. 1 H NMR (400 MHz, CDCl3) δ 9.22 - 9.17 (m, 1H), 8.31 - 8.25 (m, 1H), 7.96 - 7.89 (m, 1H), 7.60 - 7.57 (m, 1H), 7.49 - 7.46 (m, 1H), 3.91 - 3.87 (m, 2H), 3.51 - 3.49 (m, 2H), 3.41 (s, 2H), 2.71 (s, 3H), 2.50 (s, 3H), 1.51 (s, 9H), 1.46 (s, 6H).

[0518] Step 3: 7-(3,3-Dimethylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride A solution of tert-butyl 4-(2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,2-dimethylpiperazine-1-carboxylate (300 mg, 0.57 mmol) in 3M HCl / EtOAc (10 mL) was stirred at room temperature for 2 hours. The mixture was filtered, and the solid was washed with EtOAc (3 mL) and dried under vacuum to give the title compound (250 mg, 95.1%) as a yellow solid. ESI-MS (M+H) + :422.0. 1 H NMR(400MHz, MeOD-d4) δ 9.69 - 9.66 (m, 1H), 8.68 - 8.64 (m, 1H), 8.53 - 8.49 (m, 1H), 8.32 - 8.27 (m, 2H), 3.67 - 3.62 (m, 2H), 3.53 - 3.49 (m, 4H), 2.77 (s, 3H), 2.63 (s, 3H), 1.55 (s, 6H).

[0519] Example 43. Synthesis of 2-2,8-dimethylimidazo[1,2-a]pyridin-6-yl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride (Compound 126) [ka] Step 1: tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 5-Chloro-2-nitropyridine (150.0 g, 946.12 mmol), tert-butyl piperazine-1-carboxylate (185.03 g, 993.43 mmol), and potassium carbonate (326.9 g, 2.37 mol) were mixed in DMF (1000 mL), and the reaction mixture was stirred at 75° C. for 12 hours. The reaction mixture was diluted with water (4000 mL) and extracted with EtOAc (3×800 mL). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by silica gel column chromatography to give the title compound (110 g, 38% yield). 1 H NMR (400 MHz, DMSO-d6) δ 8.22 (d, J = 3.0 Hz, 1H), 8.14 (d, J = 9.0 Hz, 1H), 7.44 (dd, J = 9.3, 3.0 Hz, 1H), 3.49 (q, J = 6.0 Hz, 8H), 1.44 - 1.38 (s, 9H).

[0520] Step 2: tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate To a mixture of tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (9.5 g, 30.81 mmol) in MeOH (200 mL) was added 10% Pd / C (2 g). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 16 hours. The solvent was filtered, and the filter cake was washed with MeOH (50 mL). The filtrate was concentrated to give the title product (8 g, 93% yield). 1 H NMR(400MHz,DMSO-d6) δ7.60(d, J = 3.0 Hz, 1H), 7.17 (dd, J = 8.8, 3.0 Hz, 1H), 6.40 (d, J = 8.8 Hz, 1H), 5.48 (br s, 2H), 3.42 (t, J = 4.9 Hz, 4H), 2.84 (t, J = 5.0 Hz, 4H), 1.40 (s, 9H).ESI-MS:279.2 [M+H].

[0521] Step 3: Methyl 2,8-dimethylimidazo[1,2-a]pyridine-6-carboxylate 2,8-Dimethylimidazo[1,2-a]pyridine-6-carboxylic acid hydrochloride (10.0 g, 44.11 mmol) was dissolved in MeOH (100 mL), thionyl chloride (15.74 g, 132.34 mmol, 9.6 mL, 3.0 equiv.) was added dropwise, and the resulting mixture was stirred at room temperature for 18 hours. The mixture was then concentrated, and DCM (250 mL) was added. Saturated NaHCO (20 mL) was added, and the resulting mixture was stirred at room temperature for 15 minutes. The organic layer was washed with saturated NaHCO (150 mL), water (200 mL), and saturated aqueous NaCl (200 mL), then dried over NaSO, filtered, and concentrated to give methyl 2,8-dimethylimidazo[1,2-a]pyridine-6-carboxylate (8 g, 89% yield). 1 H NMR (400 MHz, DMSO-d6) δ 9.07 (d, J = 1.9 Hz, 1H), 7.80 (s, 1H), 7.41 - 7.35 (m, 1H), 3.85 (s, 3H), 2.46 (s, 3H), 2.34 (s, 3H).ESI-MS:205.2 [M+H].

[0522] Step 4: 2,8-Dimethylimidazo[1,2-a]pyridine-6-carboxamide To a solution of 2,8-dimethylimidazo[1,2-a]pyridine-6-carboxylate (5.8 g, 28.4 mmol) in MeOH (60 mL) was added 25% methanolic ammonia solution (80 mL), and the mixture was placed in an autoclave and heated at 80° C. for 12 h. The mixture was concentrated in vacuo to give the product (5 g, 93% yield). 1 H NMR (400 MHz, DMSO-d6) δ 8.86 (s, 1H), 7.95 (s, 1H), 7.73 (s, 1H), 7.41 (d, J = 12.4 Hz, 2H), 2.33 (s, 3H).

[0523] Step 5: 2,8-Dimethylimidazo[1,2-a]pyridine-6-carbonitrile 2,8-Dimethylimidazo[1,2-a]pyridine-6-carboxamide (5.0 g, 26.44 mmol) was dissolved in DCM (100 mL). Triethylamine (10.7 g, 105.75 mmol, 14.74 mL, 4.0 equiv.) was then added. TFAA (8.33 g, 39.66 mmol, 5.56 mL, 1.5 equiv.) was added dropwise at 0 °C. The mixture was stirred at this temperature for 20 minutes, warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (150 mL) and extracted with DCM (2 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (CHCl3 / ACN) to give the title product (2.5 g, 55% yield). ESI-MS: 172.1 [M+H].

[0524] Step 6: tert-Butyl 4-(6-2,8-dimethylimidazo[1,2-a]pyridine-6-imidamidopyridin-3-yl)piperazine-1-carboxylate To a mixture of tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (1.5 g, 5.39 mmol) in dry THF (25 mL) was added lithium bis(trimethylsilyl)amide (1.08 g, 6.47 mmol, 5.39 ml, 1.2 equiv) dropwise at −78° C. The mixture was warmed to −40° C. and stirred for 1 hour. 2,8-Dimethylimidazo[1,2-a]pyridine-6-carbonitrile (922.35 mg, 5.39 mmol) in dry THF (10 mL) was added at −78° C. The mixture was warmed to room temperature and stirred for 16 hours. The mixture was diluted with water (50 mL) and extracted with EtOAc (2×40 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (ACN / MeOH) to give the title product (1.5 g, 62% yield). ESI-MS: 450.2 [M+H].

[0525] Step 7: tert-Butyl 4-(2-2,8-dimethylimidazo[1,2-a]pyridin-6-yl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a mixture of tert-butyl 4-(6-2,8-dimethylimidazo[1,2-a]pyridin-6-imidamidopyridin-3-yl)piperazine-1-carboxylate (502.92 mg, 1.12 mmol) and triethylamine (566.28 mg, 5.6 mmol, 780.0 μL, 5.0 equiv.) in THF (15 mL) was added ditrichloromethyl carbonate (331.98 mg, 1.12 mmol). The reaction mixture was stirred at room temperature for 15 hours. The mixture was filtered, washed with THF (15 mL) and water (2×15 mL), and dried in vacuo to give the title product (0.2 g, 38% yield). 1 H NMR (400 MHz, DMSO-d6) δ 9.26 (s, 1H), 8.27 (s, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.85 (s, 1H), 7.78 (s, 1H), 7.64 (d, J = 8.7 Hz, 1H), 3.51 (s, 4H), 3.27 (s, 4H), 2.99 (d, J = 3.1 Hz, 3H), 2.34 (s, 3H), 1.41 (d, J = 5.0 Hz, 9H).

[0526] Step 8: 2-2,8-Dimethylimidazo[1,2-a]pyridin-6-yl-7-(piperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one hydrochloride To tert-butyl 4-(2-2,8-dimethylimidazo[1,2-a]pyridin-6-yl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (99.98 mg, 210.25 μmol) in MeOH (10 mL) was added HCl in dioxane (1 mL) at 0° C. The mixture was stirred at room temperature for 12 hours. After concentration, the residue was stirred with EtOAc. The precipitate was filtered and the solid was dried to give the title product (26 mg, 30% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 9.52 (s, 2H), 8.49 (s, 1H), 8.39 (s, 1H), 8.23 ​​(s, 1H), 7.77 (s, 1H), 3.59 (s, 4H), 3.24 (s, 4H), 2.67 (s, 3H).ESI-MS:376.2 [M+H].

[0527] Example 44. Synthesis of 7-2,6-diazaspiro[3.3]heptan-2-yl-2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4H-pyrido[1,2-a][1,3,5]triazin-4-one trifluoroacetate (Compound 127) [ka] Step 1: 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carboxamide To a solution of 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboxylate (8.0 g, 38.43 mmol) in MeOH (60 mL) was added 25% methanolic ammonia solution (100 mL), and the mixture was sealed in an autoclave and heated at 80 °C for 12 h. The mixture was concentrated in vacuo to give the product (5.9 g, 79% yield). ESI-MS: 194.0 [M+H].

[0528] Step 2: 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile 8-Fluoro-2-methylimidazo[1,2-a]pyridine-6-carboxamide (5.9 g, 30.53 mmol) was dissolved in DCM (100 mL). Triethylamine (9.27 g, 91.58 mmol, 12.76 mL, 3.0 equiv.) was then added. TFAA (9.62 g, 45.79 mmol, 6.42 mL, 1.5 equiv.) was added dropwise at 0 °C. The mixture was stirred at this temperature for 20 minutes, warmed to room temperature, and stirred for 16 hours. The mixture was diluted with water (150 mL) and extracted with DCM (2 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (CHCl3 / ACN) to give the title product (3 g, 56% yield). 1 H NMR (500 MHz, DMSO-d6) δ 9.17 (s, 1H), 7.91 (s, 1H), 7.54 (d, J = 11.1 Hz, 1H), 2.38 (s, 3H).ESI-MS:176.2 [M+H].

[0529] Step 3: N-(5-bromopyridin-2-yl)-8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamide To a solution of 5-bromopyridin-2-amine (2.96 g, 17.13 mmol) in THF (30 mL) was added sodium bis(trimethylsilyl)amide (3.74 g, 20.38 mmol, 8.77 mL, 1.19 equiv.) dropwise, and the reaction mixture was magnetically stirred at ice-bath temperature under Ar. After complete addition, the mixture was stirred for 30 min, and 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (3.0 g, 17.13 mmol) was added in one portion. The resulting mixture was stirred at room temperature overnight. The precipitate that formed was filtered, washed with HO and MTBE, and dried in vacuo to give the title product (4.5 g, 75% yield). 1H NMR (500 MHz, DMSO-d6) δ 9.77 - 9.71 (m, 1H), 8.72 (s, 1H), 8.22 (d, J = 2.7 Hz, 1H), 7.64 (dd, J = 8.6, 2.8 Hz, 1H), 7.49 (d, J = 3.1 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 6.58 (d, J = 13.2 Hz, 1H), 2.18 (s, 3H).

[0530] Step 4: 7-Bromo-2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4H-pyrido[1,2-a][1,3,5]triazin-4-one To a solution of N-(5-bromopyridin-2-yl)-8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamide (4.5 g, 12.92 mmol) in THF (60 mL) and triethylamine (6.54 g, 64.62 mmol, 9.01 mL, 5.0 equiv.) was added ditrichloromethyl carbonate (3.84 g, 12.92 mmol). The reaction mixture was stirred at room temperature for 12 hours. The mixture was filtered, washed with THF (2 × 50 mL) and water (2 × 45 mL), and dried in vacuo to give the title product (3 g, 62% yield). 1 H NMR (500 MHz, DMSO-d6) δ 9.25 (s, 1H), 8.81 (d, J = 2.3 Hz, 1H), 8.33 (dd, J = 8.6, 2.5 Hz, 1H), 8.07 - 7.99 (m, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 10.6 Hz, 1H), 2.34 (s, 3H).ESI-MS: [M+H] + 376.0.

[0531] Step 5: tert-Butyl 6-(2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate A mixture of 7-bromo-2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4H-pyrido[1,2-a][1,3,5]triazin-4-one (997.2 mg, 2.66 mmol), tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate hydrochloride (1.251 g, 5.33 mmol), SPhos (109.4 mg, 266.5 μmol), Pd(dba) (244.1 mg, 266.5 μmol), and cesium carbonate (2.605 g, 8 mmol) in toluene (25 mL) was stirred at 110° C. for 45 hours under Ar. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL × 2). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography to give the title compound (20 mg, 1.5% yield). ESI-MS: 492.2 [M+H].

[0532] Step 6: 7-2,6-Diazaspiro[3.3]heptan-2-yl-2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4H-pyrido[1,2-a][1,3,5]triazin-4-one trifluoroacetic acid To a solution of tert-butyl 6-(2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (20.0 mg, 40.69 μmol) in DCM (1 mL) was added TFA (232.37 mg, 2.04 mmol, 160.0 μL, 50.0 equiv) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 15 h. After concentration, the residue was purified by preparative HPLC (MeCN / 0.05% formic acid in water) to give the title product 7-2,6-diazaspiro[3.3]heptan-2-yl-2-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-4H-pyrido[1,2-a][1,3,5]triazin-4-one; trifluoroacetic acid (6 mg, 29% yield). ESI-MS: 392.2 [M+H].

[0533] Example 45. Synthesis of 7-[(3S)-3-ethylpiperazin-1-yl]-9-fluoro-2-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 128) [ka] Step 1: Preparation of tert-butyl (S)-2-ethyl-4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate Freshly prepared LDA (2.16 mmol, THF) was added dropwise to a solution of tert-butyl (S)-4-(6-amino-5-fluoropyridin-3-yl)-2-ethylpiperazine-1-carboxylate (486 mg, 1.5 mmol) in THF (5 mL) at −60° C., and the mixture was stirred at room temperature for 1.5 hours. The mixture was cooled again to −60° C. Then, 8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1 mmol) in THF (5 mL) was slowly added, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL×3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography eluted with MeCN:HO = 80% to 95% to give the title compound (120 mg, Y: 42.1%) as a yellow solid. ESI-MS (M+H)+: 500.1.

[0534] Step 2: Preparation of tert-butyl (S)-2-ethyl-4-(9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate To a solution of tert-butyl (S)-2-ethyl-4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)piperazine-1-carboxylate (100 mg, 0.20 mmol) in THF (50 mL) and pyridine (1.0 mL) was added triphosgene (178 mg, 0.60 mmol) at room temperature, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was diluted with water (500 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was treated with MeOH (10 mL) and stirred at room temperature for 1 hour. The precipitate was filtered to give the title compound (70 mg, Y: 66.7%) as a yellow solid. ESI-MS (M+H): 526.1.

[0535] Step 3: Preparation of (S)-7-(3-ethylpiperazin-1-yl)-9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one To a solution of (S)-2-ethyl-4-(9-fluoro-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)piperazine-1-carboxylate (50 mg, 0.095 mmol) in EtOAc (2 mL) was added 3M HCl / EtOAc (2 mL) at room temperature. The reaction mixture was stirred for 2 hours. The mixture was concentrated in vacuo, and saturated Na2CO3 (10 mL) was added. The resulting mixture was stirred at room temperature for 30 minutes, and the precipitate was filtered and dried to give the title compound (35 mg, 87.5%) as a yellow solid. ESI-MS (M+H): 426.1. 1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 8.32 (s, 1H), 7.96 (d, J = 11.5 Hz, 1H), 7.68 (d, J = 10.5 Hz, 1H), 7.49 (s, 1H), 3.58 - 3.57 (m, 2H), 3.22 - 3.21 (m, 1H), 3.02 - 2.93 (m, 2H), 2.88 - 2.72 (m, 1H), 2.57 - 2.56 (m, 1H), 2.50 (s, 3H), 1.57 - 1.49 (m, 2H), 1.04 (t, J = 7.3 Hz, 3H).

[0536] Example 46. Synthesis of 2-{2,7-dimethylpyrazolo[1,5-a]pyridin-5-yl}-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 129) [ka] Step 1: Preparation of tert-butyl (S)-4-(6-(2,7-dimethylpyrazolo[1,5-a]pyridine-5-carboximidamido)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate To a sterile, dry flask, DIPA (0.6 mL, 4.8 mmol) and THF (15 mL) were added, and the mixture was cooled to −60° C. Then, 1.6 M n-BuLi (3.3 mL, 5.28 mmol) was added dropwise at −60° C. under N2 and stirred for 1 h. tert-Butyl (S)-4-(6-amino-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (1.24 g, 4 mmol) in THF (10 mL) was added dropwise at −60° C., and the mixture was stirred at room temperature for 1.5 h. The mixture was cooled again to −60° C., and 2,7-dimethylpyrazolo[1,5-a]pyridine-5-carbonitrile (340 mg, 2 mmol) in THF (10 mL) was slowly added, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL x 3). The organic layer was washed with brine, dried over Na2SO4, and evaporated to give the crude title compound. The residue was purified by C18 column chromatography eluted with MeCN:HO = 80% to 95% to give the title compound (150 mg, Y: 15.8%) as a yellow solid. ESI-MS (M+H)+: 478.3.

[0537] Step 2: Preparation of tert-butyl (S)-4-(2-(2,7-dimethylpyrazolo[1,5-a]pyridin-5-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate To a solution of tert-butyl (S)-4-(6-(2,7-dimethylpyrazolo[1,5-a]pyridine-5-carboximidamido)-5-methylpyridin-3-yl)-2-methylpiperazine-1-carboxylate (130 mg, 0.273 mmol) in THF (60 mL) and pyridine (1.5 mL) was added triphosgene (242 mg, 0.819 mmol) at room temperature, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated to give the crude title compound. The residue was added MeOH (10 mL), stirred at room temperature for 1 hour, and the precipitate was filtered to give the title compound (100 mg, Y: 65.7%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.39 (d, J = 2.7 Hz, 1H), 7.73 - 7.67 (m, 2H), 6.98 (s, 1H), 6.54 (s, 1H), 4.45 - 4.44 (m, 1H), 4.05 - 4.00 (m, 1H), 3.61 - 3.56 (m, 1H), 3.45 - 3.41 (m, 1H), 3.34 - 3.27 (m, 1H), 3.10 - 3.06 (m, 1H), 2.93 - 2.86 (m, 1H), 2.80 (s, 3H), 2.72 (s, 3H), 2.56 (s, 3H), 1.50 (s, 9H), 1.32 (d, J = 6.7 Hz, 3H).

[0538] Step 3: Preparation of (S)-2-(2,7-dimethylpyrazolo[1,5-a]pyridin-5-yl)-9-methyl-7-(3-methylpiperazin-1-yl)-4H-pyrido[1,2-a][1,3,5]triazin-4-one To a solution of tert-butyl (S)-4-(2-(2,7-dimethylpyrazolo[1,5-a]pyridin-5-yl)-9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-7-yl)-2-methylpiperazine-1-carboxylate (75 mg, 0.15 mmol) in EtOAc (2 mL) was added 3 M HCl / EtOAc (3 mL) at room temperature. The reaction mixture was stirred for 2 hours. The mixture was concentrated in vacuo, and saturated Na2CO3 (10 mL) was added to the residue, stirred at room temperature for 30 minutes, and the precipitate was filtered to give the title compound (50 mg, 83.3%) as a yellow solid. ESI-MS (M+H)+: 404.2. 1 H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.40 (d, J = 2.7 Hz, 1H), 7.77 - 7.71 (m, 2H), 6.53 (s, 1H), 3.61 - 3.54 (m, 2H), 3.19 - 3.17 (m, 1H), 3.08 - 2.97 (m, 2H), 2.86 - 2.85 (m, 1H), 2.81 (s, 3H), 2.71 (s, 3H), 2.56 (s, 3H), 2.51 - 2.47 (m, 1H), 1.18 (d, J = 6.3 Hz, 3H).

[0539] Example 47. Synthesis of 7-(3,3-dimethylpiperazin-1-yl)-9-fluoro-2-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-4H-pyrido[1,2-a][1,3,5]triazin-4-one (Compound 130) [ka] Step 1: Preparation of tert-butyl 4-(5-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridine-6-carboximidamido)pyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate To a mixture of diisopropylamine (0.34 mL, 2.4 mmol) in dry THF (10 mL), n-BuLi (1.15 mL, 2.88 mmol, 2.5 M) was added dropwise at −65° C. The mixture was stirred at this temperature for 1 hour, and tert-butyl 4-(6-amino-5-fluoropyridin-3-yl)-2,2-dimethylpiperazine-1-carboxylate (620 mg, 2.0 mmol) in dry THF (4 mL) was added. The mixture was warmed to room temperature and stirred for 1 hour. 8-Fluoro-2-methyl-3,8a-dihydroimidazo[1,2-a]pyridine-6-carbonitrile (175 mg, 1.0 mmol) in dry THF (4 mL) was added to the mixture at −65° C., warmed to room temperature, and stirred for 16 hours. LCMS...

Claims

1. A compound of formula (I), 【Chemistry 1】 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NR 1 R 2 wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 1 1, 2, 3, or 4 R 6 is a heterocycloalkyl containing one nitrogen ring atom, optionally substituted with R 2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R 3 But, H, halo, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 But independently, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 are independently halogen, hydroxy, cyano, —COOH, —C(O)—C 1 -C 6 Alkyl, —C(O)O—C 1 -C 6 Alkyl, C 1 -C 7 Alkyl, C 1 -C 8 Heteroalkyl, C 1-7 Alkoxy-heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, -(CH 2 ) 0-2 -C 3 -C 8 Cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, NH 2 , NH(C 1 -C 6 Alkyl), N(C 1 -C 6 Alkyl) 2 , -NHC(O)-C 1 -C 6 Alkyl, -N(C 1 -C 6 alkyl)-C(O)-C 1 -C 6 Alkyl, —C(O)—NH 2 , -C(O)-NH(C 1 -C 6 alkyl), and -C(O)-N(C 1 -C 6 Alkyl) 2 wherein the alkyl, alkenyl, alkynyl, and alkoxy are selected from the group consisting of one or more of halogen, hydroxyl, or NH 2 and the cycloalkyl and heterocycloalkyl are optionally substituted with one or more of halogen, hydroxyl, C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Alkoxy, or NH 2 or Two R on the same carbon 6 can be taken together as keto (=O) or Two R's 6 Together, C 1-7 Forming an alkylene Each R 7 But independently, halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 cycloalkyl, 1-7 The alkyl is optionally substituted with OH; R 16 But, H, halo, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 17 But, H, halo, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 The compound, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, is cycloalkyl, or heterocycloalkyl.

2. A compound of formula (I), 【Chemistry 2】 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NR 1 R 2 wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 1 1, 2, 3, or 4 R 6 is a heterocycloalkyl containing one nitrogen ring atom, optionally substituted with R 2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R 3 But, H, halo, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 But independently, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 But independently, C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl or two R 6 Together, C 1-7 Forming an alkylene Each R 7 But independently, halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 cycloalkyl, 1-7 The alkyl is optionally substituted with OH; R 16 But, H, halo, C 1-7 Alkyl, or OR 5 and R 17 But, H, halo, C 1-7 Alkyl, or OR 5 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.

3. A compound of formula (I), 【Chemistry 3】 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a nitrogen-containing heterocycloalkyl that contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 3 But, H, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 However, independently, H, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 But independently, C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl or two R 6 Together, C 1-7 Forming an alkylene Each R 7 But independently, Halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 is haloalkoxy; R 16 But, H, halo, C 1-7 Alkyl, or OR 5 and R 17 But, H, halo, C 1-7 Alkyl, or OR 5 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.

4. A compound of formula (II), 【Chemistry 4】 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NR 1 R 2 wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 1 1, 2, 3, or 4 R 6 is a heterocycloalkyl containing one nitrogen ring atom, optionally substituted with R 2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R 3 But, H, halo, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 But independently, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 But independently, C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl or two R 6 Together, C 1-7 Forming an alkylene Each R 7 But independently, halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 cycloalkyl, 1-7 The compound, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein alkyl is optionally substituted with OH.

5. A compound of formula (II), 【Chemistry 5】 or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a nitrogen-containing heterocycloalkyl that contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 3 But, H, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 But independently, C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 But independently, C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl or two R 6 Together, C 1-7 Forming an alkylene Each R 7 are independently halo or C 1-7 The compound, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein:

6. A is a nitrogen-containing heterocycloalkyl that contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 and attached to formula (I) or (II) by one of its nitrogen atoms, Each R 6 But independently, C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl or two R 6 Together, C 1-7 The compound according to any one of claims 1 to 5, which forms an alkylene.

7. Each R 6 But independently, C 1-7 Alkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl or two R 6 Together, C 1-7 The compound according to any one of claims 1 to 6, which forms an alkylene.

8. Each R 6 are independently methyl, ethyl, isopropyl, methoxy-azetidinyl, or pyrrolidinyl, or two R 6 A compound according to any one of claims 1 to 7, wherein together form ethylene or propylene.

9. A, 【Chemistry 6】 and Y is absent, N or CH; R 9 is hydrogen, C 1-7 Alkyl, or (CH 2 ) m -NR 14 R 15 and R 10 is hydrogen or C 1-7 is alkyl, R 11 is hydrogen or C 1-7 is alkyl, R 12 is hydrogen or C 1-7 is alkyl, R 13 is hydrogen or C 1-7 is alkyl, Each R 14 and R 15 are independently hydrogen, C 1-7 Alkyl, and C 3-8 is cycloalkyl, n is 0, 1, or 2; m is 0, 1, or 2; Or R 9 and R 10 Together, C 1-7 Form an alkylene, or Or R 9 and R 12 Together, C 1-7 Form an alkylene, or Or R 10 and R 11 Together, C 2-7 Alkylene, or C 1-7 forming a 4-6 membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 12 Together, C 1-7 Alkylene, or C 1-7 forming a 4-6 membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 14 Together, C 1-7 Form an alkylene, or Or R 12 and R 13 Together, C 2-7 Form an alkylene, or Or R 12 and R 14 Together, C 1-7 Form an alkylene, or Or R 14 and R 15 Together, C 2-7 Forms an alkylene, which is 1-7 The compound of any one of claims 1 to 8, optionally substituted with alkoxy.

10. 10. The compound of claim 9, wherein Y is N.

11. Y is CH and R 9 However, (CH 2 ) m -NR 14 R 15 10. The compound of claim 9,

12. The compound according to any one of claims 9 to 11, wherein n is 1.

13. R 9 The compound according to any one of claims 9 to 10 and 12, wherein is hydrogen, pyrrolidinyl, or methoxy-azetidinyl.

14. R 10 The compound according to any one of claims 9 to 13, wherein is hydrogen, methyl, ethyl, or isopropyl.

15. R 11 The compound according to any one of claims 9 to 14, wherein is hydrogen or methyl.

16. R 12 The compound according to any one of claims 9 to 15, wherein is hydrogen or methyl.

17. R 13 The compound according to any one of claims 9 to 16, wherein is hydrogen.

18. R 9 and R 10 A compound according to any one of claims 9 to 17, wherein together form propylene.

19. R 10 and R 11 A compound according to any one of claims 9 to 17, wherein together form ethylene.

20. R 14 and R 15 A compound according to any one of claims 9 to 19, wherein together form propylene or butylene.

21. A, 【Chemistry 7】 and In the formula, R 9 , R 10 , R 11 , R 12 , and R 13 is as defined in any one of claims 1 to 20, and R 16 is hydrogen or C 1-7 The compound according to any one of claims 1 to 20, which is alkyl.

22. A is piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl, and piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl each independently represents one, two, three, or four R 6 22. The compound of any one of claims 1 to 21, optionally substituted with

23. A is NR 1 R 2 The compound according to any one of claims 1 to 22,

24. A, 【Chemistry 8】 The compound according to any one of claims 1 to 22,

25. R 4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, and one, two, or three R 7 25. The compound of any one of claims 1 to 24, optionally substituted with

26. R 4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, and one or two R 7 26. The compound of any one of claims 1 to 25, optionally substituted with

27. R 4 but, 【Chemistry 9】 The compound according to any one of claims 1 to 26,

28. R 4 but, 【Chemistry 10】 The compound according to any one of claims 1 to 26,

29. R 4 is imidazo[1,2-a]pyrazine, benzo[d]oxazole, triazolo-pyridazinyl, or imidazo[1,2-a]pyrazine, and the imidazo[1,2-a]pyrazine, benzo[d]oxazole, triazolo-pyridazinyl, or imidazo[1,2-a]pyrazine each contain 1, 2, 3, or 4 R 7 27. The compound of any one of claims 1 to 26, optionally substituted with

30. R 4 but, 【Chemistry 11】 The compound according to any one of claims 1 to 26,

31. R 4 but, 【Chemistry 12】 The compound according to any one of claims 1 to 26,

32. 32. The compound of any one of claims 1 to 31 selected from the compounds of Table 1 or the present disclosure.

33. A compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt, solvate or prodrug thereof, for use as a therapeutically active substance.

34. 33. A compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, for use as a small molecule splicing modulator.

35. 35. A pharmaceutical composition comprising a compound according to any one of claims 1 to 34, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, and one or more pharma- ceutically acceptable excipients.

36. A method of treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claims 1-34 or a pharmaceutical composition of claim 35.

37. 37. The method of claim 36, wherein the cancer is a leukemic cancer.

38. 37. The method of claim 36, wherein the cancer is colorectal cancer, breast cancer, or prostate cancer.

39. 37. The method of claim 36, wherein the cancer is a liquid cancer.

40. 37. The method of claim 36, wherein the cancer is leukemia or lymphoma.

41. 37. The method of claim 36, wherein the cancer is leukemia, acute myeloid leukemia, colon cancer, gastric cancer, acute monocytic leukemia, breast cancer, hepatocellular carcinoma, alveolar soft part sarcoma, myeloma, cutaneous melanoma, pancreatic cancer, adenocarcinoma, adenoiditis, adenoid cystic carcinoma, gastrointestinal stromal tumor, sarcoma, prostate adenocarcinoma, Hodgkin's lymphoma, ovarian cancer, non-Hodgkin's lymphoma, multiple myeloma, chronic myelogenous leukemia, acute lymphoblastic leukemia, renal cell carcinoma, transitional cell carcinoma, colorectal cancer, chronic lymphocytic leukemia, anaplastic large cell lymphoma, kidney cancer, breast cancer, or cervical cancer.

42. 37. The method of claim 36, wherein the cancer is a solid cancer or solid tumor.